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Clostridium difficile is the leading cause of health care associated diarrhoea and remains a 
burden for the NHS.  Disease symptoms can range from mild diarrhoea through to 
fulminant pseudomembranous colitis, resulting in mortality for some patients.  Recurrence 
is a major problem and estimates are that 20% of all patients with disease will either relapse 
(with the same strain) or have a re-infection (with a different strain).   
Arguably, the main virulence factors are toxins A (TcdA) and toxin B (TcdB) which cause 
disease symptoms.   The genes encoding TcdA and TcdB are located within the 
pathogenicity locus (PaLoc) along with three accessory genes; tcdR, tcdE and tcdC.  The 
regulatory network has been studied but we aimed to add to this knowledge by using two 
under investigated strains R20291 a so-called hypervirulent strain and VPI 10463 a strain 
known to produce higher levels of toxin. 
Two different methods of investigation were employed during this study to improve our 
understanding of both the regulation of TcdA / TcdB but also the genetic mechanisms 
behind clinical relapse.  These methods were; using forward and reverse genetic analysis 
to assess phenotypic differences and using bioinformatics to identify genes and / or single 
nucleotide variants (SNP) that may play a role. 
Using a combination these methods we have identified potential regulators of toxin 
production in both strains.  We have also identified unique genes and SNPs that might 
provide a fitness benefit to strains of C. difficile that were isolated from patients who had 
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1.1 Clostridium difficile 
1.1.1 Clostridium difficile and its emergence as a human pathogen 
The genus Clostridium is comprised of approximately 100 described species, the majority 
of which are  benign1.  They are ubiquitous in the environment and can be found in soil, 
marine sediments, sewage and the intestinal tracts of both humans and animals2.  Several 
species have been shown to have useful applications in a variety of fields.  Clostridium 
acetobutylicum and Clostridium beijerinckii are both examples of clostridia that are used 
for the industrial production of biofuels due to their ability to ferment organic compounds3.  
Spores of Clostridium sporogenes and Clostridium novyi have shown to have great 
potential as tumour delivery vehicles for chemotherapeutic agents4. Conversely several 
Clostridium species have the ability to cause disease in humans under favourable 
conditions of which Clostridium perfringens and Clostridium difficile are arguably the 
most notorious.  C. perfringens is known to cause gas gangrene, gastrointestinal infections 
(after consumption of contaminated foods) and necrotic enteritis in infants5.  However, in 
recent years the spotlight has been reserved for C. difficile.  It was coined a “superbug” by 
the media, along with methicillin resistant Staphylococcus aureus (MRSA)6, due to the 
increased incidence of Clostridium difficile infection (CDI) in hospitals and associated 
morbidity.  C. difficile has been implicated as the cause of extracolonic diseases, including 
reactive arthritis, bacteraemia and wound infections7, but its most prevalent site of 
infection is the gastrointestinal tract. 
C. difficile is an anaerobic, Gram-positive bacillus, of 0.3-2 x 1.5-2 µm in size, and which 
is able to form endospores.  It was first described in the literature as part of the neonatal 
gastrointestinal microflora in 1935 and named Bacillus difficilis8.  Over time, as knowledge 
improved for the class Bacilli, it was noted that certain genera within the class were 
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aerobic/facultatively anaerobic and others were obligate anaerobic.   This prompted the 
division of the class into Bacilli and Clostridia.   
C. difficile was first recognised as a human pathogen in 1978 when a number of 
pseudomembranous colitis cases were found to be associated with the use of clindamycin9.   
Screening of symptomatic patient faeces showed that C. difficile toxins were present and 
were likely the cause of symptoms.  However, the true effect of clindamycin on CDI was 
not fully understood until 1999.  Through the analysis of four distinct outbreaks, using 
susceptibility testing and typing of C. difficile strains, in combination with clinical data, 
Johnson et al.10 were able to demonstrate that the use of clindamycin increased the risk of 
CDI.  This was due to a clindamycin resistant C. difficile strain which was epidemic at the 
time.  During the 2000’s there was a steady rise in the frequency of outbreaks of CDI 
throughout Europe, North America and some parts of Asia11.  C. difficile is now recognised 
as a major cause of hospital acquired diarrhoea and has become a considerable burden for 
healthcare services due to treatment costs, patient isolation, and ward closures.  In Europe, 
the estimated incremental cost per patient associated with CDI is between £4577 and 
£884312. 
1.1.2 Clostridium difficile risk factors 
The risk of developing CDI is most significantly increased by the use of antibiotics.  This 
risk increases with prolonged duration of antibiotic treatment and by the number of 
different antibiotics received13.  The antibiotics associated with the highest risk are the 
broad-spectrum second-generation (and higher) cephalosporins, clindamycin and 
fluoroquinolones 10,14–16, but over the years almost all antibiotics have been linked to 
CDI16.  Patients are at highest risk during therapy and for the first month after therapy is 
ceased, however, this risk starts to decline between month one and three17.   
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Other important risk factors include advanced age; patients over the age of 65 have an 
increased risk of acquiring CDI.  It is also believed that for each year of age, after 18, the 
risk increases by 2% each subsequent year for health-care acquired CDI11.  Prior 
hospitalisation and/or residents of long term care facilities also have an increased risk18.  
Other risk factors associated with CDI are the use of antacids, particularly proton pump 
inhibitors (PPI)11,14,19.  Although this is still controversial and the mechanism by which 
PPIs increase the risk is not well described.  There are a number of other 
conditions/treatments which act as risk factors.  These include, irritable bowel disease, end 
stage renal disease, chronic liver disease, nasogastric feeding, chemotherapy and 
immunosuppression14,16,20. 
A further discussion of risk factors and their association with recurrent infection will be 
presented in Chapter Five. 
1.1.3 Clostridium difficile disease 
It is the ability of C. difficile to produce endospores that enables it to be a major nosocomial 
pathogen. The spore form can stay in the environment for long periods of time, resist many 
common cleaning practices, be transmitted between patients and can cause recurring 
infection21.  After ingestion of spores it is not known at what stage they germinate and 
return to vegetative cells, although the bile salts present in the intestine (e.g., taurocholate) 
play a role in this process22.  In the mouse model, germination occurs in the small intestine 
and caecum, while in the hamster model 80% of germination occurs in the small 
intestine23,24. It can be assumed that it is the same in the human host.  The environment has 
to be favourable for colonisation to occur, such as after antibiotic treatment when the 
normal gut microbiota has been disrupted and the colonisation resistance it affords ablated.    
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The disease state is caused by the production of toxins A and B.  These toxins enter the 
intestinal epithelial cells and affect the organisation of the cell cytoskeleton resulting in 
cell death25.  It is this process that leads to inflammation and the clinical symptoms of CDI.  
This will be discussed in more detail in section 1.2.  
The clinical manifestation of disease can vary depending on the severity of infection.  In 
mild to moderate infection stools are watery and the patient may exhibit signs of colitis 
such as, lower abdominal cramps, fever, leucocytosis and hypoalbuminemia20.  Severe CDI 
is associated with a white blood cell count of >15 x 109/L, a temperature of >38.5°C, an 
acute rising serum creatinine and evidence of sever colitis20,26.  In <5% of cases fulminant 
disease occurs, in which symptoms include severe abdominal pain, perfuse diarrhoea, 
hypotension, ileus, pseudomembranous colitis and/or toxic megacolon20,26,27.  Recurrent 
infection occurs in 19 – 35% of all cases, this may be re-emergence of the original strain 
or infection with a new strain, usually within 30 days of completing treatment for CDI28–
30.  After one episode of recurrent CDI the risk of further relapses increases29.  Recurrent 
infection will be discussed in more detail in Chapter Five. 
1.1.4 Treatments 
The recommendations for treatment of CDI within the UK were last updated in 2013 by 
Public Health England (PHE)31.  It is recommended that all implicated antimicrobial 
treatments are discontinued at the earliest possible timepoint.  Antibiotic treatment is 
dependent on the severity of disease.  In the case of mild and moderate disease oral 
Metronidazole is recommended as it has been shown to be as effective as Vancomycin, is 
cheaper and will not increase the risk of selection of Vancomycin Resistant Enterococci 
(VRE)32,33. Oral Vancomycin is reserved for severe cases as a number of studies have 
shown it to be superior to Metronidazole31.  If patients are at high risk of recurrent infection 
Fidaxomicin should be considered. It has been shown to be more effective at preventing 
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recurrence over Vancomycin34–36.  Patients who are not responding to Vancomycin should 
either receive Fidaxomicin or high dosage oral Vancomycin plus intravenous (IV) 
Metronidazole31.  In life threatening cases, such as toxic megacolon, septic shock or 
perforation, colectomy may be required in an attempt to prevent mortality26,27.  Rifaximin, 
when given as a “chaser” therapy after traditional CDI antibiotics, has been shown to 
reduce recurrence rates37,38.   
There are concerns about resistance, a few cases have been described where C. difficile, 
cultured after Rifaximin treatment, have shown high minimum inhibitory concentrations 
(MIC) to the drug39,40.   
1.1.5 Clostridium difficile surveillance in the UK 
Surveillance first started in England and Wales in 1990 as a voluntary scheme with 
Northern Ireland joining in 2001.  Over a 15-year period there was a steady increase in the 
number of cases of CDI (Fig 1.1)41.  As a result, in 2004 a mandatory scheme was put in 
place in England for reporting CDI in patients over 65 years of age.  Since April 2007 it 
has been mandatory for all NHS trusts in England to report all cases of CDI in all patients 





Figure 1-1: Number of positive C. difficile faecal samples reported under the voluntary 
reporting scheme for England, Wales and Northern Ireland* 1990-2014.  *Northern Ireland 
joined in 200141. 
 
In April 2007 the Clostridium difficile Ribotyping Network (CDRN) was also established 
to enhance the mandatory surveillance of CDI by providing epidemiological information 
that assists in the recognition and control of epidemic strains.  Since its inception the 
network has grown from six to nine laboratories, with one being in Northern Ireland.  
Samples are provided depending on local clinical need but are usually due to one of the 
following scenarios42: 
• Increased frequency of cases or high baseline rates of CDI 
• Increased severity/complications of cases of CDI 
• Increased mortality associated with CDI 
• Increased recurrence rate of CDI 
Since the introduction of the CDRN the rates of CDI have fallen significantly (Fig 1.1), 





1.1.6 Typing methods for Clostridium difficile 
Typing is used as an epidemiological tool to cluster isolates with regards to either 
genotypes or phenotypes.  There are multiple different typing methods available for C. 
difficile, historically phenotypic characteristics were used.  These included antibiotic 
resistance profiles, slide agglutination methods, Western immunoblotting and soluble 
protein patterns44.  These methods were acceptable for local use and showed that C. difficile 
was transmissible between patients6.  However, as the technology available evolved so did 
the typing methods.  This improved reproducibility between laboratories and enabled the 
epidemiological monitoring of C. difficile within countries and globally.  
Killgore et al.44 compared seven different typing methods; pulse-field gel electrophoresis 
(PFGE), amplified fragment length polymorphism (AFLP), multilocus sequence typing 
(MLST), restriction endonuclease analysis (REA), surface layer protein A sequence typing 
(slpAST), multilocus variable number tandem repeat analysis (MLVA) and polymerase 
chain reaction (PCR)-ribotyping.  The study found that MLVA and REA were highly 
discriminatory between strains, where both methods were able to separate the so called 
hypervirulent BI/NAPI/027 strains by source location. These methods are likely to be too 
discriminatory to be used to track routine epidemiology of CDI.  MVLA is, however, used 
as an enhanced service by the CDRN in cases where high rates of CDI are recorded within 
a Trust, in those instances where there has been a failure to meet CDI targets and/or in 
outbreak cases after agreement with the local health protection team45.  It has also been 
suggested that MLVA should be used for the phylogeny of C. difficile46.  Methods such as 
PFGE and REA are labour intensive and it can be difficult to compare data between 
laboratories, a failing partially addressed through the use of computer software44.  slpAST 
and MLST are sequence based methods that both produce highly transferable data, but 
which are relatively expensive in comparison to other methods47.  The method of typing 
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currently used in the UK by the CDRN is PCR-ribotyping.  This method employs PCR to 
amplify the intergenic spacer region between the 16s rRNA gene and the 23s rRNA gene 
48.  The genetic differences, copy number and size, in these regions are enough to produce 
a distinctive “fingerprint” for each strain6.  Kilgore et al.44 found that even when, at two 
separate laboratories, different primer sets were used there was only one disagreement 
within the 41 tested over which ribotype (RT) to assign.  There are hundreds of different 
ribotypes and each has been designated a unique three-digit code starting at RT00148.  
Another typing method, toxinotyping, was not covered by Kilgore et al.44, uses selected 
fragments of the tcdA and tcdB genes to look for differences in restriction fragments to a 
reference strain (VPI 10463) when digested with specific restriction enzymes 49.  These 
differences are known as restriction fragment length polymorphisms (RFLP).  There are 
over 30 different toxinotypes and these have been shown to  correlate with serotypes49–51.  




Table 1-1: Commonly used Clostridium difficile typing methods and their associated 
advantages and disadvantages.  Information gathered from44,52,53. 
 








Consensus between restriction 
endonucleases needed. 







Can choose the number of 
loci within one reaction. 
No prior knowledge of DNA 
sequence is required. 
Specialised equipment required if 




sequence typing  
(MLST) 
Data for comparison 
available via the internet. 
Reproducibility and 
repeatability high. 
Low discriminatory power. 
Expensive. 
Complex protocol. 









Interpretation can be difficult. 






Relevant to vaccine 
development. 
 







Reactions can be 
multiplexed using 
fluorescent probes and 
capillary PCR. 
Unsuitable for long-term 
epidemiological surveillance as loci 





Most commonly used typing 
method of C. difficile in the 
UK. 
Offers good discriminatory 
power. 
Results are reproducible. 
 
Labour intensive. 
Specialised equipment required (if 
performing capillary 
electrophoresis). 
Data not easily transferred between 
laboratories. 
Reference database not easily 
accessible. 




1.2 Clostridium difficile pathogenesis 
1.2.1 Structure and function of toxin A and B 
Toxin A (TcdA) and toxin B (TcdB) are well described as the main virulence factors of C. 
difficile.  It has been shown that non-toxigenic strains of C. difficile are able to colonise the 
colon but are not able to cause CDI, because of this these strains are being considered as a 
potential treatment for recurrent CDI infections54.  TcdA and TcdB are large (308 and 270 
kDa, respectively), homologous (47% DNA identity and 63% amino acid identity) 
proteins55.  They consist of four functional domains; the N-terminal glucosyltransferase 
(GDT) is the enzymatic component plus the C-terminal combined repetitive oligopeptides 
(CROPS), delivery/pore-forming and the autoprotease domains (Fig 1.2)56. They belong 
to the large clostridial cytotoxins (LCTs) due to their high molecular weight, glycosylating 
activity and cytopathic effect on cells57. 
Binding and internalisation of TcdA and TcdB occurs in a number of steps termed the 
ABCD model (A, biological activity; B, binding; C, cutting; D, delivery).  Firstly, the 
CROPS bind to receptors on the cell surface after which endocytosis is initiated.  TcdA 
shows specificity to carbohydrates with a Galß1-4GlcNAc core although the exact ligand 
is still unknown58,59. TcdB has recently had a receptor identified, chondroitin sulphate 
proteoglycan 4 (GSPG4)60.  After binding, toxins are internalised into endosomes and 
acidification induces a conformational change in the delivery domain resulting in insertion 
into the membrane61.  The autoprotease domain is then activated by binding to inositol 
hexakisphosphate (InsP6) resulting in cleavage of the GTD into the host cell cytosol
62.  The 
toxins can then modify and inactivate the Rho family GTPases Rho, Rac and Cdc42 
resulting in cell rounding, disaggregation of the actin cytoskeleton, loss of intestinal 
epithelium barrier function and cell death55 . 
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Figure 1-2: Schematic representations of TcdA and TcdB adapted from56. The N-terminal 
glucosyltransferase domain (GTD) (red), oligopeptides (CROPs) (green), delivery/pore-
forming (yellow), delivery domain (orange) and autoprotease (blue). 
 
Historically, using pure toxin extracts, it was established that TcdA could elicit a disease 
response in hamsters when administered alone, whereas TcdB could not.  Although, TcdB 
could cause disease symptoms if a sub-lethal dose of TcdA was administered at the same 
time63.  This caused confusion over how strains with only functional TcdB were causing 
clinical infections as this did not fit the common conception that either both toxins or TcdA 
alone were required for disease64. In the hamster model it has been shown that TcdB alone 
can cause disease 65,66.  Lyras et al.65 used homologous recombination to create single 
crossover mutants with either TcdA or TcdB deficient phenotypes.  They showed that in 
the hamster model A-B+ mutants caused CDI and animals were more likely to die than 
when infected with A+B- mutants.  Kuehne et al.67 were able to create stable, isogenic 
mutants of C. difficile using ClosTron technology68,69, meaning that not only A-B+ and 
A+B- mutants were constructed but for the first time a A-B- mutant was generated.  Using 
these mutants their findings corresponded with those of Lyras et al. in that TcdB alone 
could cause a disease state in hamsters.  However, they also showed that TcdA alone could 
also cause disease in hamsters.   The   difference in outcomes between the two studies has 
been hypothesised to be due either to different endpoints used in the animal models or the 
presence of secondary mutations in the progenitor strains used for mutant construction66.  
In both cases, the creation of the mutants required the prior independent isolation of   
erythromycin sensitive derivatives of C. difficile 630 through repeated subculture.  The 
derivative used by Kuehne et al was 630Δerm, while that made by Lyras et al. was 
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designated 630E.  It is suggested that mutations may have arisen during the extensive 
subculturing undertaken during their isolation and these may have effected their virulence 
phenotype66.  Thus, for instance, strain 630E has become non-motile66.   
In 2014 Kuehne et al.70 created similar A-B+, A+B- and A-B- mutants in the RT027 strain 
R20291.  Using the same experimental model as used previously67 they found that the A+B- 
and A-B+ mutants were both able to cause disease, although the former was less virulent.  
This was followed by Carter et al.71 creating similar mutants in a different RT027 strain 
M7404.  In this study using three different animal models they also found that A+B- mutants 
were less virulent than A-B+ mutants.  Histological findings showed that A+B- mutants 
caused more superficial and localised damage when compared to the A-B+ counterparts.  It 
appears from these data that both TcdA and TcdB have a role in pathogenesis. This is 
validated by the recent discovery of a TcdA positive/TcdB negative strain of C. difficile 
which was isolated from a clinical case in Cambrai Hospital, France72. 
1.2.2 The Pathogenicity Locus 
The pathogenicity locus (PaLoc) is a19.6kb region that encodes the genes for TcdA and 
TcdB (tcdA & tcdB) along with three accessory genes; tcdR, tcdE and tcdC73 (Fig 1.3).  
The PaLoc was first sequenced in 1995 from strain VPI 10463 and in non-toxigenic strains 
a 127bp fragment resides in its place73. 
 
Figure 1-3: Schematic of the PaLoc from type strain VPI 10463.  Arrows indicate direction 
of transcription, figure not to scale. 
TcdR, encoded by tcdR, is believed to be a positive regulator of toxin production.  It is a 
22kDa protein that is part of the group 5 of the sigma 70 family and it binds directly to the 
RNA polymerase core enzyme74.  It is thought that tcdR has two promoters, one which is 
tcdR tcdB tcdE tcdA tcdC 
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independent and allows a basal level of toxin gene transcription and another which is more 
potent and is subject to growth phase75.  To date its role in toxin production is undisputed76.   
TcdC, encoded by tcdC, is believed to be a negative regulator of toxin production.  This 
belief is based both on the observed inverse correlation between transcription of tcdC and 
the toxin genes and on biochemical data77.  TcdC is a 26kDa   anti-sigma factor74 which 
binds to TcdR-RNA polymerase core enzyme to prevent it binding to the promoter regions 
of the PaLoc77.  The tcdC gene is encoded on the reverse strand of the other four genes on 
the PaLoc and is located downstream in relation to them (Fig 1.3).  There are however 
doubts about the role of TcdC due to two different observations.  Firstly, there is variability 
of toxin production in hyper-virulent strains even though they frequently carry mutations 
in the tcdC gene76,78.  Secondly, there have been studies that show increased TcdC 
production that coincides with increased toxin production76,78.  One recent study claims 
that mutations in the tcdC gene are an “important factor in the development of 
hypervirulence in epidemic C. difficile isolates”79 postulating that the mutations in the tcdC 
gene lead to increased toxin production.  The study was performed using autonomous 
plasmids to complement mutant strains carrying dysfunctional tcdC genes.  The use of data 
derived from such studies should, however, be treated with caution has the multicopy 
nature of plasmids can affect outcomes due to the high gene dosage of the complementing 
gene.  In another recent study, Cartman et.al.80 used allelic exchange to both create and 
repair mutant strains carrying dysfunctional tcdC genes.  This study demonstrated that 
there was no significant difference in the level of toxin produced between the isogenic 
strains.  As all the mutations were performed on the chromosome it reflects a more natural 
environment.   With conflicting evidence from different studies, it is difficult to speculate 
what role TcdC has within the bacterium.  Indeed, evidence presented by van Leeuwen et 
al.81 suggests that TcdC may not even bind to the PaLoc at all.  Their data showed that 
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TcdC forms an oligonucleotide-binding fold (OB-fold) that binds to quadruplex structures 
(QSs).  However, none of the recognition sites are found within the PaLoc.  Although they 
do not rule out that the binding determinant may associate with a different structure.  The 
regulation of toxin gene expression will be discussed in more detail in Chapter Three. 
The method in which toxins are released from the bacterial cell is usually due to a C-
terminal or N-terminal signal peptide, a Tat-signal peptide or some other alternative 
definable signal peptide.  C. difficile toxins A and B do not possess any of these signal 
peptides and therefore are exported to the extra cellular space by some other means82.  It 
has been hypothesised that the tcdE gene and its product TcdE play a role in the excretion 
of TcdA and TcdB83.  TcdE is a 19kDa protein that is highly hydrophobic, it is predicted 
to contain three transmembrane domains and shares structural and sequence similarities to 
class 1 holin proteins82,84.  Holins are usually produced by bacteriophages and are small 
membrane proteins designed to release intracellular phage’s after development.  They form 
lethal holes within the membrane by oligomerisation which results in cell lysis82–84.  There 
is conflicting evidence as to whether TcdE acts as a secretion system for TcdA and TcdB.  
One study showed that functional inactivation of the tcdE gene did not affect any of their 
measured clostridial characteristics, namely growth, sporulation or release of TcdA and 
TcdB and that their release correlated with bacteriolysis which was independent of TcdE 
production84.  Another study showed that TcdE was essential for TcdA and TcdB release 
and did so by secreting the proteins rather than lysing the bacterial cell82.  Both studies 
used ClosTron mutagenesis to create insertional mutations in tcdE at position 234 so it is 
unclear why there were two different outcomes but this might be due to using two different 
erythromycin sensitive strains of CD630 (as described earlier) and/or different 
experimental methods.  A more recent study not only appears to support the hypothesis 
that TcdE is required for transporting toxins out of the cell but also gives an explanation 
38 
 
as to why Olling et al.84  found that the cells lysed more easily.  By creating tcdE mutants 
in both R20291 and CD646, Govind et al.85 were able to show that R20291 mutants were 
deficient in releasing toxin into culture medium.  However, in CD646 low levels of toxin 
were produced and the cells lysed more rapidly.  Consequently, toxins from CD646 are 
released into the culture medium independent of TcdE.  These data complements with both 
studies in that low toxin producing strains (i.e., CD646 and 630∆erm) are lysed and higher 
toxin producing strains (i.e., R20291 and 630E) are unable to efficiently transport toxins 
from the cell82,84,85.  These findings demonstrate that our understanding of species should 
not be based on individual strains. 
1.2.3 Other Clostridium difficile virulence factors 
In addition to TcdA and TcdB some strains of C. difficile also produce a third toxin known 
as binary toxin or Clostridium difficile transferase (CDT), an actin-specific ADP-
ribosylating toxin86.  The exact role of CDT in virulence remains unclear, however, it is 
interesting that the toxin is found in strains associated with severe CDI such as RT027 and 
RT07887.  Studies have shown that CDT may have a role in colonisation and adhesion88, 
but  there is conflicting evidence as to whether it can70,89 or cannot90 cause disease in 
hamsters when administered alone.  
Adherence to intestinal epithelial cells is essential for colonisation and the establishment 
of infection.  Putative virulence factors that have shown to have a role in adherence or 
colonisation are cell wall proteins (CWP), the heat shock protein GroEL, the surface layer 
(S- layer), fibronectin binding proteins, fimbriae and the flagella91. 
Endospores are the infectious particle and are a required step in the life cycle of C. difficile.  
The spores are excreted in faeces and contaminate the environment.  They are able to resist 
radiation, heat and many alcohol and chemical based disinfectants92 and can persist in the 
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environment for extended periods of time.  It has also been demonstrated in the murine 
model by Lawley et al.93 that colonised immunocompetent subjects can become high 
shedders of spores after receiving antibiotic treatment, increasing the risk to 
immunocompromised subjects. 
1.3 Genetic tools for the manipulation of the Clostridium difficile genome 
Molecular biology is widely used to inactivate genes that are proposed to have an effect of 
pathogenicity or virulence and look for a measurable difference in phenotype.  In 1988 
Falkow94 suggested that the study of singular genes required a form of molecular Koch’s 
postulate, in that there has to be a well-defined effect from the loss or gain of the gene in 
question and that restoration of this gene reverts the discovered phenotype.   
1.3.1 ClosTron insertional inactivation 
Initial mutants made in C. difficile were found to be unstable95.  In 2007, Heap et al.68 
developed ClosTron: A universal gene knock-out system for the genus Clostridium.  This 
system employs a bacterial group II intron which carries an antibiotic resistance gene 
which itself is interrupted by a group I intron.  When the ClosTron plasmid has been 
conjugated into the C. difficile host and the group II intron is transcribed, then the LtrA 
protein (which is located elsewhere on the ClosTron plasmid) binds to the transcript after 
which a ribonuclear protein (RNP) is formed.  The group I intron is then spliced out 
resulting in an intact antibiotic resistance gene, the RNP recognises and binds to the target 
site, nicks the DNA and inserts the RNA in the chromosome.  The LtrA protein then 
synthesises the complementary DNA strand and host polymerases degrade the RNA and 
synthesise new DNA.  Ligases repair the two gaps resulting in a functional antibiotic 




Figure 1-4: Schematic of ClosTron plasmid pMTL007C-E269.  The plasmid contains a Gram-
positive replicon (pCB102), a thiamphenicol resistance gene (catP) for transconjugant 
selection, a Gram-negative replicon (ColE1) and the conjugal transfer function (traJ).  The 
intron marker contains the group II intron and the erythromycin resistance gene (ermB) 
which is inactivated by the group I intron.  The ltrA gene facilitates the excision of the group 
I intron and the insertion of the group II intron into the chromosome. 
 
This technology was improved in 2010 which resulted in the ability to create multiple 
mutations in a single strain by using marker recycling69.  Fig 1.3 shows a schematic of the 
pMTL007C-E2 plasmid.  What enables the system to be used in multiple locations 
throughout the genome is the Perutka Method96 of group II intron design, this alters the 
intron RNA to complement different DNA targets.   An online algorithm 
(www.clostron.com) has automated the process of intron design where after imputing a 
target sequence a list of potential target sites is produced along with a score.  A higher 
score increases the likelihood a successful insertion will occur. 
1.3.1 Mariner Transposon random mutagenesis 
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In 2010, Cartman and Minton97 established a method of creating random mutants in C. 
difficile by utilising a mariner-transposon.  Other systems had been previously 
described98,99 but the transposons employed (Tn916 and Tn5397) showed a strong target 
site preference and multiple insertions in single clones respectively.  These are both 
undesirable features for the study of random mutant libraries.  The mariner-transposable 
element Himar1 uses a cut and paste mechanism for DNA transfer and is the only element 
required for transposition100.  The transposon is flanked by inverted terminal repeats (ITRs) 
and inserts in to TA target sites which is suitable for a low-GC content organism like C. 
difficile.  Fig 1.5 shows a schematic of the pMTL-SC1 plasmid.  This method has been 
successfully used in our laboratory to identify genes involved in auxotrophic, sporulation 
and germination deficiency97.  It has also been used to identify genes involved in toxin A 





Figure 1-5: Schematic of the mariner-transposon plasmid97.   The plasmid contains a Gram-
positive replicon (repA & orf2) from C. botulinum, an erythromycin resistance gene (ermB) 
for transconjugant selection, a Gram-negative replicon (ColE1) and the conjugal transfer 
function (traJ).  The mariner-transposon element contains the Himar1C9 upstream of the 
toxin B promoter PtcdB of C. difficile.  The transposable element is a thiamphenicol 
resistance gene (catP) and is flanked by two inverted terminal repeats.   
 
1.3.3 Allelic exchange using codA as a negative selection marker 
In 2012, Cartman et al.80 were able to repair variant tcdC genes by using allelic exchange.  
This method utilises both positive and counter-selection markers to identify possible 
mutant clones.  Previously, counter-selection markers have only been described in 
Clostridium thermocellium and C. perfringens, however, these markers have chromosomal 
homologues and therefore can only be used in mutant background strains101,102.  To 
overcome the requirement to create a C. difficile strain with a mutant background the 
cytosine deaminase gene (codA) of Escherichia coli was utilised to create a heterologous 
counter-selection marker.  Ordinarily, cytosine deaminase converts cytosine to uracil, 
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however, it is also able to convert the cytosine analogue 5-fluorocytosine (FC) into the 
toxic derivative 5-fluorouracil (FU).  FU is phosphorylated by uracil phosphoribosyl 
transferase and after a number of subsequent steps, results in the misincorporation of 
fluorinated nucleotides into DNA and RNA resulting in toxicity103.  Figure 1.5 describes 
the system in which the homologous recombination events occur and how to select for 
them.  Complementation of the altered gene can be achieved through the same method, to 
distinguish between wildtype and complemented strains a single nucleotide variant (SNP) 





Figure 1-6: Two-step allelic exchange. 
Consider a chromosomal allele to be 
divided into three regions [X, Y and Z]. 
(A) A recombinant allele, in which the 
sequence of [*Y*] differs from that in the 
chromosome [Y], is introduced on a 
plasmid vector (note, [*Y*] is omitted 
altogether if sequence is to be deleted 
from the chromosome). The plasmid 
vector is replication deficient and carries 
both a positive selection marker [+] 
(usually an antibiotic resistance marker) 
and a counter-selection marker [–]. (B) 
Positive selection enriches for single 
cross-over recombinant clones in which a 
homologous recombination event at 
either [X] or [Z] results in integration of 
the plasmid into the chromosome. (C) 
Subsequently, counter-selection selects 
for clones in which a second 
recombination event has occurred at 
either [X] or [Z] (resulting in plasmid 
excision from the chromosome) and 
which have lost the plasmid vector from 
the cell (due to its inherent instability). At 
the counter-selection stage, both wild-
type revertants and double cross-over 
recombinant clones are isolated, as the 
second recombination event may occur in 
either the same or opposite region to the 
first (i.e., [X] or [Z]).  (Taken from 





1.4 Aims of this project. 
The overall aim of this thesis was to improve our fundamental knowledge of the molecular 
pathogenesis of C. difficile. This was accomplished through a multifaceted approach that 
involved investigating; the genetic differences between strains, improving DNA transfer, 
exploring how the toxin genes tcdA and tcdB are regulated and investigating what 
mechanisms are involved in patients who suffer recurrent CDI infections.   
This thesis contains three results chapters: 
• Chapter Three will investigate regulators of TcdA and TcdB production using both 
forward and reverse genetics.  An R20291∆tcdR strain will be studied to ascertain 
the role of TcdR in toxin production.  Random mutagenesis will also be utilised to 
identify putative genes involved in toxin production either directly or indirectly. 
• Chapter Four will focus on the genetics of C. difficile strain VPI 10463, a high toxin 
producing strain.  This will involve whole genome sequencing of this strain, 
comparing genotypes with other well studied strains to predict the reasons for 
increased toxin production. This chapter will also focus on improving DNA transfer 
in to strains VPI 10463 and R20291. 
• Chapter Five will examine C. difficile isolates collected from patients with 
diagnosed CDI.  These patient samples will be studied for co-infection of multiple 
C. difficile ribotypes, reduced antibiotic susceptibility and to identify SNP’s that 














2.1 Buffer, Solutions, Culture Media and Growth Conditions 
2.1.1 Buffer and Solutions 
The following list of solutions are stated at stock concentrations, further dilutions may have 




100g sodium dodecyl sulphate 




24.6g Sodium Acetate 
Adjust to pH 5.2  




186.1g EDTA disodium salt 
Adjust to pH 8.0  




48.4g of Tris 
11.4 mL of glacial acetic acid  
20 mL 0.5M EDTA 




 16g Sodium hydroxide 




 175.3g Sodium chloride 
88.2g Sodium citrate 
Adjust to pH 7.0  
Final vol. 1 L dH2O 
 









0.5x Wash solution 
 
 0.5x SSC 
 0.1% SDS 
 Final vol. 500 mL dH2O 
 
5x Maleic acid buffer 
 
 58.04 g Maleic acid 
43.83 g Sodium Chloride 
36g Sodium hydroxide  
Adjust to pH 7.5 
Final vol. 1 L dH2O 
 
1x Maleic acid buffer-T 
 
1x Maleic acid buffer 
0.3% Tween 20 
Final vol. 500 mL dH2O 
 
1x Blocking buffer 
 
10x Blocking buffer solution (Sigma-Aldrich) 
1x Maleic acid buffer 
Final vol. 60 mL dH2O 
 
Anti-DIG Ab Probe 
 
 30 mL 1x blocking buffer 
 3 µL anti-DIG Ab 
 
1x Detection buffer 
 
 100mM Tris-HCl 
100mM NaCl 
Final vol. 30 mL 
 
2.1.2 Culture Media 
Media used to culture bacteria are listed below.  Solid media plates were made with the 
addition of 1% w/v agar (Oxoid No. 1) unless otherwise stated.  All media were sterilised 
by autoclaving at 121°C for 15 min at 100 pKa. Ingredients were sourced form Oxoid 
unless otherwise stated.  
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• Brain Heart Infusion Supplemented (BHIS); 37g brain heart infusion, 20g yeast 
extract and 1g L-cysteine in 1L dH2O.   
• Tryptose Yeast Extract medium (TY)104; 30g tryptose, 20g yeast extract and 1g 
thioglycolate in 1L dH2O.  When required 1g lichenan was added to the media prior 
to autoclaving. 
• Luria-Bertani (LB)105; 10g Bacto tryptose (BD Biosciences), 5g yeast extract, 10g 
sodium chloride in 1L dH2O.  For solid media Oxoid No. 1 added at a concentration 
of 1.5%. 
• Cycloserine Cefoxitin Egg Yolk (Lab M) (CCEY)106; 48g premixed CCEY in 1L 
dH2O.  Post autoclaving 40 mL (4%) egg yolk emulsion was added to the media. 
• Wilkins – Chalgren Anaerobe Agar (WCAA); consisted of 43g premixed WCAA 
in 1L dH2O.  Post autoclaving 50 mL (5%) defibrinated horse blood added to the 
media.  
• Cycloserine Cefoxitin Fructose Broth (CCFB)107; 40g proteose peptone, 5g sodium 
phosphate dibasic, 1g potassium phosphate monobasic, 2g sodium chloride, 0.1g 
magnesium sulphate, 6g fructose, 1g sodium taurocholate, 0.5g L-cysteine, 0.03g 
neutral red.  For solid media Oxoid No. 1 added at a concentration of 2% and 
neutral red was omitted.   
• Cycloserine Cefoxitin Mannitol Broth with Taurocholate and Lysozyme (CCMB-
TAL)108; 40g proteose peptone, 5g sodium phosphate dibasic, 1g potassium 
phosphate monobasic, 2g sodium chloride, 0.1g magnesium sulphate, 6g mannitol, 
1g sodium taurocholate, 0.5g L-cysteine, 0.5g Lysozyme,0.03g neutral red. 
• SOC medium (Invitrogen) consists of 2% tryptone, 0.5% yeast extract, 10 mM 
sodium chloride, 2.5 mM potassium chloride, 10 mM magnesium chloride, 10 mM 
magnesium sulphate, and 20 mM glucose. 
• Clostridium difficile minimal media (CDMM)97. 
• ChromID C. difficile (bioMérieux); a chromogenic agar plate that enables C. 
difficile to be identified quickly from mixed cultures. 
• Tryptone Soy Agar (Thermo Scientific) with 5% sheep blood. 
2.1.3 Antibiotic Media Supplements 
Antibiotics were prepared as recommended by Sambrook and Russell109, filter sterilised 
and stored under the recommended conditions.  Antibiotics were used in the following 
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working concentrations; Ampicillin 100 µg/mL, Chloramphenicol 25 µg/mL, Cycloserine 
250 µg/mL, Cefoxitin 8 µg/mL, Erythromycin 10 µg/mL, Kanamycin 50 µg/mL, 
Lincomycin 20 µg/mL and Thiamphenicol 15 µg/mL. 
2.1.4 Growth Conditions 
C. difficile were routinely cultured in an anaerobic cabinet (Don Whitley, UK) containing 
CO2:H2:N2 (80:10:10 v/v/v) at 37°C.  Media were reduced in anaerobic conditions for a 
minimum of 4h or 8h for plates and broths, respectively, before use.   E. coli strains were 
cultured in aerobic conditions at 37°C, broth cultures were shaken at 200 rpm. 
2.2 Bacterial Strains and Plasmids 
2.2.1 Bacterial Strains and Storage 
Bacterial reference strains and constructed mutants are listed in Table 2-1.  Two different 
R20291 strains were used in this study, NM-R20291 (Synthetic Biology Research Centre, 
University of Nottingham) and BW-R20291 (London school of Hygiene and Tropical 
Medicine).  Briefly, NM-R20291 has improved growth kinetics when grown in either 
BHIS broth or minimal media containing glucose, fructose and mannitol.  NM-R20291 
demonstrates a reduced motility, produces more toxin, sporulation occurs later and can 
form biofilms better than BW-R20291.  Full details given in Appendix One.   
During this study a number of C. difficile strains were isolated from clinical stool samples, 
these strains are described in Chapter Five of this thesis.   
C. difficile strains were stored at -80°C in 10% glycerol and BHIS broth stocks.  E. coli 




Table 2-1: Bacterial strains used in this study. 
 
*For specific details on the differences between these strains see Appendix One.
Strains Characteristics Origin 
E. coli   
TOP10 F- mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 ∆lacX74 nupG recA1 
araD139 ∆(ara-leu)7697 galE15 galK16 rpsL(Strr) endA1 λ- 
Invitrogen 
CA434 E. coli HB101 [F- mcrB mrr hsdS20(rB
- mB
-) recA13 leuB6 ara-14 proA2 
lacY1 galK2 xyl-5 mtl-1 rpsL20(Smr) glnV44λ-] with plasmid R702 
105,110 
NEB express fhuA2 [lon] ompT gal sulA11 R(mcr-73::miniTn10--TetS)2 [dcm] R(zgb-
210::Tn10--TetS) endA1 Δ(mcrC-mrr)114::IS10 
NEB 
   
C. difficile   
630 Wild type, PCR ribotype 012  
NM-R20291* Wild type, PCR ribotype 027 (Stoke Mandeville outbreak strain) Jon Brazier (Anaerobe Reference Laboratory, 
Cardiff, United Kingdom) 
BW-R20291* Wild type, PCR ribotype 027 (Stoke Mandeville outbreak strain) Brendan Wren (London School of Hygiene and 
Tropical Medicine, London, United Kingdom) 
VPI 10463 Wild type, PCR ribotype 087 ACTC 43255 
M120 Wild type, PCR ribotype 078, non-motile strain Brendan Wren (London School of Hygiene and 
Tropical Medicine, London, United Kingdom)  
CRG4603 BW-R20291::hsdR(ermB) This study 
CRG4605 VPI 10463:: hsdR(ermB) This study 
CRG2521 NM-R20291∆tcdR Clostridia Research Group (unpublished) 
CRG3972 NM-R20291::tcdR(EcoRI) Clostridia Research Group (unpublished) 
RS-7 NM-R20291∆tcdB::licB  Clostridia Research Group (unpublished) 
BBM4 NM-R20291 mariner-transposon mutant, insertions in genes 
R20291_2908 & R20291_jag 
This study 
CRG4250 NM-R20291::2908(ermB) This study 




All plasmids were stored at -20°C in dH2O. 
Table 2-2: Plasmids used in this study.   
 
Plasmid Description Reference 
pMTL82151 E. coli – C. difficile Shuttle Vector (pBP1, catP, ColE1, traJ) 111 
pMTL83151 E. coli – C. difficile Shuttle Vector (pCB102, catP, ColE1, traJ) 111 
pMTL84151 E. coli – C. difficile Shuttle Vector (pCD6, catP, ColE1, traJ) 111 
pMTL85151 E. coli – C. difficile Shuttle Vector (pIM13, catP, ColE1, traJ) 111 
pMTL84152 E. coli – C. difficile Shuttle Vector (pCD6, catP, ColE1, traJ, Pthl) 111 
pMTL007-E2::Cdi-R20291_2908-
1042s::CT(ermB) 
ClosTron plasmid with intron designed to insert into gene 2908 of 
R20291 
This study 
pMTL007-E2::Cdi-R20291_jag::96s::CT(ermB) ClosTron plasmid with intron designed to insert into gene jag of 
R20291 
This study 
pMTL007-E2::Cdi-R-subunit-527s::CT(ermB) ClosTron plasmid with intron designed to insert into gene hsdR of 
R20291and VPI 10463 
This study 
pMTL007-E2::Cdi-BI9_3942::CT(ermB) ClosTron plasmid with intron designed to insert into gene  
Ga0114281_1134 of VPI 10463 
This study 
pMTLSC7215 Vector for homologous recombination using codA as a negative 
selection marker.  Gram positive replicon - pBP1  
80 
pBSK::∆hsdR Storage plasmid for ∆hsdR exchange cassette. This study 
pMTLSC7215::∆hsdR Allelic exchange plasmid for creation of ∆hsdR strains. This study 
pMTL84151::p2908 Complementation plasmid for R20291::2908(ermB) This study 
pMTL84152::2908 Over expression plasmid for R20291::2908(ermB) This study 
pMTL-SC0 pMTL82151 containing mariner-transposon. No promoter driving 
expression of the transposon. 
97 
pMTL-SC1 pMTL82151 containing mariner-transposon 97 
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2.3 Polymerase Chain Reaction (PCR) 
For all PCR reactions annealing temperatures were calculated using the NEB Tm calculator 
(http://tmcalculator.neb.com/#!/) and extension times were estimated by predicted product 
length. 
2.3.1 General Protocol for Colony PCR 
Colony PCR was performed using OneTaq Quick Load 2X Master Mix (NEB) at a final 
volume of 25 µL containing 0.5µM of each primer.  Three to four colonies were emulsified 
into 30 µL molecular grade water and heated to 94°C for 20 min, 1 µL was added to the 
reaction to serve as a template.  PCR conditions were; 94°C for 30s, 30 cycles of 94°C for 
15s, 45 - 68°C for 30s and 68°C for 1 min/Kb followed by a final extension step of 68°C 
for 5 min. 
2.3.2 General Protocol for PCR with a Non-Proofreading DNA Polymerase 
Non-proofreading PCR was performed at a final volume of 25 µL containing 0.5µM of 
each primer, 2.5 units of OneTaq (NEB) and 12.5 µL FailSafe PCR 2X PreMix E (Cambio).  
Template DNA was used at a concentration of 100 ng/µL.  PCR conditions were; 94°C for 
30s, 30 cycles of 94°C for 15s, 45 - 68°C for 30s and 68°C for 1 min/Kb followed by a 
final extension step of 68°C for 5 min. 
2.3.3 General Protocol for PCR with a Proofreading DNA Polymerase 
Proofreading PCR was performed at a final volume of 25 µL containing 0.5µM of each 
primer, 0.5 units of Q5 (NEB) and 12.5 µL FailSafe PCR 2X PreMix E (Cambio).  
Template DNA was used at a concentration of 100 ng/µL.  PCR conditions were; 98°C for 
30s, 30 cycles of 98°C for 10s, 50 - 72°C for 30s and 72°C for 30 s/Kb followed by a final 




2.3.4 Inverse PCR 
Genomic DNA at a concentration of 50 ng/µL was digested overnight by HindIII (NEB) 
and ligated at a concentration of 5 ng/µL as described above.  PCR was performed using 
2X KOD Hot Start PCR Master Mix (Novagen) at a final volume of 25 µL containing 
0.5µM of each primer and 10 µL of ligated DNA template.  PCR conditions were; 95°C for 
2 min, 35 cycles of 95°C for 20s, 50°C for 10s and 70°C for 3 min 25s followed by a final 
extension step of 70°C for 10 min. 
2.3.5 Primers 
Primers were designed using Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/) and synthesised by Sigma-Aldridge.  A full list of primers used in this study can be 




Table 2-3: Primers used in this study 
Primer Sequence Reference 
ClosTron    
EBS universal CGAAATTAGAAACTTGCGTTCAGTAAAC 68 
ErmRAM-F ACGCGTTATATTGATAAAAATAATAATAGTGGG 68 







M13F TGTAAAACGACGGCCAGT 68 
M13R CAGGAAACAGCTATGACC 68 
   






















jag_F1 AAACTTGCAGCTTCTTTGCCTT This study 


















AGAGCAACTAGAATTGGCGGT This study 
CDR20291_0447
R 
GCTTGGTGCTGGCTCATGTA This study 
CDR20291_1065
F 
AAGGGATTACCTCCTACACCAA This study 
CDR20291_1065
R 
ACCAATTGCACATCCTACTTCT This study 
CDR20291_1086
F 
CAAGTGGAAGCGCCAAACTT This study 
CDR20291_1086
R 
CTCCACAATTTGGGCATTCCA This study 
CDR20291_1439
F 
TCAAGCAATTGTAGATGGGTGGA This study 
CDR20291_1439
R 





TGGAGGTAACACTTTCTTGTGT This study 
CDR20291_0853
R 
GGTTGACTATATACCTCTCCTGCT This study 
CDR20291_2848
F 
GCCACATGGATATGGAACTGGT This study 
CDR20291_2848
R 
AGTTGTATCACCAGAAGCACG This study 
   
Chapter Four   
hsdR_Fs1 TTCCCAACCTGCAAGTTTA This study 
hsdR-Rs1 AGAAGACTTTAGAGCTTGCAGT This study 
BI93941_Fs2 CTCCATCAGCAGAAGTGCAT This study 
BI93943_Rs1 GGGGCTAGAACAAAACCCAA This study 
Chapter Five   
P3 CTGGGGTGAAGTCGTAACAAGG 48 
P5 GCGCCCTTTGTAGCTTGACC 48 
 
2.4 Preparation and Manipulation of DNA 
2.4.1 Preparation of Chromosomal DNA 
Chromosomal DNA was extracted from stationary phase cultures after centrifugation at 
12,000 x g.  Culture pellets were pre-treated with 180 µL 10 mg/mL lysozyme at 37°C for 
30 min followed by 25 L 10 mg/mL proteinase K solution, 85 l dH2O and 110 l 10% 
(w/v) SDS solution incubated at 65°C for 30 min. For general PCR screening DNA was 
extracted using the GenElute Bacterial Genomic DNA Kit (Sigma Aldrich).  Final elution 
of DNA was into 50 µL molecular grade water (Thermo Scientific) at 50°C.  For high 
quality DNA, phenol chloroform extraction was utilised.  Equal volumes of 
Phenol:Chloroform:Isoamyl Alcohol (25:24:1, v/v/v) were added to pre-treated culture 
pellets and mixed by inversion.  Liquid was transferred to phase lock tubes and centrifuged 
at 20,000 x g for 3 min.  The top layer was transferred into a fresh phase lock tube and the 
process repeated a further two times.  The final top layer was transferred into a 1.5 mL 
Eppendorf tube containing 40 µL 3M NaAC and 800 µL ice cold 100% EtOH, mixed gently 
by inversion and placed onto ice.  DNA was transferred into 1 mL ice cold 70% EtOH by 
57 
 
5 mL glass pipette and then into a clean 1.5 mL Eppendorf tube for evaporation.  DNA was 
rehydrated in 50 µL molecular grade water (Thermo Scientific).   
2.4.2 Plasmid Extraction 
Plasmids were extracted from 1 mL stationary phase cultures after centrifugation at 12,000 
x g using the GenElute HP Plasmid Mini Prep Kit (Sigma Aldrich) as directed by the 
manufacturer.  Final elution of plasmid was into 50 µL molecular grade water (Thermo 
Scientific) at 50°C. 
2.4.3 Restriction Digest 
Restriction digests were performed on ice with DNA at a concentration of 1µg, 1 unit of 
restriction endonuclease and 1x Cut Smart Reaction Buffer (50mM Potassium Acetate, 
20mM Tris-Acetate, 10mM Magnesium Acetate and 100 µg/mL BSA) at a final volume of 
25 µL.  Reactions were incubated at 37°C for 2-3 h and heat inactivated at 65°C for 30 min.  
All enzymes were sourced from NEB and were stored according to the manufacturer’s 
instructions at -20°C. 
2.4.4 DNA ligation 
DNA ligations were performed on ice at a molar ratio of 1:3 (vector to insert), 1 unit T4 
ligase (NEB) and 1x T4 DNA ligase buffer (50mM Tris-HCl, 10mM Magnesium Chloride, 
1mM dithiothreitol) at a final volume 25 µL.  Exact concentrations were calculated using 
NEB BioCalculator (http://nebiocalculator.neb.com/#!/). Reactions were incubated at 16°C 
overnight and heat inactivated at 65°C for 30 min.  Plasmids were dialysed into dH2O using 
0.025 µm millipore filters (Millipore Corporation) for 1 h before transformation.  
2.4.5 DNA Analysis by Agarose Gel Electrophoresis 
Electrophoresis for the visualisation of DNA samples was performed using 1% agarose 
gels (Sigma-Aldrich) in 1x TAE buffer.  SyberSafe (Invitrogen) was added at a 1x 
58 
 
concentration. to allow for visualisation of DNA fragments.  Prior to loading on to the gel, 
6x loading dye (NEB) were added to DNA samples.  For estimation of fragment size an 
appropriate ladder (NEB) containing 6x loading dye was included into each run.  Gels were 
run at 100 V until appropriate migration of loading dye was observed.  Visualisation of 
PCR products and image capture was carried out on Gel Doc XR system (BioRad). 
2.4.6 DNA Purification from Agarose Gels 
DNA fragments were extracted from agarose gels using a scalpel and purified using the 
Sigma Gel Extraction Kit according to the manufactures instructions.  Final elution of 
fragments was into 50 µL molecular grade water (Thermo Scientific) at 50°C. 
2.4.7 Cleaning of PCR product 
PCR products were purified using the Sigma PCR Clean-up Kit according to the 
manufactures instructions.  Final elution of fragments was into 50 µL molecular grade 
water (Thermo Scientific) at 50°C. 
2.4.8 DNA Quantification 
DNA was quantified either by micro spectrophotometry measuring absorbance at 260nm 
using the NanoDrop 2000 (Thermo Scientific) or by fluorometric quantification using the 
Qubit with the Qubit deDNA HS Assay Kit (Life Technologies).  
2.5 Cloning 
2.5.1 Preparation of Electro-competent E. coli 
A 1:100 dilution of fresh overnight E. coli cells were added to 200 mL pre-warmed (37°C) 
LB broth.  Seed cultures were grown at 37°C with 200 rpm shaking until mid-log phase 
(OD600 0.5 – 1.0).  Cells were then harvested by centrifugation at 4°C for 15 min at 4000 x 
g after cooling on ice for 30 min.  Pellets were resuspended in 60 mL ice cold dH2O and 
cells harvested as before.  Pellets were resuspended in 10 mL 10% glycerol and harvested 
59 
 
as before.  The final pellet was resuspended in 500 µL 10% glycerol, aliquot into 50 µL 
volumes and stored at -80°C. 
2.5.2 Transformation of Bacteria via Electroporation 
Electro-competent E. coli cells were thawed on ice before the addition of 1 – 10 ng plasmid 
DNA.  Transformation of plasmid DNA was performed using a Bio Rad MicroPulser using 
a 0.2 cm electroporation cuvette, 2.5 kV voltage, 25 µF capacitance and 200 Ω resistance.  
After which 300 µL SOC medium (Sigma Aldrich) was added to the cuvette and the content 
aliquoted to a fresh Eppendorf tube and incubated at 37°C for 1 h at 200 rpm.  The resulting 
mixture was then plated onto LB agar containing appropriate antibiotics. 
2.5.3 Conjugation of Plasmid DNA into C. difficile 
Conjugation of plasmid DNA into C. difficile was performed as previously described112.  
Briefly, 1 mL stationary phase donor cells were centrifuged at 4000 x g and pellets washed 
in PBS to remove trace antibiotics.  Centrifugation of donor cells was repeated and resulting 
pellets were transferred to the ANO2 chamber and resuspended in 200 µL of recipient cells 
taken from an overnight culture.  The resulting mixture was inoculated onto BHIS agar in 
discrete spots and incubated at 37°C.  For conjugation into C. difficile 630 suspensions 
were incubated for 4 – 8 h and for conjugation into C. difficile R20291 and VPI 10463 
suspensions were incubated for a minimum of 18 h.  Mating mixtures were then harvested 
into 500 µL PBS and inoculated onto BHIS agar containing antibiotics appropriate to 
counter select the donor strain.  Resulting transconjugants were visible and ready for 
purification after 48 – 72 h.  To calculate conjugation efficiency, the following calculation 
was applied: 
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑟𝑎𝑛𝑠𝑐𝑜𝑛𝑗𝑢𝑔𝑎𝑛𝑡𝑠




2.6 Genetic Manipulation of Chromosomal DNA 
2.6.1 ClosTron Knock-Out Mutagenesis 
Plasmids for the insertional inactivation of specific genes were designed using the Perutka 
method available free of charge at http://www.clostron.com96.  Plasmids were constructed 
by DNA2.0.  Plasmids were conjugated into recipient C. difficile strains as described above.  
Transconjugants selected for using BHIS agar containing cycloserine, cefoxitin and 
thiamphenicol were restreaked to purity on the same media.  After which, pure isolates 
were inoculated onto BHIS agar containing cycloserine, cefoxitin and lincomycin to select 
for clones that have undergone splicing of the group I intron from the RAM to leave the 
functional ermB gene.  Lincomycin resistant colonies were restreaked to purity and 
screened for correct insertion using EBS universal primer and a primer designed to flank 
the insertion site (Table 2-3).  PCR products were also sequenced using the EBS universal 
primer to verify intron insertion to the correct location.  Single intron insertion was 
confirmed by Southern blot using primers EBS2 and Intron SalI-R1 (Table 2-3) for probe 
synthesis.   
2.6.2 Allelic Exchange using CodA as a Negative Selection Marker 
Allelic exchange was performed as previously described80 with slight modifications.  
Exchange cassettes flanked by restriction sites XhoI and SacI were constructed by Biomatik 
and provided on pBMH vectors (Table 2-3).  Before cloning, exchange cassettes were 
amplified using universal M13 primers (Table 2-3) and resulting PCR products were cloned 
into pMTLSC7215 or pMTLSC7315 using XhoI and SacI for C. difficile R20291 and C. 
difficile VPI 10463 or C. difficile 630 respectively.  Resultant plasmids were stored in E. 
coli TOP10 and sequence verified using primers M13_F and CodA_Seq_F (Table 2-3).  
After re-transformation into E. coli CA434, resulting codA plasmids and a vector only 
control (i.e. pMTLSC7215 or pMTLSC7315) were conjugated into donor strains as 
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described above.  Transconjugants were selected for using BHIS agar containing 
cycloserine, cefoxitin and thiamphenicol.  Resulting transconjugants were restreaked onto 
the same media and faster growing single colonies were selected as potential single 
crossovers and restreaked to purity.  Single crossover events were screened for using a 
flanking chromosomal primer and a plasmid specific primer (Table 2-3) for each homology 
arm.  Confirmed single crossover clones were then streaked on the non-selective medium 
(i.e. BHIS) and allowed to grow for up to four days.  After which colonies were harvested 
into 500 µL PBS, serially diluted (1x10-1 to 1x10-5) and plated onto C. difficile minimal 
media containing 5-fluorocytosine and allowed to incubate for 48h.  Well defined single 
colonies were then patch plated onto BHIS agar and BHIS agar containing thiamphenicol.  
Colonies that were thiamphenicol sensitive were restreaked onto BHIS agar and then 
screened by chromosome flanking PCR to identify double crossover mutants.  Confirmed 
clones were then stored as described above. 
2.6.3 Random Mutagenesis using mariner-Transposon 
Random mutagenesis was performed as previously described97 with slight modifications.  
Plasmids pMTL-SC0 and pMTL-SC1 (Table 2-2) were transformed into E. coli Top10 and 
conjugated in to C. difficile RS-7 (Table 2-1) as described above.  Transconjugants were 
selected for on BHIS agar containing cycloserine, cefoxitin and lincomycin.  
Transconjugant colonies were then restreaked onto TY agar containing cycloserine, 
cefoxitin and lincomycin.  After five days incubation, growth was harvested into BHIS 
10% glycerol until further use, this creates passage zero. Transconjugant stocks were 
cultured onto TY agar containing cycloserine, cefoxitin and lincomycin, one replicate for 
the pMTL-SC0 control and five replicates for the pMTL-SC1 transposons.  After overnight 
incubation, growth was harvested in to 1 mL PBS and 10-fold serial dilutions to 10-8 were 
made.  Subsequently 100 µL of each dilution was plated onto BHIS agar containing 
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cycloserine, cefoxitin and thiamphenicol, to select for transposon mutants and count mutant 
CFU, and 3 x 20 µL spots were inoculated onto ¼ BHIS agar for calculation of total CFU.  
To allow for the frequency of transposition to be calculated, total CFU and mutant CFU 
were enumerated at a dilution where approximately 50 and 100 colonies were present 





To ensure mutant diversity three passages of this procedure was performed.  For creation 
of the next passage, colonies were harvested from the dilution plate below to the one used 
for the mutant CFU calculation and stored in BHIS 10% glycerol.   
To confirm mutant diversity, 10 mutant colonies were taken from the dilution plate used to 
calculate mutant CFU and restreaked onto BHIS agar containing cycloserine, cefoxitin and 
thiamphenicol.  DNA extractions were performed on resultant cultures.  Inverse PCR was 
performed as described above to determine if double insertions were present that had 
occurred during transposition.  Once all passages had been screened the most diverse 
mutant pool was selected by discerning the passage with a high transposition frequency 
with a low double insertion rate. 
Toxin phenotypes were screened for using a plate lichenase reaction, 100 µL of stock 
mutant library was inoculated onto BHIS agar containing cycloserine, cefoxitin and 
lincomycin and incubated for 24 h.  Colonies were then patch plated twice onto TY agar 
containing 0.2% lichenan, one for analysis at 24 h and one for 48 h.  Plates were stained 
with 0.2% Congo Red (Sigma-Aldrich) solution and zones of clearance were examined.  
Interesting phenotypes were categorised as larger, smaller or no zone of clearance and 
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colonies were re-streaked onto BHIS agar containing cycloserine, cefoxitin and 
thiamphenicol for phenotype and PCR conformation.  Phenotypes were confirmed by 
inoculating 20 µL volumes of overnight culture onto TY agar containing 0.2% lichenan 
and analysed as per the screening method.  To verify the location of the transposition in 
interesting phenotypes, inverse PCR was performed as described above.  Purified gel 
extracts were sequenced with primer catP-INV-R2 (Table 2-3).  Single insertions were 
confirmed by Southern blot using catP-F1 and catP-R1 primers (Table 2-3) for probe 
synthesis.  Toxin phenotype analysis was confirmed in the wild type by using the ClosTron 
group two intron gene knockout system. 
2.6.4 Southern Blot 
To generate a Southern Blot probe a digoxigenin-dUTP randomly labelled DNA product 
was produced using DIG-high prime (Sigma-Aldrich) and a standard Phusion PCR.  In this 
work probes to detect ermB insertion of ClosTron mutants were created using EBS2 and 
Sa1I-R1 primers and probes to detect catP insertion of the mariner-transposon were created 
using CatP_F1/R1 (Table 2-3).  The probe was labelled by denaturing DNA (ca. 1 ug) at 
100°C and snap freezing on ice before adding 4 µL DIG-High Prime and incubating 
overnight at 4°C.  The reaction is halted using 2 µL 0.2M EDTA and heating to 65°C or 10 
min.  The ladder probe is created using the same method except 1 µL λ DNA/HindIII 
marker (Promega) and 14 µL H2O is used as a template. 
DNA was isolated using phenol-chloroform extraction and quality checked on 1% (w/v) 
gel.  Genomic and plasmid DNA at 2µg was digested with HindIII and/or EcoRI overnight 
in separate reactions. Control plasmids for each experiment were pMTL007C-E2 
(ClosTron) or pMTL-SC1 (mariner-transposon).  Digested DNA checked on 0.8% agarose 
gel prior to blotting procedures. 
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DNA transfer on to the Nitrocellulose membrane was achieved by laying blotting paper 
into 0.4M NaOH to create a wick.  The gel was positioned on top of the wick followed by 
the Nitrocellulose membrane.  This was followed by several blotting pads the first being 
pre-wet in 0.4M NaOH.  To aid in the transfer a weight (ca. 500 g) was placed on top the 
blotting paper and was left for at least 3 h. 
The nitrocellulose membrane is UV fixed for 2 min on each side and then washed in 2x 
SSC to remove excess 0.2M NaOH.  The membrane was then placed into a hybridisation 
tube (DNA side in), 10 mL reconstituted DIG-Easy Hyb (Sigma-Aldrich) was added and 
incubated at 42°C for 1 h.  Probes were prepared by boiling 20 µL labelled probe and 10 
mL DIG-Easy Hyb for 10 min then snap freezing on ice to prevent reversion of ssDNA to 
dsDNA.  The probe mixture was incubated on the membrane overnight at 42°C.  Following 
this a number of washes were performed, 2x low stringency washes using 100 mL 2x wash 
solution for 5 min at room temperature then 2x high stringency washes using 100 mL 0.5x 
wash solution for 15 min at 68°C.  The membrane was then equilibrated using 100 mL 
Maleic acid buffer-T for 1 min at room temperature followed by a blocking step using 25 
mL 1x blocking buffer for 30 min at room temperature.  The membrane was then probed 
using Anti-DIG Ab (Sigma-Aldrich) diluted 1:10,000 in 1x blocking solution (3 µL in 30 
mL) by incubation for 30 min at room temperature.  This was followed by 2x washed suing 
100 mL Maleic acid buffer-T for 15 min at room temperature and then membrane 
equilibration in 25 mL 1x detection buffer for 2 min at room temperature. 
To develop the Southern blot the membrane was placed onto an acetate sheet. 1.5 mL CDSP 
(Sigma-Aldrich) was pipetted directly on to the membrane and then a second acetate sheet 
placed on top.  The edges sealed and then the membrane incubated at 37°C for 10 min to 
enhance enzyme reaction.  The membrane was then transferred to the dark room for 
developing into photo film. 
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2.6.5 Complementation and overexpression plasmids. 
Promoters were predicted for complementation plasmids using BPROM113 if unknown.  
Cassettes were amplified using wildtype genomic DNA from the parental strain utilising 
primers that added flanking restriction sites, NotI and XhoI for complementation and EcoRI 
and XhoI for overexpression.  Complementation plasmids cassettes were cloned directly 
into the lacZα multiple cloning site of pMTL84151.  Over expression plasmids were also 
cloned directly into the lacZα multiple cloning site but upstream of the Pthl of pMTL84152. 
2.7 DNA sequencing and Analysis Techniques 
2.7.1 DNA Sequencing 
DNA Sanger sequencing was performed by Source Bioscience, Nottingham, UK. 
2.7.2 Illumina MiSeq and Single Molecule, Real-Time (SMRT) sequencing 
High quality DNA at 10µg was prepared by phenol/chloroform extraction with an 
additional RNAse step.  For Illumina MiSeq, DNA was sent to either the University of 
Nottingham DeepSeq facility, Dr. Alan McNally at Nottingham Trent University or 
MicrobesNG Facility at University of Birmingham for library preparation and sequencing.  
For SMRT sequencing DNA was sent to McGill University and Genome Québec, Canada. 
2.7.3 Bioinformatics 
General Sequence Analysis 
Sanger sequence data were analysed using GENtle (Last accessed: 11 November 2017  
http://gentle.magnusmanske.de/) and Basic Local Alignment Search Tool (BLAST) (Last 
accessed: 13 August 2017 http://www.ncbi.nlm.nih.gov).  Multiple sequence alignments 
were performed using Clustal Omega (Last accessed: 12 March 2017 
http://www.ebi.ac.uk/Tools/msa/clustalo/).  Protein analysis was performed using InterPro 
(Last accessed: 27 March 2017 http://www.ebi.ac.uk/interpro/) and predicted interactions 
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by String (Last accessed: 27 March 2017 http://string-db.org/). Protein amino acid 
variations and their effects on biological function were predicted using PROVEAN (Last 
accessed: 27 March 2017 http://provean.jcvi.org/).  Prophage regions within genomes were 
identified using PHASTER (Phage Search Tool Enhanced Release)114.  Whole genome 
browsing and annotation were performed using Artemis115. 
VPI 10463 Genome Map Assembly 
Illumina MiSeq reads obtained for the VPI 10463 genome were trimmed using Scythe 
(https://github.com/vsbuffalo/scythe) and quality trimmed using Sickle 
(https://github.com/najoshi/sickle) by DeepSeq, University of Nottingham.  PacBio RSII 
sequencing reads were corrected using proovread116, a hybrid correction pipeline and were 
assembled using Canu by DeepSeq.  Mapping to the VPI 10463 genome sequence was 
performed using the Burrows-Wheeler Aligner (BWA)117 version 0.7.17 using standard 
settings and the PacBio index flag.  Output files were then sorted and indexed using 
SamTools118 version 1.5.  Visualisation of BAM files was performed using CLC genomics 
workbench version 8.5.3 using standard settings.  Annotation of the VPI 10463 genome 
were performed by the Joint Genomes Institute Integrated Microbial Genomes Pipeline 
(Last accessed: 18 September 2017 http://jgi.doe.gov/). Restriction site generation was 
performed using SiteFind119.  Appendix Three provides all code performed by the user. 
De novo assembly of clinical C. difficile strains 
De novo assembly and mapping reads to reference of Illumina short reads were perfumed 
using CLC genomics workbench V8.5.3 using standard settings.  Contigs were rearranged 
using progressiveMauve120 with strains 630 and R20291 as templates.  Rapid annotation 
followed using Subsystem Technology (RAST)121 and the Seed122.  Fixed Ploidy Variant 
Detection was performed using CLC genomics workbench V8.5.3 using settings described 
67 
 
in Appendix Two.  Genome comparisons were performed using either progressiveMauve120 
or Artemis Comparison Tool (ACT)123.   
Whole genome sequences used in this study; CD630 (AM180355), R20291 (FN545816) 
and M120 (FN665653).  Statistical analysis was performed using GraphPad Prism V6.  
2.8 Characterisation of Clostridium difficile. 
2.8.1 Growth curve analysis 
Cell growth was recorded over a 48 h time period, starting from a lag growth phase after 
culture in TY broth.  This was achieved by culturing glycerol strain stocks on to BHIS agar 
supplemented with cefoxitin and cycloserine.  Three colonies where picked into 1 mL TY 
broth and incubated for 8h.  For all experiments individual 1 mL starter cultures were used 
to ensure biological replicates rather than technical replicates.  In fresh TY broth, serial 
dilutions (10-1 to 10-8) were made and incubated for 16h.  The most dilute inoculum, with 
visible growth, was then used for the start of the assay and diluted 1 in 100 in TY broth.  
Optical density (OD600) or CFU was then measured at 0, 3, 6, 9, 12, 24 and 48h.  To count 
CFU, cell suspensions were serially diluted and plated onto BHIS agar, allowed to incubate 
for 24 h before enumeration.  
2.8.2 Toxin ELISA 
Toxin supernatants were collected during growth curve analysis at points 0, 3, 6, 9, 12, 24 
and 48h.   Supernatants of 1 mL were centrifuged at 12,000 x g for 1 min, filter sterilised 
(0.2µm pore size) and stored at -20°C until required but for no longer than a month.  Toxin 
levels were measured using C. difficile TOX A/B II ELISA (TechLab) as recommended by 
the manufacturer, using a toxin A/B standard.  Clostridium difficile toxin A and B standards 
(The Native Antigen Company) were used at a starting concentration 125 ng/mL and 
serially diluted 1:2 until a concentration of 1.95 ng/mL was reached. 
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2.8.3 Cell culture and toxin neutralisation 
Each well of a 96-well microtiter plate was seeded with 100 µL of Vero (African green 
monkey kidney) cell suspension at a density 2 x 105 cells/mL to create a cell monolayer.  
The cell culture media, Dulbecco’s modified Eagles medium (DMEM), contained 1% 
streptomycin/penicillin (vol/vol) and 10% fetal calf serum (vol/vol).  To allow the creation 
of monolayers, cells were incubated at 37°C 5% CO2 for 48h.  To the cell monolayer 20 
µL of toxin supernatant was added, if required serial dilutions were made in PBS. Cultures 
were then incubated for 24 h (37°C 5% CO2) before examination by phase contrast 
microscopy (Nickon Eclipse TS100).  End point titre was expressed as “1/toxin endpoint 
titre” due to the inverse relationship between the endpoint titre and the amount of toxin in 
a sample. This was defined as the first dilution in the succession where cell morphology 
could not be differentiated from the negative controls.  Toxin neutralisation assays were 
performed on 96-well microtiter that were identical to the cell culture assay using C. 
difficile Tox-B Test (TechLab).  Cells showing no toxic effect should be identical to the 
negative controls.  Pure toxin B and the control provided in the C. difficile Tox-B Test kit 
were used as positive and/or negative controls depending on which assay was being 
performed. 
2.8.4 Quantitative Lichenase assay 
Lichenase activity was assessed through the incubation of the supernatant with a substrate 
containing a known concentration of lichenan for a set period of time.  Cell growth was 
recorded over a 48 h time period, starting from a lag growth phase after culture in TY broth.  
This was achieved by culturing glycerol strain stocks on to BHIS agar supplemented with 
cefoxitin and cycloserine.  Three colonies where picked into 1 mL TY broth and incubated 
for 8h.  For all experiments individual 1 mL starter cultures were used to ensure biological 
replicates rather than technical replicates.  In fresh TY broth, serial dilutions (10-1 to 10-8) 
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were made and incubated for 16h.  The most dilute inoculum, with visible growth, was then 
used for the start of the assay and diluted 1 in 100 in TY broth.  Lichenase supernatants 
were collected at points 0, 3, 6, 9, 12, 24 and 48h.   Supernatants of 1.5 mL were centrifuged 
at 6,000 x g for 1 min and stored at -20°C until required.  To start the assay, 300 µL of 
supernatant was added to an Eppendorf containing 200 µL of TY with 0.1% lichenan. A 
control of 300 µL of TY was added to an Eppendorf containing 200 µL of TY + 0.1% 
lichenan.  Test and controls were incubated at 50°C for 40 min.  Reactions were halted by 
addition of 100 µL of 0.2M Sodium carbonate.   After which 50 µL of 0.1% (w:v) Congo 
red solution was added to each reaction, tubes were inverted several times, and then add 
200 µL of 2M NaCl, to stabilise the colour.  Absorbance reading at 530nm (using 500 µL 
TY broth, 100 µL 0.2M Sodium carbonate, 50 µL Congo red solution, 200 µL 2M NaCl as 
a blank).   
2.8.5 Motility assay 
Motility of strains was assessed using standard BHIS agar plates with 10 mL 0.3% BHIS 
top agar.  Single colonies were stab inoculated into the top agar using a sterile toothpick.  
Plates were incubated for 24 h and zones measured using a bidirectional method.  Averages 
of these measurements were taken as the total distance travelled. 
2.8.6 Transmission Electron Microscopy 
Transmission electron microscopy was performed by Dr. E. Stevenson and Denise Creasy.  
Cells were collected at mid-exponential phase and absorbed onto a Formvar-coated copper 
grid for 5 min, the excess removed with blotting paper. Fixation was achieved using 1% 
glutaraldehyde for 1 min, the grid was then washed three times with sterile distilled water.  
Cells were negatively stained with Uranyl Acetate for 30 s and then allowed to air dry.  A 
JOEL JEM1010 transmission electron microscope was used for the visualisation of cells 
operating at 80kV. 
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2.9 Clinical Isolation of Clostridium difficile 
2.9.1 Isolation of Clostridium difficile from stool samples 
For each patient sample three CCEY agar plates were reduced in anaerobic conditions for 
a minimum of four hours.  Stool samples were homogenised 1:1 with PBS and then heat 
shocked at 80°C for 15 mins, after which samples were centrifuged for five mins at 1500 x 
g.  Samples were transferred to the anaerobic chamber where 50 µL of supernatant was 
inoculated on to CCEY in triplicate; plates were incubated for 48 h.  Individual colonies 
that have the appearance of C. difficile were picked by toothpick and inoculated into a 96 
microtiter plate containing 200 µL BHIS broth, one per well and up to 20 per patient 
sample.  Microtiter plates were sealed with breathable sterile film and incubated overnight 
in anaerobic conditions.  A separate 96 well microtiter plate contained 180 µL PCR grade 
H2O where a 1:10 dilution was made from the overnight broth cultures.  A drop of glycerol 
was then added to the broth cultures and resealed using fresh breathable sterile film and 
stored at -80°C.  The H2O culture mix was also covered in breathable sterile film and stored 
at -20°C to be used later as a PCR template. 
2.9.2 Ribotyping 
Ribotyping of the clinical isolates were adapted from O’Neil et al124. and Walk et al.125 The 
PCR template created in 2.10.1 was DNA extracted by heating at 95°C for 20 min after 
initially being defrosted.  The PCR process was completed as in 124 and products were 
visualised using a Qiaexcel (Qiagen) using the Qiaexcel DNA High Resolution Kit.  Bands 
were inspected by eye and one example of each banding pattern per sample was stored for 





2.9.3 Antibiotic Minimum Inhibitory Concentration (MIC) Assay 
MIC were determined by Minimum Inhibitory Concentration Evaluator (MICE) strips as 
described by Baubet et al.126 with slight modifications.  Colonies of C. difficile were 
resuspended in PBS to a McFarland standard of 1.  Cultures were swabbed onto Wilkins – 
Chalgren Anaerobe Agar with 5% horse blood in three directions and air dried for 15 min.  
MICE strips of Vancomycin and Metronidazole were applied and incubated for 24h in 
anaerobic conditions.  MICs were determined to be where the zone of complete inhibition 
intercepted with the scale.  CD630 was used as a control with each batch tested.  
Intermediate or resistant MICs were repeated twice more for confirmation. 
2.10 Statistical Analysis 
All data and statistical analysis were carried out using GraphPad Prism version 7.03 or 
lower.  Individual comparisons were analysed using two tailed students T-test to determine 
if Group A has a statistically higher or lower value than Group B, a p value of <0.05 was 
deemed statistically significant result.  Clinical data was analysed using Fishers exact test 
due to low sample numbers, a p value of <0.05 was deemed statistically significant result.  
2.11 Ethics 
The C. difficile isolation study in which the hamster faeces was collected was performed in 
strict accordance with the recommendations in the United Kingdom’s Home Office 
Animals (Scientific Procedures) Act of 1986 which outlines the regulation of the use of 
laboratory animals for the use of animals in scientific procedures.  Colleagues within the 
Synthetic Biology Research Group gathered faeces from uninfected hamsters. 
Clostridium difficile isolates and clinical information was collected as part of a University 
of Nottingham Hospitals NHS Trust Service Improvement Project.  Stool samples and 
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anonymised clinical information from patients with CDI were provided by clinicians in the 



















3.1.1 TcdR and its homologues 
As briefly described in 1.2.2 TcdR, is a 22kDa protein that contains a C-terminal helix-
turn-helix DNA-binding motif75.  Moncrief et al.127 first presented evidence that TcdR had 
a role in TcdA and TcdB regulation by activating tcdA and tcdB reporter fusions through 
expression of tcdR, in trans, in E. coli.  Later Mani et al.75,128 in two separate studies 
demonstrated similar findings in C. perfringens (as a surrogate host) and C. difficile.  
Furthermore, they were able to show biochemical and genetic evidence that TcdR acts as 
an σ-factor directing the RNA polymerase (RNAP) to the tcdA and tcdB promoters by 
binding directly to the RNAP core128.  Although, the tcdA and tcdB promoters show 
similarity to each other, they do not resemble traditional σ70 promoter sites found in 
prokaryotes104.  Additionally, TcdR is able to activate its own expression, consistent with 
the presence of two prospective TcdR-dependent promoters upstream of tcdR75. 
Due to a high degree of similarity of structure and function of TcdR and other σ-factors 
found in pathogenic Clostridia that regulate toxin expression, they have been assigned their 
own group, group V, of the σ70- family129.  The other σ-factors include TcsR of C. sordelli 
which transcribes both the lethal and haemorrhagic toxins130, TetR that transcribes tetanus 
neurotoxin131, BotR that transcribes botulinum neurotoxin131, and the UviA and TpeR of 
C. perfringens which transcribe a bacteriocin and a cytotoxin, respectively132.  These σ-
factors share such similarity they are able to be interchanged and still function129,130.  In 
comparison with TcdR the other σ-factors are auto-regulated and are induced by 





3.1.2 PaLoc gene expression and regulation. 
Nutritional signals play a role in the control of toxin expression including carbon sources 
and some amino acids.  In complex medium the addition of glucose or other rapidly 
metabolisable carbon sources inhibit toxin production104,135,136.  The effect of glucose on 
toxin regulation has been demonstrated in multiple C. difficile strains and shown to occur 
at the transcriptional level suggesting a general mechanism75,104.  Since the majority of 
carbon sources that inhibit toxin expression are transported into the cell via the 
phosphoenolpyruvate-dependent carbohydrate phosphotransferase system (PTS), it can be 
inferred that carbon catabolite repression (CCR) is involved in toxin gene expression104.  
When more than one carbon source, such as glucose, is available to the cell, CCR promotes 
the use of this preferred resource.  The requirements of both PTS and CcpA for toxin 
suppression have been demonstrated using C. difficile mutants deficient in these systems137.  
CcpA regulates fermentation, sugar uptake and amino acid metabolism; glucose dependent 
repression of toxin production occurs by direct binding of CcpA to the promoter regions of 
tcdR, tcdA, tcdB and tcdC138.  It appears that glucose availability and toxin synthesis are 
controlled by a complex regulatory network where CcpA plays a central role and interacts 
with other regulators such as CodY138.   
CodY is a global transcriptional regulator that is involved in the adaptive response to 
nutrient concentrations in the environment139.  Repression of all the PaLoc genes has been 
demonstrated when nutrients are plentiful139.  In Bacillus subtilis CodY binds to co-factors, 
branched-chain amino acids and GTP, which increases its affinity for its binding 
targets140,141, reinforcing the link between toxin suppression and nutrient / co-factor 
availability.  Consequently, when nutrients and co-factors are limited CodY no longer 
represses genes associated with bacterial adaptation to starvation.  In a generated codY 
mutant strain, higher levels of toxin were produced during exponential phase when 
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compared to the wild type strain.  Derepression of PaLoc genes was also observed in that 
mutant strain139.  CodY was found to bind directly to the tcdR promoter region139 and it has 
been shown to control more than 140 different genes142.   
When added to culture media, proline and glycine have been shown to have an inhibitory 
effect on toxin synthesis136.  The PrdR regulator responds to the addition of proline, 
represses toxin gene expression, glycine-reductase and activates the expression of proline-
reductase.  The latter are both enzymes involved in Stickland metabolism, a chemical 
reaction that requires the coupled oxidation and reduction of amino acids to organic 
acids143.  Cysteine is also reported to have an inhibitory effect on toxin synthesis144. 
σ-factors other than TcdR have been implicated in toxin regulation.  A sigH mutant, for 
instance, resulted in the over expression of tcdA, tcdB and tcdR145. No SigH promoters have 
been located upstream of any of the PaLoc genes suggesting that there is an indirect 
mechanism of toxin repression145.  The sigH mutant could not sporulate, but could still 
produce toxins.   This implies there is no link between these two events, which is further 
validated by there being no transcriptional control via four other sporulation specific σ-
factors (SigE, SigF, SigG and SigK)146.  However, there has been evidence of strain specific 
toxin regulation by Spo0A the master regulator of sporulation.  Inactivation of spo0A in 
some RT027 strains resulted in suppressed toxin expression147,148, conflicting results were 
found for 630∆erm147–151 and marginal to no effect on RT078 strains147.  Again, no Spo0A 
promoters have been identified within the PaLoc suggesting an indirect mechanism.  This 
area requires further investigation to identify the regulators that are under the control of 
both SigH and / or Spo0A145,149.  RstA is an additional regulator that has a negative effect 




Evidence has been presented indicating that both intra- and inter-species quorum sensing 
has an effect on toxin synthesis.  All sequenced strains of C. difficile to date have an 
incomplete agr-locus that contains agrBD, together these genes produce and export the 
autoinducing peptides (AIP)153,154.  A full agr-locus (agrACBD) has been described in 
strain R20291 and other clinical strains and the two loci have been termed Agr1 and Agr2 
respectively154,155.  An agrA mutant in R20291 demonstrated diminished toxin production 
and was less able to colonise mice during infection153,156.  Suggesting that the Agr2 system 
has a role in toxin production for lineages where it is present.  Similarly, the peptide 
produced by the Agr1 system has been shown to induce toxin synthesis156.  A second class 
of quorum sensing molecules, autoinducer-2 (AI-2) is present in several bacterial species 
and its synthesis is dependent on the LuxS enzyme157,158.  C. difficile has a quorum sensing 
system that can detect this molecule and when added to culture medium during early-log 
phase tcdA, tcdB and tcdE are upregulated157 but not during stationary phase158. 
Cyclic di-guanosyl-5’monophosphate (c-di-GMP) is a signalling molecule in second 
messenger bacterial systems that control flagella motility159.  High levels of c-di-GMP were 
shown to repress tcdA, tcdB, tcdR and sigD159.  Further to this, tcdA, tcdB and tcdR 
transcripts were reduced in a sigD mutant160.  In the same study it was established that SigD 
directs the RNAP core enzyme to the tcdR promoter but not the tcdA or tcdB promoters.  
These data suggest that c-di-GMP has an indirect effect on toxin synthesis through SigD. 
The flagellar proteins FliC and FliD (the flagellin and capping protein respectively) also 
have an effect on toxin production.  Increased expression of all PaLoc genes except tcdC 
was described in a fliC mutant in 630∆erm161 and then in a later study tcdA transcripts were 
shown to be increased in both fliC and fliD mutants162.  These data have been confirmed in 
cell culture and in some in vivo studies163.  However, in a CD0240 mutant, a gene involved 
in the glycosylation of the flagellum, toxin levels were not significantly altered161.  This 
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mutation resulted in a non-motile phenotype but unglycosylated FliC subunits were still 
expressed on the cell surface164 suggesting it is the loss of flagellin rather than a non-
functional flagellum that affects toxin production165.  In R20291 there was no difference in 
the cytotoxicity between the fliC and fliD mutants and wild-type162.  This could be 
attributed to the differences in R20291 strains as described in Appendix One. The described 
study was performed in NM-R20291 which only produces a single flagellum when 
compared to BW-R20291 which is peritrichously flagellated as is 630.  Identical studies in 
BW-R20291 may reveal different results. 
Bacteriophages have been identified in a number of different C. difficile genomes166. 
Lysogens derived from isolates after infection with phage ΦCD119 and ΦCD27 
demonstrated a repressed toxin expression when compared to the parental strains167,168.  
Conversely, lysogenisation of a RT027 strain by ΦCD38-2 resulted in an increased toxin 
synthesis phenotype with toxin titres higher in culture supernatants, but not the cytosol 
when compared to the wild-type strain169.  This has been attributed to an increased 
expression of all PaLoc genes; however the expression of tcdE was much stronger. The 
mechanism behind this is as yet unknown169.  In another study tcdE-like genes were 
identified in C. difficile strains containing the prophages ΦC2, ΦC6 and ΦC8170.  Increased 
toxin titres were observed in some of these lysogens even though gene expression was 
not170. The mechanism behind this was not identified in the study, but may be attributed to 
the presence of the tcdE-like genes. 
LexA is the SOS response master regulator involved in DNA repair. A lexA mutant was 
found to produce more TcdA in the presence of sub-inhibitory concentrations of 
levofloxacin171.  Similarly, an mfd (transcription-repair coupling factor) mutant also 
increased toxin expression at the transcriptional level172. 
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3.1.3 The use of transposon libraries to identify novel TcdA and TcdB regulators. 
Using reverse genetics to fully understand the complex mechanisms of PaLoc gene 
expression would be difficult, time consuming and expensive.  Another method is to create 
random mutant libraries using transposable elements and then to screen for altered 
phenotypes.  The use of random mutagenesis has been described in C. difficile to find 
regulators of sporulation and / or auxotrophs97.  We aimed to use this system with some 
modification to identify altered toxin phenotypes. However, traditional methods for 
measuring toxin titres i.e. ELISA and / or cell culture are laborious and relatively expensive.  
To overcome this, a reporter strain (RS-7) was constructed which substituted tcdB in NM-
R20291 with the lichenase gene licB of Clostridium thermocellum (Dr. S. Cartman 
unpublished).   Lichenase hydrolyses the (1-4) bond after a (1-3) bond of ß-(1-3)(1-4)-
glucans (lichenan) and shows high specificity for this substrate173,174.  Congo red 
preferentially binds to contiguous polysaccharides containing both ß-(1-3)-glucans and ß-
(1-4)-glucans, but if the lichenase has depolymerised the polysaccharide this binding does 
not occur and no colour change is observed173,174.  Therefore, when media containing 
lichenan (and no other reducing sugars) is stained with 0.2% Congo Red solution, the media 
will acquire a deep red colouration unless the lichenan has been degraded by lichenase.  As 
the lichenase is excreted out of the cell and into the media a zone of clearance around 
discrete colonies is identifiable after straining, resulting in BI-7 producing a phenotype that 
is rapidly and economically identifiable. 
3.1.4 Aims  
• Use a TcdR null mutant in NM-R20291 to assess its role in toxin synthesis. 
• Identify and characterise novel toxin regulators using a random transposon mutant 





3.2.1 The functional inactivation of tcdR in strain NM-R20291 
To further understand the role of TcdR in regards to the regulation of tcdA and tcdB two 
isogenic strains, NM-R20291::∆tcdR and NM-R20291::tcdR(EcoR1), were constructed via 
allelic exchange utilising codA as a negative selection marker80 (strains created by Dr. S 
Cartman & Ms. M Kelly).  NM-R20291::∆tcdR was constructed using two homology arms 
at ~500bp directed either side of tcdR which also incorporated the first 9bp and last 9bp of 
tcdR in the left homology arm and right homology arm respectively.  This resulted in a 
537bp in-frame deletion in tcdR of NM-R20291 (Figure 3-1A) and a deletion of codons 4 
through 181 of TcdR.  NM-R20291::tcdR(EcoR1) was constructed by complementing the 
NM-R20291::∆tcdR strain with a tcdR sequence that had a silent mutation at position 295 
(T to C) which resulted in an EcoR1 restriction site (Figure 3-2).   
Before phenotypic analysis of the isogenic strains was performed, PCR and sequencing was 
used to check the genotype for each strain, resulting in products of 1500bp for NM-R20291 
and NM-R20291::tcdR(EcoR1) and 1000bp for NM-R20291::∆tcdR (Figure 3-1B).  To 
further check the genotype for each strain the PCR products were digested with EcoR1, 
resulting in products of 1500bp for NM-R20291, 1000bp for NM-R20291::∆tcdR and 
750bp for NM-R20291::tcdR(EcoR1) (Figure 3-1C).   
3.2.2 Phenotypic analysis of the NM-R20291 tcdR null mutant. 
To measure the effect of the tcdR genotype on growth and toxin production each strain was 
grown in TY medium and samples taken over a 48h time course in triplicate.  There were 
no measurable differences in growth between the strains (Figure 3-3A).  Toxin supernatants 
were measured by C. difficile Tox A/B II ELISA (TechLab), detection limit 1.0 ng/mL, and 
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toxin concentrations were determined using a standard curve (TcdA & TcdB mixture at 
125 ng/mL – 1.95 ng/mL).   
 
Figure 3-1: PCR analysis of recombinant NM-R20291 strains. (A) Schematic of the tcdR locus 
in wild-type NM-R20291.  The half-arrows indicate annealing regions of primers tcdR-F1 and 
tcdR-R1.  The triangle below the arrow depicting the tcdR ORF indicates the deletion made 
in NM-R20291::∆tcdR.  The approximate location of the EcoR1 site introduced into NM-
R20291::(tcdR[EcoRI]) is shown above the ORF.  (B) PCR analysis was performed with 
primers tcdR-F1 and tcdR-R1.  (C) The subsequent PCR products after EcoR1 digestion.  




Figure 3-2: Nucleotide sequence of tcdR of NM-R20291, NM-R20291::∆tcdR and NM-
R20291::tcdR(EcoR1).  Strain NM-R20291::∆tcdR has a 537bp deletion leaving the first and last 
9bp.  Strain NM-R20291::tcdR(EcoR1) has a complemented sequence with a single nucleotide 
substitution at position 300 (T to C) resulting in a silent mutation and the addition of an EcoR1 
restriction site (highlighted in red). 
 
Toxin production for both NM-R20291 and NM-R20291::tcdR(EcoR1) followed the expected 
temporal pattern.  Accordingly, toxin levels steadily increased throughout the exponential 
growth phase and peaked during the stationary growth phase (Figure 3-3B).  Interestingly, toxin 
production in NM-R20291::∆tcdR also followed the same temporal pattern, although toxin 
production was reduced by an order of 1,000-10,000-fold at 48 h.  Differences in toxin 
production were statistically significant from 12 h by unpaired T test (Figure 3-3B).   
tcdR             ATGCAAAAGTCTTTTTATGAATTAATTGTTTTAGCAAGAAATAACTCAGTAGATGATTTG 60 
tcdR(EcoRI)      ATGCAAAAGTCTTTTTATGAATTAATTGTTTTAGCAAGAAATAACTCAGTAGATGATTTG 60 
ΔtcdR            ATGCAAAAG--------------------------------------------------- 9 
                  
tcdR             CAAGAAATTTTATTTATGTTTAAGCCATTAGTAAAAAAACTTAGTAGAGTTTTACATTAT 120 
tcdR(EcoRI)      CAAGAAATTTTATTTATGTTTAAGCCATTAGTAAAAAAACTTAGTAGAGTTTTACATTAT 120 
ΔtcdR            ------------------------------------------------------------  
 
tcdR             GAAGAGGGAGAAACAGATTTAATAATATTTTTTATTGAATTAATAAAAAATATTAAATTA 180 
tcdR(EcoRI)      GAAGAGGGAGAAACAGATTTAATAATATTTTTTATTGAATTAATAAAAAATATTAAATTA 180 
ΔtcdR            ------------------------------------------------------------ 
 
tcdR             AGTAGCTTTTCAGAAAAAAGCGATGCTATTATAGTCAAATATATTCATAAATCATTACTG 240 
tcdR(EcoRI)      AGTAGCTTTTCAGAAAAAAGCGATGCTATTATAGTCAAATATATTCATAAATCATTACTG 240 
ΔtcdR            ------------------------------------------------------------ 
 
tcdR             AATAAGACTTTTGAGTTGTCTAGAAGATATTCTAAAATGAAGTTTAATTTTGTAGAATTT 300 
tcdR(EcoRI)      AATAAGACTTTTGAGTTGTCTAGAAGATATTCTAAAATGAAGTTTAATTTTGTAGAATTC 300 
ΔtcdR            ------------------------------------------------------------ 
 
tcdR             GATGAAAATATCTTAAATATGAAAAATAATTATCAAAGTAAGTCTGTTTTTGAGGAAGAT 360 
tcdR(EcoRI)      GATGAAAATATCTTAAATATGAAAAATAATTATCAAAGTAAGTCTGTTTTTGAGGAAGAT 360 
ΔtcdR            ------------------------------------------------------------ 
 
tcdR             ATTTGTTTTTTCGAATATATTTTGAAAGAATTATCTGGTATTCAAAGAAAAGTTATTTTT 420 
tcdR(EcoRI)      ATTTGTTTTTTCGAATATATTTTGAAAGAATTATCTGGTATTCAAAGAAAAGTTATTTTT 420 
ΔtcdR            ------------------------------------------------------------ 
 
tcdR             TATAAATATTTAAAAGGATATTCTGATAGAGAAATATCAGTGAAATTAAAAATATCTAGA 480 
tcdR(EcoRI)      TATAAATATTTAAAAGGATATTCTGATAGAGAAATATCAGTGAAATTAAAAATATCTAGA 480 
ΔtcdR            ------------------------------------------------------------ 
 
tcdR             CAAGCTGTTAATAAGGCTAAAAATAGAGCATTTAAAAAAATAAAAAAAGACTATGAAAAT 540 
tcdR(EcoRI)      CAAGCTGTTAATAAGGCTAAAAATAGAGCATTTAAAAAAATAAAAAAAGACTATGAAAAT 540 
ΔtcdR            ------------------------------------------------------------ 
 
tcdR             TATTTTAACTTGTAA 555 
tcdR(EcoRI)      TATTTTAACTTGTAA 555 




Figure 3-3: Cell growth and toxin production by recombinant C. difficile NM-R20291 strains in 
TY medium for 48h. Figure legend; (●) NM-R20291; (∎) NM-R20291::∆tcdR; (▲) NM-
R20291::tcdR(EcoRI). (A) Growth was measured at OD600. (B) Toxin concentration determined 
by C. difficile Tox A/B II ELISA using a standard curve of known Toxin A and B concentrations.  
(C)  Cell culture using Vero cells for Toxin B at 48h.  Data represent the mean ± SEM (n=3).  * 
indicates statistical significance (p = <0.005) by unpaired T-test.  
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To further check the rate of toxin production, cell cytotoxicity assays were performed using 
Vero (African green monkey kidney) cell monolayers.  Vero cells (detection limit 25pg/mL, 
toxin B) were subjected to titrated toxin supernatants taken at 48h.  End-point titre was defined 
when cell morphology was indistinguishable from the negative controls. The cell cytotoxicity 
assay confirmed the results obtained by ELISA at 48h.  Thus, toxin production by the null 
mutant strain NM-R20291::∆tcdR was not eliminated but reduced by 100-1,000 times which 
was observed with both the wild-type NM-R20291 and the complemented NM-
R20291::tcdR(EcoR1) strains (Figure 3-3C).  Toxin neutralisation assays using C. difficile 
Tox-B Test (TechLab) in parallel to the cell cytotoxicity assays were performed to ensure that 
all of the observed cytotoxic effect was specific to the toxin and not due to another artefact.  
All toxin activity was successfully neutralised (data not shown). 
3.2.3 Random Transposon Mutagenesis to Identify Altered Toxin Phenotypes 
As discussed in 3.1.3 random mutagenesis has an advantage over reverse genetic analysis as it 
does not require a hypothesis or target genes of interest that will produce a measurable 
phenotype.  It does require a robust screening method so that multiple mutants can be assessed 
in parallel for altered phenotypes.  To overcome this a reporter strain was created, RS-7, in 
which the tcdB gene has been replaced with licB to allow for rapid phenotype identification 
using a lichenase plate assay. 
3.2.4 Random mutant screening. 
Random mutant libraries were produced using RS-7 as a host as described in 2.6.3 by Miss. B 
Boyle and after screening of passage 0 – 2 via PCR and sequencing it was deemed passage 1 
was the most diverse.  A number of mutants with altered phenotypes were identified using the 




Table 3-1 List of random transposon mutants created in RS-7 that produce an altered phenotype. 
 
*This insertion was later termed BBM4. 
3.2.5 Random mutant BBM4. 
The most notable phenotype seen was in mutant BBM4, which was isolated initially by Miss. 
B Boyle.  Initial phenotype screening using a tooth pick to stab inoculate TY agar containing 
1% lichenan showed no zone of clearance of lichenan at 24 h and a reduced zone of clearance 
at 48 h when compared to RS-7 after staining with Congo red (data not available).  To confirm 
this phenotype 20 µL of overnight culture was inoculated on TY agar containing 1% lichenan 
and cultures were incubated for 24 h and 48 h.  This confirmed the phenotype previously seen 
where there was no zone of clearance of lichenan at 24 h (Figure 3-4A) and a reduced zone of 
clearance at 48 h (Figure 3-4B) when compared to RS-7 after staining with Congo red. To 
locate the insertion site of the transposon inverse PCR was employed, repeated sequencing of 
inverse PCR products after HindIII digestion showed a mixed signal indicating a double 
insertion site.  To confirm the double insertion Southern blot was employed to detect the 
transposon containing the catP gene.  Digestion with HindIII and MfeI in separate reactions 
(Figure 3-5C) showed a single band and a double band respectively.  Estimated band sizes in 
the Southern Blot cannot be calculated due to overloading of ladder and product.   
 
ORF interrupted Assigned function 
R20291_0774 Cell surface protein 
R20291_1065 Putative O-methyltransferase 
R20291_1439 Putative uncharacterised protein 
R20291_0853 ABC transporter 
R20291_1086 Conserved hypothetical protein 
R20291_2848 Putative glycosyl hydrolase 
R20291_2908 putative uncharacterized protein 






SpoIIIJ-associated protein (jag) 




Figure 3-4: Phenotypic screening of transposon mutant BBM4 on TY agar containing 1% 
lichenan.  Zones of clearance visualised by the addition of Congo red after incubation for (A) 24 
h and (B) 48 h.  Figure legend; “BI-7” is the RS-7 control strain and “4” is the BBM4 transposon 
mutant. 
 
To identify the location of the transposons in BBM4 inverse PCR on MfeI digested products 
was performed and sent for Sanger sequencing.  This revealed that the genes of interest were 
located in R20291_2908 at base pair 3,441,942 and in the intergenic spacer region of jag 
(R20291_3537) and oxaA1 (R20291_3538) at base pair 4,189,071.  To confirm the Southern 
blot findings a schematic to identify product length for the insertion at R20291_2908 and the 
jag/oxaA1 region was created by using Artemis.  Using this software restriction sites were 
identified and estimated product lengths calculated for R20291_2908 (Figure 3-5A) and 
jag/oxaA1 (Figure 3-5B).  This identified that the two products from the HindIII digestion 
should be 5380bp and 4333bp for R20291_2908 and jag/oxaA1respectivly.  They are different 
sizes and should be distinguishable on a 0.8% agarose gel.  It has not been investigated further 
as to why this band cannot been seen, however it could be due to a nutation in the restriction 
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site or an annotation error in the sequence map.  This could be investigated by Sanger 
sequencing the region.  The two products from the MfeI digestion should be 3740bp and 
4915bp for R20291_2908 and jag/oxaA1respectivly and can clearly be seen as separate bands 
on the Southern Blot. 
ClosTron plasmids were designed to interrupt the R20291_2908 and R20291_jag.  It was 
decided to target jag rather than oxaA1 as jag is located in the downstream location.  ClosTron 
mutants were created resulting in NM-R20291_2908(ermB) and NM-R20291::jag(ermB) as 
described in 2.6.1. ClosTron insertion was screened for by junction PCR (Figure 3-6C) with a 
schematic representation for NM-R20291_2908(ermB) (Figure 3-6A) and NM-
R20291::jag(ermB) (Figure 3-6B). Southern Blot confirmed the single insertion of ClosTron 
group II introns (Figure 3-7C) with the expected product size (Figure 3-7A and B). To measure 
the effect of the insertional inactivation of genes CDR20291_2908 and jag on growth and toxin 
production each strain was grown in TY medium and samples taken over a 48h time course.  
There was no significant difference between growth for any of the strains (Figure 3-8A). NM-
R20291::2908(ermB) displayed a small initial increase in toxin production until 9 h which was 
then surpassed by both NM-R20291 and NM-R20291::jag(ermB) (Figure 3-8B).  A significant 
difference in toxin concentration between NM-R20291 and NM-R20291::2908(ermB) was 






Figure 3-5: Schematic diagrams and Southern 
blot of transposon insertion into BBM4.  Figure 
legend; Red box indicates insertion of the catP 
transposon at an AT site; green arrows indicate 
the predicted affected genes due to transposition. 
(A) Schematic of transposon insertion into 
R20291_2908, location of HindIII and MfeI 
digestion sites and estimated Southern blot band 
sizes.  (B) Schematic of transposon insertion into 
the intergenic spacer region of jag and oxaA1, 
location of HindIII and MfeI digestion sites and 
estimated Southern blot band sizes.  (C) One 
band observed from Southern blot analysis after 
HindIII digestion.  Two bands observed from 
Southern blot analysis after MfeI digestion due 
to double insertion.  All indicated by orange 
arrows.  Red arrow indicates the approximate 
location of the missing HindIII digestion 
product. catP probe was generated by PCR of 
pMTL-SC1 using primers catP-F1 and catP-R1. 
Calculation of estimated band sizes have not 
been performed due to the overloading of ladder 
product.  0.8% gel. 
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Figure 3-6: PCR screening of ClosTron mutants NM-R20291::jag(ermB) and NM-
R20291::2908(ermB). Figure legend, Blue arrow represents the interrupted gene of interest, Grey 
arrow indicates the Group II intron, Green arrow indicates RAM containing the lincomycin 
resistance gene ermB (A) A schematic representation of the ClosTron insertion into NM-
R20291_2908 showing primer binding sites for junction PCR and expected product sizes. (B) A 
schematic representation of the ClosTron insertion into NM-R20291_jag showing primer binding 
sites for junction PCR and expected product sizes.  Schematics not to scale.  (C) Junction PCR of 
four clones of each ClosTron mutant showing expected band sizes.  NM-R20291 wildtype (W/T) 
used as negative control and a no template control (NTC) to assess for contamination.  Product 





Figure 3-7: Southern blot analysis of ClosTron mutants NM-R20291_2908(ermB) and  NM-
R20291::jag(ermB).  Figure legend; Red box indicates insertion of the group II intron, green 
arrows indicate genes of interest.  (A) Schematic of ClosTron insertion into NM-R20291_2908, 
location of HindIII digestion sites and estimated Southern blot band sizes.  (B) Schematic of 
ClosTron insertion into jag, location of HindIII digestion sites and estimated Southern blot band 
sizes.  (C) Southern blot analysis using intron probe generated using primers EBS2 and 
IntronSalR.  Lambda/HindIII ladder used for the estimation of band sizes.  Single bands 
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identified for NM-R20291_2908(ermB) (~6.5kb) and NM-R20291::jag(ermB) (~5.5kb), 
highlighted in Red boxes. ClosTron plasmid used as positive control at ~6000bp and NM-R20291 




Figure 3-8: Cell growth and toxin production by recombinant C. difficile NM-R20291 strains in 
TY medium for 48h.  Figure legend; (●) NM-R20291; (∎) NM-R20291::2908(ermB); (▲) NM-
R20291::jag(ermB). (A) Growth measured at OD600. (B) Toxin production determined by C. 
difficile Tox A/B II ELISA using a standard curve of known Toxin A and B concentrations.  (C)  
Toxin concentration at 48h.  Data represent the mean ± SEM (n=3).  * indicates statistical 
significance (p = <0.05) by unpaired T-test. 
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To restore functional activity of CDR20291_2908 both complementation and overexpression 
plasmids were constructed.  Prediction of the native promoter region was performed using 
BPROM (Last accessed 12/03/17,  
http://www.softberry.com/berry.phtml?topic=bprom&group=programs&subgroup=gfindb).  
A schematic representation is shown in (Figure 3-9).  For the complementation plasmid, the 
native gene and predicted promoter were PCR amplified from NM-R20291 using primers, 
which introduced NotI (5’), and XhoI (3’) restriction sites.  The resulting product was cloned 
into plasmid pMTL84151.  The overexpression plasmid was constructed using only the native 
gene using primers to introduce EcoR1 (5’) and XhoI (3’) restriction sites.  The product was 
cloned in to pMTL84152; this plasmid contains a thialase promoter (Pthl) from Clostridium 
acetobutylicum, which is constitutive.  Resulting plasmids pMTL84151::p2908 and 
pMTL84152::2908 were Sanger sequenced to ensure sequence accuracy. 
The initial strategy for testing was to transform empty vectors into both NM-R20291 and NM-
R20291::2908(ermB) and test these alongside the complementation, overexpression plasmids.  
Strains containing plasmids were grown in TY broth containing thiamphenicol (15mg/mL) to 
ensure retention of the plasmid.  The control strains containing empty vectors were shown to 
have an inhibited growth pattern through OD measurements (data not available) and were 
unable to produce toxin comparable to their counterparts (Figure 3-10A).  To overcome this, 
we decided to test all the strains in TY without thiamphenicol and after the 48h time point plate 
a 10 µL volume the remaining culture onto BHIS agar containing thiamphenicol (15mg/mL) 
to assess plasmid retention.  This method will not account for any cells that have lost their 
plasmids throughout the assay resulting in altered phenotype populations, therefore is not 100% 
accurate.  The control strains were found to lose the plasmids during the assay, the 
complementation, overexpression plasmids were retained in strain NM-R20291::2908(ermB).    
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Figure 3-9: Schematic of predicted promoter region of gene R20291_2908.  Prediction performed 
by BPROM and identified a -35 and -10 promoter region downstream of R20291_2908, which is 
located on the antisense strand.  A sequence of 109 non-coding bp are located between the -10 and 
the start codon of the gene.  
 
The assay was repeated on two separate occasions, in the both attempts the parental strain NM-
R20291 was found to produce the same amount of toxin as NM-R20291::2908(ermB) over the 
48 h time course.  In these assays the complementation and overexpression strains were shown 
to produce equal (Figure 3-10C) or increased (Figure 3-10E) levels of toxin compared to both 
NM-R20291 and NM-R20291::2908(ermB) despite similar growth patterns (Figure 3-10B and 




Figure 3-10: Cell growth and toxin production by recombinant C. difficile NM-R20291 strains in 
TY medium for 48h. Toxin concentrations determined using C. difficile Tox A/B II ELISA with a 
standard curve of known Toxin A and B concentrations. Figure legend; (●) NM-R20291 
containing pMTL-84151; (∎) NM-R20291::2908(ermB) containing pMTL-84151; (▲) NM-
R20291::2908(ermB) containing pMTL-84151::2908; (●) NM-R20291::2908(ermB) containing 
pMTL-84152::2908.  (A) Toxin concentrations from cultures grown in TY plus thiamphenicol.   
(B) Growth in TY only measured at OD600 experiment one (C) Toxin concentration from cultures 
grown in TY only experiment one.  (D) Growth in TY only measured at OD600 experiment two (C) 
Toxin concentration from cultures grown in TY only experiment two.  Data represent the mean 





3.2.6 Quantitative Lichenase Assay 
The lichenase plate assay is a useful tool for screening but it does not provide quantitative data.  
To overcome this, a previously developed protocol (Dr. C. Humphreys, unpublished) used for 
the quantification of lichenase in a Clostridium botulinum licB reporter system was assessed.  
This method measures lichenase activity through incubation, for a set period of time, of a 
supernatant with a substrate containing a known concentration of lichenan.  Lichenase activity 
is terminated by the addition of 0.2M NaOH, the remaining lichenan is measured by the 
addition of 0.1% Congo Red solution resulting in a similar deep red colouration as described 
for the plate assay.  Supernatant / substrate mixtures are measured at A530 and compared to a 
control sample that contains lichenan but no lichenase.  The reduction in A530 between the two 
samples is directly proportional to the rate of lichenase activity (ΔA530). 
Initial testing of the quantitative lichenase assay, as described in 2.8.5, for use in the C. difficile 
licB reporter system was performed by Dr. E. Stevenson (unpublished results).  It was shown 
that the addition of NaOH before the addition of 0.1% Congo Red solution resulted in no 
measurable difference in A530 between samples that did and did not contain lichenase.  
Conversely, if 0.1% Congo Red solution was added first and allowed to incubate for a set time, 
then 0.2M NaOH added, a measurable difference in A530 was observed.   However, this 
produces no defined endpoint of enzymatic activity therefore it is not a reliable method.    
Reasons for this phenomenon are unclear and review of the literature showed no possible 
explanation but it was assumed that the NaOH played role.  To overcome this substitute enzyme 
altering solutions were tested for stopping the lichenase reactions.  These included 0.5M 
Sodium acetate, 0.5M Sodium carbonate and 2% Trizma base and were chosen because of their 
high pH.  Different substrate/enzyme incubation times were also considered to improve ΔA530 
(Figure 3-11).     
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The difference in ΔA530 increased with correlation to the enzyme incubation time and 0.5M 
Sodium carbonate produced a significantly increased difference in ΔA530 when compared to 
0.5M Sodium acetate (p = <0.001) and 2% Trizma base (p = <0.001) after a 40 minute 
incubation (Figure 3-11).  
A modified quantitative lichenase assay was trialled where a 40 minute enzyme incubation and 
0.5M Sodium carbonate stop solution was utilised.  A 48 h assay was performed to assess the 
new protocol.  It was found that no measurable difference in A530 could be seen in supernatants 
taken at <48 h between samples containing lichenase and samples that did not contain lichenase 
(data not shown).  Multiple attempts to obtain reproducible results using 48 h supernatants 





Figure 3-11: Lichenase enzyme activity over multiple incubation time points.  Each bar indicates 
a different stop solution (■) 0.5M sodium acetate, (■) 0.5M sodium carbonate and (■) 2% Trizma 
base.  Data represent the means of three independent experiments, error bars represent standard 






TcdR is a known regulator of PaLoc gene expression. There have been studies looking at the 
role of TcdR in C. difficile toxin synthesis, these have involved using fusion reporter 
systems75,128,129 or insertional gene inactivation159, but there has yet to be an example of a tcdR 
null mutant.  In this study we created a clean deletion of tcdR in strain NM-R20291 to overcome 
the drawbacks from using the previously described methods, such as, polar effect, non-native 
hosts and expression of genes from plasmids.  The deletion was then complemented with tcdR 
in the same chromosomal location that contained a silent nucleotide substitution resulting in an 
EcoR1 restriction site as a watermark to distinguish from the parental strain.   
The isogenic strains NM-R20291::∆tcdR and NM-R20291::tcdR(EcoR1) did not show any 
difference in growth kinetics when compared to NM-R20291.  There was however a 
statistically significant difference in toxin concentration after 12 h in NM-R20291::∆tcdR 
compared to the parental strain which was restored in the complemented strain NM-
R20291::tcdR(EcoR1).  At 48 h toxin concentration was reduced by an order of 1,000 to 
10,000-fold and 1,000-fold when assessed by Toxin ELISA and cell cytotoxicity respectively.  
The variance in the estimates of toxin production obtained suggests that the ELISA lacks the 
sensitivity of cell-based cytotoxicity assay.  Toxin neutralisation assays were used to ensure 
that the observed findings were due to TcdA and TcdB and not another artefact in the 
supernatant.   This agrees with other published data which have shown that tcdR is a regulator 
of toxin but is not required to initiate expression of tcdA and tcdB75,127,128. 
Reverse genetic analysis as described above is suitable in situations where a gene of interest 
has been identified and a hypothesis is available.  However, in C. difficile strain 630 there are 
3,903 identified genes and of these 53% encode either putative, unknown or pseudo proteins175, 
with similar figures seen in NM-R20291154.  To identify novel genes for regulation of any 
system using a reverse genetic method would be inappropriate without first an idea of a 
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phenotype. Forward genetics provides a more convenient way to identify these novel regulators 
so long as there is a suitable screening method.   
Random mutagenesis has been employed to identify altered sporulation, auxotrophic 
phenotypes and gene essentiality in C. difficile97,176 but there is no described method for 
assessing altered toxin phenotypes.  To overcome the laborious method of measuring toxin 
concentrations in toxin supernatants, i.e. cell culture or ELISA, a reporter strain was created.  
The reporter strain RS-7 was created previously in an NM-R20291 background where tcdB 
was replaced with licB of C. thermocellum a lichenase gene.  This resulted in the creation of 
an easily identifiable phenotype when mutants with an altered phenotype were screened on 
agar plates containing lichenase.   
Random mutant libraries were created and screened for diversity previously.  From said 
libraries eight gene candidates were identified with altered lichenase patterns when compared 
to RS-7 suggesting either a direct or indirect link to toxin regulation (Table 3-1).  One random 
mutant produced a striking phenotype in which no lichenase activity was detected at 24 h and 
reduced lichenase activity was identified at 48 h.  This mutant designated BBM4 was found to 
have two transposon insertions within the genome in R20291_2908 and in the intergenic spacer 
region of jag and oxaA1.   
An InterPro search of R20291_2908 revealed a hypothetical protein containing two functional 
domains, a ParB-like and HNH nuclease motif domain.  ParB (IPR003115) is involved in 
chromosomal partition and a HNH nuclease domain is associated with the catalytic centre of 
homing endonucleases.  Recent literature suggests this protein maybe involved in a 
programmed cell-death system and / or Type I restriction modification systems177. In Bacillus 
subtilis there are orthologues of jag (spoIIIJ) and oxaA1 (ygjG) that have been shown to be 
involved in sporulation178.  Inactivation of spoIIIJ in B. subtilis resulted in cells that are unable 
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to sporulate as SpoIIIJ is essential for a pre-spore specific σ-factor activation178.  Both spoIIIJ 
and ygjG are linked with outer membrane biogenesis, including insertion of subunits of the 
cytochrome or oxidase and ATP synthase complexes178. 
ClosTron mutants were created to interrupt the genes where transposon insertion had occurred 
resulting in strains NM-R20291::jag(ermB) and NM-R20291::2908(ermB).  The ClosTron 
insertional inactivation had no effect on growth for either of the mutant strains.  Data at 48 h 
showed a significant difference in toxin concentration for NM-R20291::2908(ermB) but not 
NM-R20291::jag(ermB), suggesting this is the gene responsible for the lichenase phenotype.  
To confirm this complementation and overexpression plasmids were created containing the 
native NM-R20291_2908 promoter (pMTL84151::p2908) and a thialase promoter 
(pMTL84152::2908) respectively.  As discussed earlier, results were inconsistent after the 
introduction of the complementation and overexpression plasmids even in identical 
experimental conditions.  Unusual results included all four strains producing the same 
concentration of toxin and both NM-R20291 and NM-R20291::2908(ermB) producing reduced 
levels of toxin when compared to the complementation and overexpression strains.  After 
consideration these data maybe due to during the initial growth and toxin assays, NM-
R20291::jag(ermB) and NM-R20291::2908(ermB) were miss labelled and it was in fact NM-
R20291::jag(ermB) that produced the reduced toxin phenotype.  Therefore, the 
complementation would not produce an altered phenotype.  The current literature would also 
suggest that the more likely candidate to produce an altered toxin phenotype would be the NM-
R20291::jag(ermB) mutant as there are suggestions that sporulation and toxin production are 
linked165. 
Screening of transposon mutants could be improved by the implementation of a rapid semi-
quantifiable assay.   This can be achieved by measuring the relative zone of clearance on TY 
agar with 1% lichenan and subtracting the diameter of the colonial growth when using 20 µL 
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of overnight culture at 24, 48 and 72h.  The average size of triplicate replications would be 
compared to the calculated ZOC produced by the control (RS-7).  A “more than” “less than” 
result would be definitive as an effect on PaLoc regulation. 
A liquid semi-quantitative assay was in part developed for use in C. difficile, through the 
adaptation of an assay proved to work within our group in C. botulinum. The early stages of 
this development used culture medium that did not contain lichenan.  This substrate was added 
at the time of the enzymatic assay. This resulted in no measurable difference in A530 in 
supernatants taken at 48 h from transposon mutants and the control strain in a C. difficile host.  
Dr. E. Stevenson showed that the addition of NaOH appeared to have a role in this occurrence, 
demonstrated by a difference in A530 if NaOH is added after the colour change reaction.  As 
this does not result in a defined endpoint we assessed different enzyme altering solutions (0.5M 
Sodium acetate, 0.5M Sodium carbonate and 2% Trizma base) to end the reaction along with 
different enzyme incubation periods (10, 20, 30 and 40 minutes). 
Unsurprisingly, with supernatants taken from 48 h cultures, the difference in ΔA530 increased 
with correlation to the increased enzyme incubation time.  0.5M Sodium carbonate produced a 
significantly increased difference in ΔA530 when compared to 0.5M Sodium acetate and 2% 
Trizma base after a 40 minute incubation.  A 48 h assay was performed to assess the new 
protocol over a set time period.  No measurable difference in A530 could be seen in supernatants 
taken at <48 h and the results seen at 48 h were not reproducible over several attempts.  Even 
though the original method was shown to work in C. botulinum.  The reason for the differences 
in the quantitative assays between reporter strains created in a C. difficile and a C. botulinum 
host have not been investigated here but may be due to subtle differences in growth and toxin 
regulation.  Although not completely comparable due to too many variables i.e. different 
growth media, C. botulinum is able to grow to a higher OD within exponential phase and 
produce ~10x more toxin within 24 h compared to C. difficile strain R2029178,179.  This could 
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suggest that a high enough concentration of lichenase is not being produced for a reliable assay 
in C. difficile. 
On refection, the main issue with the semi-quantitative liquid assay was most probably due to 
the length of time that the lichenase could act on the lichenan.  In the plate assays this time-
period was between 24 and 48 h whereas in the liquid assay the maximum time was 40 min.  
To see assess if this was the case the experiment should be repeated but using TY with 1% 
lichenan and halting the enzymatic reaction after the removal of 1 mL aliquot at each time-
point.  A solution of Congo red would be added after the enzymatic reaction for a set period of 
time and the absorbance measured.  This data when compared to the control sample, a 
supernatant of liquid culture containing only the reporter strain RS-7 taken at the same time 
points, would be used to calculate the ΔA530.  This assay would require some optimisation. 
Other screening methods have been considered, these would ideally be designed using a wild-
type strain as the host for the mutant library generation.  This is so that the method could be 
used in multiple C. difficile strain backgrounds without the need to create new reporter strains 
which can be laborious.  One alternative is using the methods described by Darkoh et al.180,181, 
where they utilise TcdA and TcdB ability to cleave a chromogenic substrate, p-nitrophenyl-β-
D-glucopyranoside (PNPG), that has stereochemical characteristics similar to their natural 
substrate UDP-glucose.  They have demonstrated that this method can work in both a plate 
assay180 and a semi-quantitative assay181 filling both requirements for a robust screening 
method.   
3.4 Key outcomes 
• Significant reduction of TcdA and TcdB concentration was observed in a tcdR null NM-
R20291 strain after 12 h of growth. 
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• Altered toxin phenotypes can be identified using the RS-7 reporter strain and the 
lichenase plate assay. 
• Either gene NM-R20291::jag or NM-R20291::2908 has an effect on toxin production. 
3.5 Future work 
• Repeat the original NM-R20291, NM-R20291::jag(ermB) and NM-
R20291::2908(ermB) toxin assay to confirm which strain showed the reduced toxin 
phenotype. 
• Perform complementation and over expression assays. 
• Optimise the semi-quantitative assay using TY and 1% lichenan as the culture medium. 
• Trial screening of random mutant libraries using p-nitrophenyl-β-D-glucopyranoside as 
a chromogenic substrate. 


















4.1.1 Whole Genome Sequencing a Brief History 
The first bacterial genome sequences were completed in 1995 by Fraser et al.182 and 
Fleischemann et al.183 in Mycoplasma genitalium and Haemophilus influenza respectively.  
These projects employed the first generation sequencing method Sanger sequencing to produce 
shotgun sequenced DNA libraries.  The principle behind Sanger sequencing is being able to 
detect the termination of DNA chain elongation by the incorporation of didexoyNTPs 
(ddNTPs).  Since its inception the process has been improved, originally four separate reaction 
tubes were required and sequence identification was performed using visualisation of the size 
of the bands after denaturing gel electrophoresis and autoradiography184.  Fluorescently 
labelled ddNTPs improved this method by allowing visualisation after capillary electrophoresis 
via computer185.  This method, although accurate and able to produce relatively long reads 
(~1000bp), is time consuming, laborious and expensive.  It also has difficulty in defining long 
repetitive regions of DNA due to the read length produced. 
In 2004 the 454 Pyrosequencer was the first second generation sequencing platform to become 
commercially available and has a 100-fold greater throughput compared to Sanger 
sequencing186.  The increase is due to the parallelism in which multiple DNA strands can be 
sequenced at the same time.  Emulsion PCR is utilised to amplify a single DNA template fixed 
to a bead by a DNA adapter, beads are then planted in to picolitre-volume wells, one per well.  
During the sequencing by synthesis only one type of dNTP is available at any one time.  The 
polymerase activity is coupled to the activity of a luciferase by an ATP sulfurylase, the amount 
of light generated is proportional to the number of dNTPs incorporated at a time.  After the 
reaction an apyrase degrades the ATP and dNTPs present, a different dNTP is added and this 
starts the process again.  Disadvantages of this system compared to Sanger sequencing are the 
inability to resolve long homopolymer runs due to the saturation of the charge coupled device 
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(CCD) which is used to record the amount of light created and the reduced read length to 
~400bp. 
Illumina sequencing was the next second generation sequencing platform to be released.  The 
method is similar to the 454 pyrosequencing in that it utilises sequencing by synthesis but 
adapter linkage is to a glass slide separated into eight lanes187.  Fragmented DNA is bound to 
the slide and DNA clusters are formed during amplification resulting in approximately one 
million copies of the original fragment.  The attachment of different adaptors allows several 
genomes to be sequenced at once (multiplexing).  As with the 454 pyrosequencing method 
significantly shorter read lengths are achieved compared to Sanger sequencing187. 
The second generation sequencing platforms made whole genome sequencing more accessible 
as costs were reduced.  However, these technologies are better suited to re-sequencing projects, 
where a reference genome is available, rather than for de novo assembly188.  At an assembly 
level this is because the short reads are unable to accurately resolve repeat sequences and may 
misassemble sequences189.  Regions of high or low coverage might signify a single 
polymorphic locus that has been classified as two distinct loci or a merged repetitive region 
respectively190.  At the sequencing level errors can be substitutions, insertions or deletions but 
these should be overlooked in the consensus sequence after assembly. 
More recently third generation sequencing platforms have become available, one example 
being Pacific Biosciences (PacBio) single molecule real time sequencing technology (SMRT).  
This method also uses a sequencing by synthesis approach, it utilises a polymerase held in a 
zero-mode waveguide which visualises the incorporation of a single fluorescently labelled 
nucleotide191.  This technology has improved read length by 30 to 200 times compared to 
second generation platforms192.  Due to this issues with de novo assemblies are reduced 
allowing resolution of repeat sequences, closing gaps and increasing quality over GC rich or 
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poor regions192.  It should be kept in mind that individual reads do contain more errors than 
what is seen in short read sequences, but with sufficient coverage an accurate consensus 
sequence is achievable192.  To further check the quality of the consensus sequence, Illumina 
short reads can be used for corrections. 
Not all sequencing platforms have been discussed in this section; a comprehensive list can be 
seen in Table 4-1. 





4.1.2 C. difficile strain VPI 10463 
C. difficile strain VPI 10463 (reference strain ATCC 43255) was first isolated from an 
abdominal wound and was the first strain to have both TcdA and TcdB purified194.  Although 
the PaLoc sequence in other strains had been partially characterised it was in VPI 10463 that 
the full 19.6Kb toxigenic element was identified73.  This study also showed that there were five 
ORFs present within the element, later known as tcdR, tcdB, tcdE, tcdA and tcdC, although 
only tcdR had not been previously identified195.  It was similarly confirmed that the PaLoc was 
located on the chromosome during this study73.  A few years later a new toxinotyping scheme 
was developed for epidemiological reasons and VPI 10463 was used as the reference strain49. 
VPI 10463 has been utilised in a number of TcdA and TcdB regulatory studies namely due to 
its ability to produce high levels of these toxins in vitro127,136,144,196,197 and is frequently used in 
in vivo models198–200.  Despite this, even since the advances of molecular techniques, there has 
been very little to no genetic manipulation performed in this strain.  Reasons for this remain 
unclear but it seems possible that there is a defence mechanism that is preventing DNA transfer 
into this strain and potentially other C. difficile strains, possibly a restriction modification 
system.  To identify such mechanisms and for future genetic manipulations a high quality 
reference genome is required.  At the beginning of this project there was an unpublished draft 
genome for VPI 10463 available through the NCBI submitted by the McGill University 
(GenBank CM000604.1).  The whole genome shotgun sequence contained 22 contigs which 
were ordered and orientated against the complete 630 genome along with 32 contigs which 
could not be placed with certainty.  We aimed to improve upon the genome sequence for use 
in future molecular studies in VPI 10463 as well as improve DNA transfer into this strain. 
4.1.3 Experimental Aims 
• Produce a high-quality reference genome for strain VPI 10463. 
• Comparative analysis of strain VPI 10463 against 630 and BW-R20291. 
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• Identify putative genes that might be involved in TcdA and TcdB regulation in VPI 
10463 that are not present in 630 and R20291.  






4.2.1 Phenotypic analysis of strain VPI 10463. 
Although it has been shown previously that VPI 10463 can produce higher levels of toxin 
compared to 630, BW-R20291 and M120 (a low toxin producer), initially we wanted to check 
this phenotype.  A 48 h growth curve and toxin assay was performed in TY broth over a 48h 
time course as described in 2.9.1 for this purpose.  Toxins A and B were measured in the 
supernatants by C. difficile Tox A/B II ELISA (TechLab), detection limit 1.0 ng/mL, and toxin 
concentrations were determined using a standard curve (TcdA & TcdB mixture at 125 ng/mL 
– 1.95 ng/mL). The results confirmed previous findings and showed that although all the strains 
grew in a similar manner (Figure 4-1A) VPI 10463 produced 10-fold more toxin than both 630 
and BW-R20291 and 100-fold more than M120 at the 48 h time point (Figure 4-1B). 
4.2.2 Whole Genome sequencing 
Whole genome sequencing was performed by both PacBio RSII and Illumina MiSeq 
technologies.  Illumina MiSeq was performed by University of Nottingham DeepSeq Facility 
and raw reads were returned after filtering reads with low sequencing score as well as reads 
aligned to adaptor sequences. DeepSeq firstly trimmed raw reads against adaptors using Scythe 
(https://github.com/vsbuffalo/scythe). Then reads were quality trimmed using Sickle 
(https://github.com/najoshi/sickle).  A total of 1,294,739 paired end reads were obtained with 
a sequence length of 35-251 and an average GC content of 28%.  Pacbio RSII sequencing was 
performed at the McGill University and Genome Quebec using a sheared large insert library 





Figure 4-1: Cell growth and toxin production by C. difficile strains VPI 10463, 630, BW-R20291 
and M120.  Figure legend; (●) BW-R20291; (∎) 630; (∎) VPI 10463; (●) M120. (A) Growth was 
measured at OD600. (B) Toxin concentration determined by C. difficile Tox A/B II ELISA using a 
standard curve of known Toxin A and B concentrations.  Data represent the mean ± SEM (n=3).    
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As a full consensus sequence was not achieved through PacBio RSII sequencing alone, the 
generated raw long reads were corrected with the MiSeq paired end reads by DeepSeq, 
University of Nottingham using proovread116, a hybrid correction pipeline.  The resulting 
corrected reads were assembled using Canu, a fork of the Celera Assembler designed for high-
noise single-molecule sequencing201.  The resulting assembly produced six contigs, the largest 
at 4,319,225bp.  The remaining five contigs were mapped back onto the largest contig using 
CLC genomics workbench V8.5.1 and therefore discarded.  Analysis of the sequence showed 
complementary sequences at each end of the sequence comprising of 5224bp suggesting the 
contig is circular and encompassing of the whole genome.  This complementary sequence was 
trimmed at one end of the sequence and the consensus sequence circularised.  
Table 4-2: PacBio sequencing library and assembly statistics. 
 
Library size 15,000 

































Estimated coverage (X) 110 
Total contigs 22 
Minimum contig length 3142 





4.2.3 Annotation of the VPI 10463 genome 
The corrected genome sequence was annotated using the Joint Genome Institute (JGI) 
Integrated Microbial Genomes & Microbiome Samples (IMG/MS) annotation pipeline MGAP 
v.4202,203.  Genome statistics can be seen in Table 4-3.  Functional Clusters of Orthologous 
Groups (COG) categories were predicted during the annotation process and can be seen in 
Table 4-4. 
Table 4-3: General genome statistics of strain VPI 10463 as predicted by the JGI IMG annotation 
pipeline 
 Number % of total 
DNA total number of bases 4,314,004 100 
Number of coding bases 3,631,788 84.19 
Number of G/C bases 1,243,772 28.83 
Number of genes 4037 100 
Protein coding genes 3887 96.28 
Protein coding genes with function 
prediction 
3111 77.06 
RNA genes 150 3.72 
rRNA genes 35 0.87 
5s rRNA 11 0.27 
16s rRNA 12 0.30 
23s rRNA 12 0.30 





For ease of comparison, the sequence was then orientated with dnaA as the first CDS as is with 
strains 630 and R20291. 
4.2.4 Comparative analysis of 630, R20291 and VPI 10463 
To assess the overall similarity of VPI 10463 to 630 and R20291 a Mauve120 alignment was 
performed using standard settings.  Analysis shows there are five conserved regions within the 
genomes each depicted by a locally collinear block (Figure 4-2).  Interestingly there appears to 
be a large inversion in VPI 10463 which is flanked by two lineage specific regions (positions 
308054 – 358721, 3849698 – 3900424).  The zoomed in images in Figure 4-2 show an ~21kb 
homologous sequence (blue dotted boxes at positions 317517 – 338086, 3866365 – 3887294) 
containing 37 CDS with functions ranging from iron (III) transport systems, FAD synthetase, 
Holliday junction resolvase, several phage related genes to multiple hypothetical proteins.  The 
remaining sections of the lineage specific regions are highly similar but not homologues.  It is 
interesting to note that within each lineage specific region there are three genes that are 
involved in recombination events; xerD, dnaD and recT.  Although their potential involvement 




Table 4-4: Predicted COG categories for C. difficile strain VPI 10463.  Table shows number of 
genes and percentage total.  The associated pie chart shows the breakdown of the functional 
categories. 
COG Categories Gene 
Count 
Percent 
  Amino acid transport and metabolism 1057 9% 
  Carbohydrate transport and metabolism 1078 10% 
  Cell cycle control, cell division, chromosome partitioning 116 1% 
  Cell motility 169 2% 
  Cell wall/membrane/envelope biogenesis 570 5% 
  Chromatin structure and dynamics 3 0% 
  Coenzyme transport and metabolism 502 5% 
  Cytoskeleton 4 0% 
  Defence mechanisms 367 3% 
  Energy production and conversion 674 6% 
  Extracellular structures 21 0% 
  Function unknown 573 5% 
  General function prediction only 925 8% 
  Inorganic ion transport and metabolism 553 5% 
  Intracellular trafficking, secretion, and vesicular transport 104 1% 
  Lipid transport and metabolism 277 2% 
  Mobilome: prophages, transposons 99 1% 
  Nucleotide transport and metabolism 341 3% 
  Posttranslational modification, protein turnover, chaperones 276 2% 
  Replication, recombination and repair 448 4% 
  Secondary metabolites biosynthesis, transport and catabolism 145 1% 
  Signal transduction mechanisms 808 7% 
  Transcription 1243 11% 




Figure 4-2: Mauve genome alignment of C. difficile strains.  Top 630; middle VPI 10463 and 
bottom R20291.  Alignment shows five conserved regions in each genome depicted by a different 
colour for each.  VPI 10463 appears to have undergone a large recombination event depicted by 
the blue and green conserved regions having been shifted down.  Red dotted lines indicate a 
zoomed in view of the region.  The zoomed in view shows two unique regions that flank the 
inversion.  The blue dotted boxes show two regions that are reverse complements of each other 
(positions 317517 – 338086, 3866365 – 3887294). 
 
An inversion like this has not been previously described in C. difficile, to check these data the 
PacBio/Illumina corrected reads provided by DeepSeq were de novo assembled again in Canu 
in-house using the standard settings.  The resulting consensus sequence was then compaired to 
the orignial genome sequence returned from DeepSeq (Figure 4-3).  Because the new genome 
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mapping was shown to be almost identical to the annotated DeepSeq genome sequence all 
further work was performed on the sequence VPI 10463_DS.  The corrected PacBio/Illumina 
sequences were mapped back to VPI 10463_DS genome sequence using the Burrows-Wheeler 
Aligner (BWA)117 using standard settings and the PacBio index flag.  The output files were 
then sorted and indexed using SamTools118.  Commands used in this process can be found in 
Appendix Three. 
Mapping data was analysed using CLC genomics workbench version 10.1.1.  The mapping 
statistics showed an average coverage of 93x (minimum 21x & maximum 238x) no zero 
coverage regions and a total of 103,808 mapped reads.  The read mapping over the two 
homologous and proposed inversion regions was assessed in more detail.  Using CLC genomics 
workbench it was shown that sequence specific mapping occurred at regions spanning the 
beginning and end of the homologous regions as indicated by green (forward) and red (reverse) 
reads in the middle regions of Figure 4-4 A&B.  This specifies that these mapped sequences 
are specific and only occur once in the whole genome and that the flanking regions are unique 
to each homologous region.  The mapping also showed non-specific mapping as indicated by 
yellow reads in the middle of these homologous regions further confirming that these two 21kb 





Figure 4-3:  Genome comparison of VPI 10463 using Mauve.  Top genome sequence was provided by DeepSeq at the University of Nottingham.  The 
bottom genome sequence was recreated using the corrected PacBio/Illumina reads in Canu.  The comparison produced one locally collinear block 
indicating that the two sequences are highly similar.  The genome assembly produced in-house is presented in the opposite orientation to the genome 





Figure 4-4:  Mapping coverage over the two proposed inversion regions in VPI 10463.  Figure legend (A) Region 1 of the homologous sequence at 
positions 308054 – 358721; (B) Region 2 of the homologous sequence at positions 3849698 – 3900424.  Top section for A & B show the CDS location 
and orientation for the specific region being analysed, depicted by blue arrows.  Middle section for A & B shows the sequence mapping over each 
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respective region; green mapping indicate alignment in the forward orientation; red mapping indicate alignment in the reverse orientation; yellow 
mapping indicates non-specific alignment signifying that these reads can map in more than one place in the sequence.  These data show location specific 
mapping over the junction regions of the homologous sequencing indicating that these are unique locations within the genome sequence.  Bottom 
region for A & B shows an orange arrow depicting the exact position of the homologous sequence in each location.    
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Using the Mauve export orthologues option with standard settings a list of putative orthologues 
was created.  This showed the pan-genome in these strains consists of 4680 genes with 512 
genes unique to strain VPI 10463 (Figure 4-5), of these 512 genes 284 are categorised as 
hypothetical proteins.  The remainder of unique genes comprises of phage and transposon 
related genes, transcriptional regulators, recombinases and antibiotic resistance genes.  A 
comprehensive list is available in Appendix Four. 
During analysis, a second holin like gene was identified as a candidate gene which could 
potentially explain the increased toxin production in VPI 10463.  There were also two putative 
type I restriction modification systems identified as candidates for the reduced ability to 
transfer DNA into this strain.  These are discussed in more detail later in this chapter. 
 
Figure 4-5: Predicted orthologues for C. difficile strains 630, VPI 10463 and R20291. The pan-
genome comprises a total of 4680 genes with 512 being unique to VPI 10463. 
4.2.5 Flagella operon analysis.  
As discussed in 3.1.2 there has been evidence to suggest that the flagella operons play a role in 
the regulation of toxin production and so we looked at the three flagella operons at the sequence 
level.  An ACT comparison revealed that VPI 10463 shows an 89% and 96% sequence identity 
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in the F1 and F3 operons respectively, but not in the F2 operon when compared to 630.  There 
is a 98% sequence identity in all three operons when compared to R20291 (Figure 4-7).  
Comparison of the genes at sequence level revealed two potential mutations in FlgE and FliJ, 
which might explain the increased toxin phenotype.  To check what affect the altered amino 
acid sequence would have on function both sequences were analysed using PROVEAN 
compared to the amino acid sequences of the same proteins found in R20291.  The analysis 
indicated that all the changes were neutral in FlgE but a change in DNA sequence in FliJ 
resulted in a nonsense mutation (fliJ111del results in an I37X).  As this change in DNA 
sequence occurs in a sequence of nine adenine residues (Figure 4-7) it was confirmed by Sanger 





Figure 4-6: ACT comparison of the three flagella operons.  Top 630; middle VPI 10463 and bottom R20291.  Green box indicates F1 operon, red box 
indicates F2 operon and blue box indicates F3 operon.  F1 and F3 operons are highly similar between all three strains.  The F2 operon is divergent in 








Figure 4-7: ACT comparison of fliJ.  Top 630; middle VPI 10463 and bottom R20291.  Black box 
indicates a sequence of nine adenine residues. In VPI 10463 fliJ111del results in an I37X and a 
truncation of the protein FliJ. 
 
To evaluate if the nonsense mutation in fliJ affected the motility phenotype plate motility 
assays using 0.3% BHIS top agar were performed.  This showed that both 630 and BW-R20291 
were motile as previously described (Figure 4-8A & B), M120 and VPI 10463 had a reduced 
motility (Figure 4-8C & D). VPI 10463 showed a statistically significant reduced motility 
compared to these 630 and BW-R20291 (Figure 4-8E).  To check if this phenotype was due to 
a lack of flagella we employed transmission electron microscopy which revealed that VPI 
10463 is monotrichous, whereas 630 and BW-R20291 are both peritrichous as reported 







Figure 4-8: Motility assay for Clostridium difficile strains.  Figure legend; (A) 630, (B) BW-R20291, (C) VPI 10463 and (D) M120 on 0.3% BHIS Top 
agar.  Each image represents one example of triplicate experiments.  Single colonies were stab inoculated into the top agar using a sterile toothpick 
and incubated at 37°C overnight.  (E) Motility zones were measured in two directions and averaged after 24 h incubation.  Bar chart data represent 
the mean ± SEM (n=3).  ** indicates statistical significance (p = <0.005) by unpaired T-test between 630 and VPI 10463.  * indicates statistical 







Figure 4-9: Transmission electron micrograph of Clostridium difficile strains.  Figure legend (A) 
630, (B) BW-R20291, (C) VPI 10463 and (D) M120.  Images reveal strains 630 and BW-R20291 
are peritrichous, M120 have no flagella and VPI 10463 are monotrichous.  
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4.2.6 Second Holin-like gene 
The unexpected second holin-like gene (Ga0114281_1134) was studied in more detail.  A 
BLAST search showed that this gene shows 100% query coverage and identity to genes 
identified in two C. difficile strains, two C. difficile plasmids and one C. difficile phage with 
100% query coverage and 94% identity (Table 4-5).  
Table 4-5: BLAST comparison of gene Ga0114281_1134  
 
 
An InterPro search of the amino acid sequence for this gene concluded that the protein belongs 
to the phage holin four superfamily along with TcdE.  At the sequence level, when comparing 
Ga0114281_1134 to C. difficile genome sequences, there is an 86% identity of this sequence 
to tcdE of 630. 
To assess if this second holin-like gene has an effect on toxin levels found in the supernatant 
we attempted to make a ClosTron insertional mutant within the gene.  During the ClosTron 
design stages using the design tool (www.clostron.com) the highest algorithm score was 4.969 
where a score of over seven is recommended.  We decided to proceed further with the low 
scoring target sequence but even though we were able to successfully conjugate pMTL007-
E2::Cdi-BI9_3942::CT(ermB) into VPI 10463 no lincomycin resistant colonies were recovered 
suggesting intron insertion was not achieved.   
Description Query cover E value Identity Accession 
C. difficile ATCC 9689 = 
DSM 1296, complete genome 
100% 0.0 100% CP011968.1 
C. difficile ATCC 9689 = 
DSM 1296 plasmid, 
complete sequence 
100% 0.0 100% CP011968.1 
C. difficile BI9 chromosome 100% 0.0 100% FN668944.1 
C. difficile BI1 plasmid 
pCDBI1, complete 
sequences 
100% 0.0 100% FN668942.1 
C. difficile phage 
phiCDHM19, complete 
genome  
100% 0.0 94% JX145342.1 
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4.2.7 Restriction modification system 
We hypothesised that the two putative type I restriction modification systems (RMS) were the 
mechanism preventing DNA transfer into VPI 10463.   During the comparative genetic analysis 
we also identified that R20291 carried a putative type I RMS which showed 99% homology to 
the hsdR gene (Ga0114281_112960 in VPI 10463 and CDR20291_2909 in R20291) and 98% 
homology to the hsdM gene (Ga0114281_112965 in VPI 10463 and CDR20291_2912 in 
R20291) (Figure 4-10) but no homology was found for the hsdS gene (Ga0114281_112964 in 
VPI 10463 and CDR20291_2911 in R20291) (Figure 4-10), suggesting a different nucleotide 
target site for these type I RMSs.  The second type I RMS in VPI 10463 does not show 
homology to the first type I RMS in VPI 10463 nor is there a corresponding RMS in the genome 
sequence for R20291 (Figure 4-11). 
As PacBio sequencing technology is capable of identifying methylation patterns based on 
statistical analysis of the polymerase kinetics during sequencing204,205 we were able to infer the 
recognition motifs for the two VPI 10463 type I restriction modification systems.  This was 
achieved by submitting the motif summery to the Restriction Enzyme Database (REBASE)206 
for analysis, also confirming the presence of two type I RMS in VPI 10463.  Using the same 
database we were able to retrieve the recognition motif for the type I RMS in R20291 from a 
previously published data set154.    
Using CLC genomics workbench (V8.5.1) the three recognition motifs were compared to the 
modular plasmid maps for pMTL8*151 (* represents 2, 3, 4 or 5111) to identify cleavage sites.  
In all plasmids there was one recognition site for the R20291 type I RMS located in the catP 
gene and one recognition site for the first VPI 10463 type I RMS which was also located in the 
catP gene (Figure 4-12).  The second type I RMS in VPI 10463 has three recognition sites in 
all the plasmids located in lacZα, catP and traJ with an additional site in pMTL84151 in orfB 




Figure 4-10: Comparative analysis of two type I restriction modification systems identified in VPI 10463 and R20291. Top sequence is R20291 bottom 
sequence is VPI 10463. Red boxes indicate hsdR genes and blue boxes indicate both hsdS then hsdM gene.  The hsdR genes show 99% homology and 
the hsdM genes show 98% homology.  The hsdS genes are not homologous suggesting different recognition sites. 
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Figure 4-11: Comparative analysis of VPI 10463 and R20291. Top sequence R20291 bottom sequence VPI 10463.  In the VPI 10463 sequence; red box 
indicates hsdR gene and blue box indicates both hsdS then hsdM gene.  These boxes indicate the second type I restriction modification system which 
does not have a homologue in R20291. 
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To test the hypothesis, we created ClosTron mutants in the restriction modification subunit 
(hsdR) of the type I RMS in BW-R20291 and the hsdR is the first VPI 10463 type I RMS 
(from herein known as hsdR1) as the same ClosTron plasmid could be used in both strains 
(pMTL007-E2::Cdi-R-subunit-527s::CT(ermB)).  ClosTron mutants were created as 
described in 2.6.1 over a period of eight months.  Due to the restriction modification system, 
there were issues around the initial conjugation of the plasmid, over 50 individual attempts 
were made.  Numerous reconfigurations of the protocol included altering the donor / 
recipient volumes, age of starter cultures, OD of starter cultures and the time in which the 
donor and recipient cultures were mixed before plating onto non-selective agar.  The latter 
appeared to be the most effective variable to change, this was increased to 1 hour rather 
than direct plating.  Once transconjugants were isolated they were restreacked on BHIS 
agar containing antibiotics appropriate to counter select the plasmid and glycerol stocks 
were preserved.  From there integration events were selected for using lincomycin.  There 
were many apparent mutants that showed the ability to grow on lincomycin but did not 
show the appropriate genotype.  Eventually after screening 30 individual colonies for both 
BW-R20291 and VPI 10463, from 6 different attempted recombination events, three 
potential mutants were isolated.  A schematic representation of the ClosTron insertion and 
the junction PCR products can be seen in Figure 4-13A.  The insertions were confirmed by 
flanking PCR (Figure 4-13B) and junction PCR (Figure 4-13Figure 4-13C) using primers 
hsdR_Fs1, hsdR_Rs1 and EBS universal (Table 2-3).  The junction PCR products were 
sent for Sanger Sequencing to further confirm the location of insertion.   Single insertion 
of the retargeted group II introns was confirmed by Southern blot using a probe designed 
to target the RAM and gDNA digestion with HindIII (Figure 4-14), VPI 





Figure 4-12: Schematic of pMTL84151 showing cleavage sites for each type I restriction 
modification system. Figure legend; yellow boxes indicated plasmid gene names; red boxes 
indicate cleavage site of the R20291 type I restriction modification system; green boxes 
indicate cleavage site of the first type I restriction modification system in VPI 10463; blue 







Figure 4-13: PCR screening of lincomycin resistant colonies for the integration of the 
retargeted group II intron into the hsdR and hsdR1 genes of BW-R20291 and VPI 10463 
respectively.  (A)  A schematic representation of the hsdR in BW-R20291 and hsdR1 in VPI 
10463 showing primer binding sites for wildtype PCR and expected product sizes.  (B) A 
schematic representation of the ClosTron insertion into hsdR in BW-R20291 and hsdR1 in 
VPI 10463. showing primer binding sites for junction PCR and expected product sizes. (C) 
PCR screen using primer hsdR_Fs1 and hsdR_Rs1 which flank the intron insertion site 
~500bp bands can only be seen in the BW-R20291 and VPI 10463 wildtype strains.  (B) PCR 
screening of integrants using intron-exon junction primers hsdR_Rs1 and EBS universal, 





Figure 4-14: Schematic diagrams and Southern blot to confirm ClosTron insertion in the 
hsdR gene of BW-R20291 and the hsdR1 gene of VPI 10463.  Figure legend; Red box indicates 
insertion of the class II intron; green arrows indicate effected genes due to insertion.  (A) 
Schematic representation of the class II intron at position 327 of hsdR in BW-R20291.  
Locations of the HindIII restriction sites result in a product of 3737bp.  (B)  Schematic 
representation of the class II intron at position 327 of hsdR1 in VPI 10463.  Locations of the 
HindIII restriction sites result in a product of 2501bp.  (C)  Southern blot analysis using intron 
probe generated using primers EBS2 and IntronSalR. Lambda/HindIII ladder used for the 
estimation of band sizes.  Single bands identified for BW-R20291_hsdR(ermB) (~3.5kb) and 
single bands identified for VPI 10463_hsdR(ermB) clones 1 and 3 (~2.5kb).  Double insertion 
identified in VPI 10463_hsdR(ermB) clone 2, this was excluded from further analysis.  Plasmid 
137 
 
pMTL007C-E2::Cdi-327-::CT(ermB) at ~6000bp as the positive control.  BW-R20291 and 
VPI 10463 wildtype strains used as negative controls.  Products visualised on a 0.8% gel. 
 
After confirmation of single integration, conjugation frequencies were calculated as 
described in 2.5.3.  C. difficile strain 630 was used as a control as there is no type I RMS 
described in this strain.  Each of the modular plasmids was conjugated into each strain in 
three separate experiments to ensure results were not due to an artefact in the media.   
Conjugation frequency is defined as number of transconjugants per recipient cell.   
When compared to 630 using the modular plasmids111 analysis showed in both VPI 10463 
and BW-R20291 wild type strains that conjugation frequency was reduced by 100 – 1000 
fold or that conjugation occurred at a level below the detection limit of the assay.  
Conjugation frequencies in the VPI 10463::hsdR1(ermB) mutant were more efficient than 
what is established in 630 by ~10-fold for all of the modular plasmids (Table 4-6).  The 
conjugation frequencies of VPI 10463::hsdR1(ermB) compared to the parental strain were 
statistically significant for plasmids pMTL82151 (P= <0.0001) and pMTL84151 (P= 
<0.0005) by paired T-test.  Transconjugants were detectable in VPI 10463::hsdR1(ermB)  
pMTL83151 and pMTL85151.   
Conjugation frequencies in the BW-R20291::hsdR1(ermB) mutant were comparable to 
what is observed in 630 (Table 4-7).  The conjugation frequencies of BW-
R20291::hsdR1(ermB)  compared to the parental were statistically significant for plasmids 
pMTL82151 (P= <0.0001) and pMTL84151 (P= <0.0001).  Transconjugants were 
detectable in pMTL83151 but not in pMTL85151.  These data suggest that an insertional 
inactivation of the restriction subunit (hsdR) genes in the type I RMS improved conjugation 




Table 4-6: Mean conjugation frequencies of C. difficile strains 630, VPI 10463 and the 




Table 4-7 Mean Conjugation frequencies of C. difficile strains 630, BW-R20291 and the 





It has been demonstrated in numerous studies that drawing conclusions on any metabolic 
regulation from just one strain can lead to inaccurate inferences.  This is likely due to the 
wide genomic diversity that is displayed by C. difficile166.  The aim of these analyses was 
to provide an accurate genome sequence for a high toxin producing strain VPI 10463, to 
look for unique genes that may contribute to this phenotype and to improve the ability of 
DNA transfer into this strain. 
Firstly, we looked at the toxin phenotypes of four different C. difficile strains, 630, BW-
R20291, M120 and VPI 10463.  These strains were chosen due to their specific 
characteristics.  Derivatives of strain 630 are the most commonly studied due to the relative 
ease of DNA transfer into the strain111.  Strain R20291 is a clinically relevant strain and a 
so-called hyper-virulent strain of the 027 PCR-ribotype207.  Strain M120 (PCR-ribotype 




pMTL82151 6.18x10-6 4.84x10-8 7.05x10-5 <0.0001 
pMTL83151 8.93x10-7 - 4.04x10-6  
pMTL84151 4.36x10-6 9.67x10-9 4.79x10-5 <0.0005 
pMTL85151 2.98x10-8 - 4.73x10-8  
 630 BWR20291 BWR20291::hsdR 
(ermB) 
P 
pMTL82151 6.18x10-6 6.79x10-9 1.32x10-6 <0.0001 
pMTL83151 8.93x10-7 4.94x10-9 7.88x10-8  
pMTL84151 4.36x10-6 1.42x10-8 1.58x10-6 <0.0001 
pMTL85151 2.98x10-8 - -  
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078) is a non-motile low toxin producing strain which was chosen as a control154.  Although 
there have been studies showing the relative toxin production of these strains they have all 
been at specific time points and not over a set time course.  This initial phenotypic study 
was to confirm the increased toxin production previously shown in VPI 1046378. Growth 
curve analysis showed that over a 48-hour period in TY broth each of the four strains grew 
in a similar temporal pattern.  Toxin supernatants taken at 48 hours showed that M120 
produced 10-fold less toxin than 630 and BW-R20291 and 100-fold less toxin than VPI 
10463 which had produced approximately 10,000 ng/mL.  Despite the dissimilar quantities 
of toxin being produced by each strain, they all followed the same temporal pattern.   
To investigate possible genetic factors that may give rise to this increased toxin phenotype 
we employed whole genome sequencing of VPI 10463.  This was performed using two 
different technologies to compliment the weaknesses from using only one.  The genomic 
DNA of VPI 10463 was sequenced using PacBio RSII and Illumina MiSeq.  The Illumina 
short reads were used to correct mistakes made in the long reads produced by the PacBio 
RSII using a hybrid approach as described by Hackl et al116.  Annotation and comparison 
of the genome to 630 and R20291 revealed a number of interesting differences.   
Using progressiveMauve it could be seen that there was a large scale genomic 
rearrangement present in VPI 10463 when compared to 630 and R20291.  Closer 
investigation of this inversion showed that when the reads were mapped back to the genome 
the coverage was sufficient to suggest that this was not a mistake in the de novo assembly 
process.  The reorganisation appears to occur within two lineage specific regions which are 
almost equidistant from dnaA and the predicted oric208.  These regions contain two ~21kb 
inverted repeats containing highly conserved head and tail phage genes209.  A BLAST 
search of this sequence identified a high similarity to a number of C. difficile phage’s.  This 
may suggest two separate phage integration events as although the other genes within the 
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lineage specific regions are phage related they do not show homology to each other.  This 
type of large scale recombination has not been described in C. difficile previously but it has 
been in other bacterial species including other low G+C members of the Firmicutes 210–213.  
In fact, it is now believed these large scale recombination events are required for bacterial 
evolution, and that genomes have a high plasticity214–216.   Although the mechanism behind 
this genome rearrangement has not been investigated in this study there has been evidence 
to show that large scale recombination occurs in IS elements, rRNA operons and prophage 
regions210,212,217,218.  One study showed spontaneous recombination after repeated 
subculture between prophage regions in E. coli O157:H7 strain EDL993217.  Many of these 
studies suggest either a RecA recombination event has occurred or that of a phage mediated 
integrase, both of which are found in VPI 10463, and that these events are likely to occur 
during chromosomal replication210,211,213,217. 
Although an interesting feature the inversion does not appear to explain why VPI 10463 is 
able to produce more toxin than other strains.  Flagella are known to be important for 
motility, colonisation, to enhance growth, for survival and as discussed in 3.1.2 flagellar 
proteins have been linked to toxin regulation.  The flagella operons for C. difficile are 
known to comprise of three operons; F1 late stage flagellar genes; F2, flagellar 
glycosylation genes; F3, early stage flagellar genes161.  Early microarray analysis showed 
that there was high diversity in these three operons when 630 was compared to other C. 
difficile strains215,219.  With regards to the strains used in this analysis, previous microarray 
data has shown that the F2 region in 630 consists of four genes which in R20291 and M120 
have been replaced by six different genes220.  The F3 operon is completely missing in the 
M120 strain rendering it non-motile219.  However, the F3 operons between 630 and R20291 
show high levels of sequence identity and the F1 operons show high levels of sequence 
identity between all three strains.   
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To assess if the VPI 10463 flagella operons were divergent from either 630 or R20291 we 
performed an ACT comparison of the three strains.  From this it was shown that the F1 and 
F3 operons in VPI 10463 had high levels of sequence identity to both 630 and R20291.  
VPI 10463 also had high levels of sequence identity to the F2 operon in R20291.  The only 
major difference between all three strains was a nonsense mutation that was introduced by 
a deletion of an adenine at position 108 in fliJ resulting in a 36-amino-acid truncated 
protein.   FliJ is a 147-amino-acid protein that has been shown to be a general chaperone 
for the delivery of rod/hook flagella proteins to the export gate221.  In Salmonella 
spontaneous mutants in fliJ have been shown to result in “leaky” motility phenotypes 
suggesting that it is required for efficient flagella substrate export but flagella synthesis can 
occur in its absence222.  To test this hypothesis, we conducted motility assays on all three 
strains using M120 as a non-motile control.  Motility assays showed that VPI 10463 had a 
reduced motility phenotype when compared to 630 and R20291 but was not completely 
inhibited as was seen in the Salmonella fliJ mutants222.  Due to this finding transmission 
electron microscopy was performed to assess the flagella structures.  TEM revealed that 
VPI 10463 produced a single flagellum (monotrichous) whereas 630 and BW-R20291 
produced multiple flagella (peritrichous), this also supports the findings seen in the 
Salmonella fliJ mutants.   
The current understanding is that mutations in the late stage flagella operon F1 increase 
toxin production and the inverse is true for the early stage flagella operon F3161,162.  If this 
holds true for all genes in the F3 operon, then it would be expected that a mutation in fliJ 
would decrease toxin production.  We propose that the loss of flagellin on the cell surface 
as seen in VPI 10463 results, at least in part, in the increased toxin produced by this strain 
as this would fit into previous observations161–165. 
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Whether this influences toxin regulation has not been experimentally examined in this 
study however this would be suitable for future work by creating mutations in fliJ in 
additional strains of C. difficile and measuring resulting toxin levels.   
A holins primary functions are to form pores in cytoplasmic membranes of bacterial cells 
for the release of phage particles after replication within the host genome.  Although it is 
now becoming more apparent that holins may have a wide variety of functions in phage 
free prokaryotic cells223.  These include bacterial gene transfer and biofilm formation224,225.  
As discussed in 1.2.2, it is believed that the holin like protein TcdE is responsible for the 
transportation of TcdA and TcdB out of the bacterial cell.  Analysis of the unique genes 
found in VPI 10463 identified a second holin-like gene Ga0114281_1134 that shared an 
86% sequence identity to tcdE of 630.  A BLAST search revealed that this gene was also 
present in C. difficile strain DSM1296 chromosome and plasmid, the BI9 chromosome and 
the BI1 plasmid.  It was also present in the ΦCDMM19 genome.  We hypothesised that this 
extra holin like gene was responsible for the high levels of toxin present in culture 
supernatant by allowing TcdA and TcdB to pass through the cell wall more freely as similar 
findings have been observed before in C. difficile strains containing holin-like genes170.  To 
test this hypothesis, we attempted to construct an insertional mutation of Ga0114281_1134 
using ClosTron technology, however this was unsuccessful due to not being able to identify 
a suitable integration site for the group II intron.  If improved DNA transfer into VPI 10463 
is achieved it would be possible to make a clean deletion of Ga0114281_1134 to assess its 
function, if any, in toxin release.  It would also be interesting to compare the TcdA and 
TcdB supernatant levels of the other strains in which Ga0114281_1134 homologues have 
been identified.   
During the analysis two type I RMS were identified in VPI 10463 and one in R20291.  They 
were hypothesised to be the cause of low conjugation frequencies into these strains when 
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compared to 630 which does not have any type I RMSs.  Using CLC genomics workbench 
the predicted cleavage points were identified on our most commonly used plasmids, the 
modular plasmid series111.  This identified different recognitions sites in catP for the type 
I RMS in R20291 and the first type I RMS in VPI 10463.  There were also three recognition 
sites for the second type I RMS in VPI 10463 located in lacZα, catP and traJ with an 
additional site in pMTL84151 in orfB.  We were able to functionally inactivate the hsdR in 
BW-R20291 and hsdR1 in VPI 10463 using ClosTron technology.  This would enable the 
methylation of DNA to still occur but inhibit the restriction of unmethylated DNA at the 
recognition sites.  Using this method, we were able to show that DNA transfer was 
improved to levels similar to those found in a strain without a type I RMS namely 630 when 
analysing conjugation frequencies.   
This work further validates that restriction modification systems are a barrier for DNA 
transfer into C. difficile112,226 which has also been described in other bacterial species227–
229.  There have been alternative methods for evading these systems described in the 
literature.  One such method is termed plasmid artificial methylation (PAM) in which 
plasmid DNA is pre-methylated in the E. coli host.  This is achieved by cloning the 
specificity and modification subunits of the RMS either into the E. coli genome or onto a 
plasmid where they are heterologously expressed, for a number of different bacterial 
species an improvement of DNA transfer has been observed227,230,231.  The very nature of 
this method gives it a significant limitation as well, for each strain that would be studied a 
new E. coli donor would have to be created and to achieve this the RMS would have to be 
described for the recipient strain beforehand.  Although as PacBio SMRT sequencing 
becomes more widely used this will become easier.   
A less complex method which was only recently described in C. difficile is the use of heat-
shock of the recipient cells before conjugation and/or transformation232–234.  The premise is 
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that the heat-shock temporarily inactivates the host defence systems, including any RMS, 
and allows DNA transfer into the cell.  Although, efficiency is variable and maybe 
dependent on the type of RMS present within the recipient genome232 and modified 
protocols maybe required for different strains of the same species234.   
The inception of CRISPR (clustered regularly interspaced short palindromic repeats)-Cas9 
(CRISPR-associated proteins) genome editing offers a new method of evading RMS by 
functionally inactivating the hsdR.  CRISPR are part of the bacterial immune system, short 
palindromic repeats are interspersed with spacer sequences which are homologous to 
bacteriophage DNA235.  These sequences are flanked by Cas associated genes and together 
they are able to defeat invading bacteriophages236.  When the CRISPR and spacer 
sequences are transcribed this produces crRNA which acts as a template for the Cas 
proteins and tracrRNA to find and destroy foreign DNA.  Recent advances in the 
technology now make it possible to introduce a synthetic CRISPR-Cas system into a host 
cell on a plasmid which contains a synthetic crRNA and tracrRNA termed gRNA (guide 
RNA)236.  This system then introduces a double strand break which is repaired by 
endogenous non-homologous end joining (NHEJ) or homology-directed repair 
pathways235.  There have only been a small number of publications citing the use of this 
technology in prokaryotes, possibly due to the inability of bacteria to efficiently repair these 
breaks caused by the CRISPR-Cas9 system235.  However, this method has recently been 
shown to work in Clostridium pasteurianum using the CRISPR-Cas9 but also by co-opting 
native Cas proteins237.  The rational for using the native system was due to low 
transformation frequencies of the Cas9 plasmids into Clostridium, however, this might be 
overcome by using a heat-shock method as described earlier.  Once the mutation has been 




4.4 Key outcomes 
• A high quality genome map for VPI 10463. 
• A large scale genome rearrangement was identified in VPI 10463, the first 
described in C. difficile. 
• Identification of two putative genes that potentially have a role in the increased 
levels of toxin produced by VPI 10463; Ga0114281_1134 and a nonsense mutation 
in fliJ. 
• VPI 10463 has low motility and is monotrichous. 
• Circumvention of the type I RMS in R20291 and one of the type I RMS in VPI 
10463 increases genetic transfer from an E. coli donor. 
4.5 Future work 
• A more in-depth comparative analysis of the VPI 10463 genome compared to other 
clinically relevant strains. 
• Creation and characterisation of FliJ mutants in C. difficile strains to assess its role, 
if any, in the regulation of toxin production.  
• Restoration of FliJ in VPI 10463 to measure a reduction, if any, of toxin production. 
• Create a clean deletion of the holin-like gene Ga0114281_1134 in VPI 10463 and 
assess if toxin supernatant levels are reduced. 













Chapter Five  Analysis of co-infection, antibiotic resistance and isolate 





5.1.1 Clinical diagnosis of Clostridium difficile 
Historically, the diagnosis of Clostridium difficile infection (CDI) were performed using a 
Cytotoxin Neutralisation (CTN) assay which detects TcdA and TcdB in the supernatants 
of patients’ faeces and was classed as the gold standard until recently238.  Although CTN is 
a sensitive assay it is time consuming, taking on average 24 – 48 h to complete. When an 
enzyme linked immunosorbent assay (ELISA) method was developed to detect (initially 
only) TcdA in faecal samples many clinical laboratories discontinued the use of CTN239.  
In recent years the method of diagnosis has changed due to the low sensitivity of using just 
a TcdA/B ELISA alone and currently a twostep assay is performed240.  Firstly, either an 
ELISA for glutamate dehydrogenase (GDH) or a nucleic acid amplification test (NAAT) 
for tcdB, to screen samples for the presence of C. difficile240.  If this test is positive, then an 
ELISA for TcdA/B is performed to confirm clinical infection.  If the GDH/NAAT are 
negative, symptoms are caused by another aetiology.  If the GDH/NAAT are positive and 
the EIA is negative, then toxigenic C. difficile may be present and the patient is a potential 
excretor240.   
5.1.2 Epidemiology and hypervirulence of Clostridium difficile 
Hypervirulent strains of C. difficile have been implicated in more severe disease states and 
have recently been reported to have become epidemic in many countries241.  The most 
renowned offender is classified as RT027, PFGE type NAP1 and REA type BI 
(027/B1/NAP1) and belongs to toxinotype III242.  It has been suggested that this strain gets 
its hypervirulence, resulting in a more severe disease, not only from producing an additional 
toxin; binary toxin but also having a variant tcdC repressor gene, producing higher levels 
of toxin A and toxin B and an increased sporulation rate243.  Although these findings are 
becoming more controversial244–247.  In the UK, during 1990-2003, cases of 027/NAP1/B1 
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isolates were relatively infrequent with RT001 and RT106 being the most prominent248.  
During 2005-2007 there was a change in the ribotype distribution with RT001, RT027 and 
RT106 all sharing approximately 25% each of the total incidences249.  In 2007/08 RT027 
became the most common at 55.3% of all isolates, but since 2008/09 the prevalence has 
steadily been falling although in 2010/11 it was still the most frequently isolated at 12.4%42.  
Other ribotypes recently associated with hypervirulence are RT078, RT056 and 
RT018250,251.     
In the Clostridium difficile ribotype network (CDRN) report for 2013 – 15 the shift in 
ribotype distribution discussed above can be seen over the six years the service has been 
mandatory (Figure 5-1)252.   
Figure 5-1: Ribotype distribution over a six-year period (2009 – 15) for all regions of England.  
Different coloured blocks indicate a different ribotype which has a prevalence of over 2%, 
other ribotypes are classed as sporadic. Image taken from252. 
 
Although the incidence of RT027 has decreased new “emergent” ribotypes are increasing 
including RT078, RT002, RT005, RT014/020, RT023 and RT015252.  RT078 is prevalent 
in the Netherlands and has caused outbreaks in Northern Ireland251,253. 
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In the East Midlands the incidence of RT027 has decreased although there was a slight rise 
in the last quarter of 2014 – 15 (Figure 5-2).  The most isolated ribotypes within the East 
Midlands, from the latest published figures, are RT027, RT015, RT002, RT078, RT014, 
RT005, RT023, RT020, RT017 and RT026 (Figure 5-2). 
Figure 5-2: Ribotype distribution over a six-year period (2009 – 15) for the East Midlands 
region.  Different coloured blocks indicate a different ribotype which has a prevalence of over 
2%, other ribotypes are classed as sporadic. Image taken from252 
5.1.3 Hospital acquired vs. community acquired Clostridium difficile infection 
Traditionally CDI was seen as a nosocomial infection but over the past decade there has 
been an increase of reports of CDI from the community254.  This patient demographic have 
not usually had any exposure to antibiotics, no history of recent hospital stays and they are 
usually younger and healthier255.  Community acquired (CA-CDI) generally refers to 
patients with CDI who show symptoms within the first 48 h of admission to hospital or 
after four weeks following discharge256.  Hospital acquired CDI (HA-CDI) is usually 
defined as presentation of symptoms after 48 h of admission and within four weeks of 
discharge256.   However, this narrow classification does not take into account patients who 
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have had out-patient exposure or residents of long term care facilities257.  The differences 
of definitions for these patient cohorts and a lower incidence of testing for CDI in the 
community258 may not fully reflect the true number of CA-CDA cases.  Initially, there 
appeared to be a small range of epidemic ribotypes that were associated with CA-CDI16,259 
but a more recent study has shown similar ribotype distributions between both CA- and 
HA-CDI258. 
5.1.4 Recurrence of Clostridium difficile infection 
Recurrent CDI is defined as the return of symptoms after successful treatment, which 
occurs in 19 – 35% of patients with CDI, these figures increase after every subsequent 
episode28–30.  Recurrent infection can be classed as either relapse or re-infection where 
infection is caused by the same strain as the initial infection or where a different strain is 
the causative agent of infection respectively260.  Within the clinical setting, if a patient has 
had a second independent episode within 8 weeks of successful treatment it would be 
classed as a recurrence episode261.  It is currently estimated that relapse and re-infection are 
approximately equal in incidence262 but these figures may change as whole genome 
sequencing becomes more commonplace. 
Phenotypic characteristics i.e. toxin production, sporulation and germination were shown 
not to be a factor in recurrent infection in one study263 but another has found that increase 
in germination efficiency was seen more in strains from recurrence cases than non-
recurrence cases264.  However, both studies only used small sample sizes therefore more 
investigation is required before a definite conclusion can be made. 
Host risk factors include advancing age, a high Horn index score which clinically assesses 
the severity of underling illness/co-morbidities29 and low anti-toxin antibody responses to 
C. difficile colonisation and initial symptomatic infection increase risk of infection265.  C-
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reactive protein (CRP) is a known marker of inflammation with reference ranges of 10 – 
50 mg/L as an indication of viral infection and >100 mg/L for bacterial infection266.  CRP 
is a general measure of inflammation and an increase in levels could be caused by diseases 
such as coronary artery disease, myocardial infarction or cancer266 and so is generally used 
as a guide of infection in conjunction with other pathology assays.  Although, Eyre et al. 
described CRP to be an indication of first recurrence if a level of ≥85 mg/L was observed 
when used in their scoring matrix267.   Other risk factors involve use of antibiotics and / or 
proton pump inhibitors after treatment of CDI260 and the use of fluoroquinolones268.   The 
nature of common typing practices i.e. ribotyping and MLST, are not discriminatory 
enough and may lead to miss-classification of relapse and reinfection269. 
5.1.5 Co-infection of Clostridium difficile strains 
Currently there are only a few studies looking at the effect of co-infection with two or more 
strains of C. difficile and their effect on relapse and / or epidemiology.  It currently stands 
that 7.7% – 13% of CDI cases are co-infected with multiple strains270–272, but there is no 
definitive answer for this question.  The isolation of single colonies for epidemiology can 
result in the under representation of transmission events, although this method is the most 
cost effective, relapse / recurrent infections maybe miss-classified270,273. 
5.1.6 Emerging resistance to Metronidazole and Vancomycin 
Accounts of resistance to first line treatments of C. difficile have been increasingly reported 
over the past twenty years126,274–276.  With routine susceptibility testing not performed on 
clinical isolates the exact level of resistance within the community and hospital reservoirs 
remains unknown.  A recent study, where 953 isolates from 22 European countries were 
assessed for their resistance to Vancomycin and Metronidazole, showed that 96.84% and 
97.82% of isolates were sensitive respectively.  In the latest CDRN report the analysis of 
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200 isolates showed four of these displayed increased MICs to metronidazole (n= 3 RT027, 
n= 1 RT106) and one showed increased MIC to vancomycin (RT001)252. 
5.1.7 Isolation of Clostridium difficile from stool samples 
The isolation of C. difficile from stool samples is known to be difficult, with historical 
recovery rates of 87.5% recorded in 2008 – 09 from the CDRN252.  This issue most likely 
arises due to low numbers of spores / vegetative cells following antibiotic treatment of the 
patient or small sample availability.  A number of studies focusing on the isolation of C. 
difficile from stool samples277–280 or the environment281 have focused on using expensive 
commercial agar that may not be affordable in the research and potentially the clinical 
setting.  These studies focused only on recovery of C. difficile from clinical samples and 
not the semi-quantification of a known concentration of viable spores which may also be 
of importance in the research setting. 
5.1.8 Nottingham University Hospitals NHS Trust 
Nottingham University Hospitals NHS Trust (NUH) is a large multi-centre acute teaching 
trust which provides services for 3 – 4 million people from across the region282.  In this 
study, we identified the first 100 patients without an episode of C. difficile within the 
previous six months from the period 1st November 2013 until 30th November 2014 from 
both the hospital and community settings.  These patients were followed up for at least 
three months to monitor recurrence episodes.  Clinical information was gathered at the time 
of infection to assess co-factors that may indicate recurrent infection including age, sex, 
site of acquisition, initial CDI treatment, use of PPI and other antibiotics at the time of 
infection and CRP.  Where possible multiple colonies of C. difficile were isolated to 




5.1.9 Experimental aims 
• Develop a cost effective and reliable method of isolating C. difficile from stool 
samples. 
• Measure the level of co-infection and recurrent CDI within the NUH NHS region. 
• Evaluate clinical information and perform MIC levels on all isolates to identify a 
role in recurrence episodes. 
• Use whole genome sequencing on isolates from recurrence episodes and their index 





5.2.1 Development of a Clostridium difficile culture method 
Initially we aimed to develop a method of culturing C. difficile from stool samples where 
low numbers of spores / vegetative cells may be present.  The first step was to identify 
which of two broths (CCFB and CCMB-TAL) performed better as an enrichment step.  
Hamster faeces which contained either C. difficile 630 (samples 1069 and 1076) or NM-
R20291 (samples 1547 and 1557) were used at this stage.  0.5 g of faeces was added to 1 
mL PBS, homogenised and heat shocked for 10 min at 80°C.  After which samples were 
centrifuged (4000 xg for 1 min) and 100 μL supernatant was added to 5 mL CCFB and 
CCMB-TAL and incubated for 24 – 96 h at 37°C in anaerobic conditions.  Both broth 
recipes contained 1% Neutral Red as a pH indicator.  Growth was defined by turbidity and 
a pH change altering the colour of the broth from red to yellow.  After a positive indication 
50 μL broth were subcultured onto CCFA using a four-quadrant streak method then further 
incubated for 24 – 48 h.  Recovery of C. difficile was enumerated semi-quantitatively (0 = 
no growth. 1 = growth in the 1st quadrant, 2 = growth in the 2nd quadrant, 3 = growth in 
the 3rd quadrant, 4 = growth in the 4th quadrant). Each sample was examined in triplicate.  
Recovery of C. difficile from two different broth compositions is represented in Table 5-1. 
Table 5-1: Recovery of C. difficile from two broth compositions. 
 
 CCFB CCMB-TAL 
Sample Time (h) Recoverya Time (h) Recoverya 
1069 36 1 48b 3 
1076 36 1 48b 3 
1547 24 1/3c 36 1 
1557 24 1 24/36d 1/3e 
a Recovery semi-quantified as 0 = no growth. 1 = 1st quadrant, 2 = 2nd quadrant, 3 = 3rd quadrant, 4 = 4th quadrant. 
b Growth was only detected in one of the three broths tested. 
c Recovery was semi-quantified as one in two broths and three in one broth. 
d Positive broth recorded as 1 at 24h and two at 36h. 




When trialling the different broth compositions, growth was detected in all CCFB samples.  
For samples 1069 and 1076 in CCMB-TAL growth was only detected in one of the 
triplicate broths for each (Table 5-1).  In the samples where growth was detected in CCMB-
TAL it was always 24 h after it had been detected in the CCFB (Table 5-1).  The semi-
quantification of positive broths revealed that CCMB-TAL gave a superior recovery rate 
over CCFB (Table 5-1).  This observation appears to confirm previous studies’ findings 
that the presence of lysozyme increases the recovery rate of C. difficile283.  To assess this, 
we added lysozyme to CCFB and repeated the experiment, however, this addition did not 
improve recovery (data not shown).  For this reason, CCFB was chosen for the enrichment 
step. 
For the assessment of the solid medium, serial dilutions of 630∆erm spore stocks were 
prepared in PBS homogenised non-infected mouse faeces (0.5 g in 5 mL) to give final 
concentrations of 101 to 104 spores / mL.  Before use prepared samples were heat shocked 
and centrifuged as previously described.  For each dilution samples were either directly 
plated onto solid media (CCFA, CCEY, ChromID C. difficile and TSA with 5% sheep's 
blood) or first subjected to a broth enrichment step using CCFB.  An aliquot of 100 μL of 
heat shocked supernatant was added to CCFB and incubated for up to 120 h.  When a 
positive broth was indicated or 120 h had passed 50 μL broth was inoculated onto all four 
solid agar or CCFB (to ensure a negative result) respectively using a four quadrant streak 
method.  50 μL heat shocked samples were also directly plated on to CCFA, CCEY, 
ChromID C. difficile and TSA with 5% sheep's blood using a four-quadrant streak method.  
Solid agar was allowed to incubate for up to 72 h in both cases.  As before recovery of C. 
difficile was enumerated semi-quantitatively and examined in triplicate.   
The enrichment in CCFB resulted in no positive indication for samples containing 101 to 
103 spores and after plating onto CCFA no growth was observed after 72 h.  Samples that 
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contained 104 spores gave a positive reaction in CCFB and were subsequently plated onto 
all four solid media.  Growth was detected up to and including the 4th quadrant on CCEY 
and ChromID C. difficile after 24 h, on CCFA and TSA (5% sheep blood) after 48 h.   
TSA with 5% sheep blood performed the poorest of the four solid media, when direct 
plating was employed, with no spores being recovered after 72 h incubation (Table 5-2).  
The most sensitive of the media trialled was CCEY agar supplemented with egg yolk, with 
102 spores being detected in one of the replicates in the first quadrant after 72 h incubation 
(Table 5-2).  In samples containing 104 spores, colonies large enough for manipulation were 
also observed in the 1st quadrant of CCEY for all three replicates after 48 h (Table 5-2).  
Recovery was only seen in one replicate after 72 h incubation with 104 spores in CCFA 
with growth being detected in the first quadrant (Table 5-2).  ChromID C. difficile delivered 
the best recovery rate of the four agars in this study with growth being detected in the 2nd 
quadrant in one replicate but it was not as sensitive as CCEY agar being able to recover 104 
spores (Table 5-2).  
Table 5-2: Recovery of C. difficile from spiked non-infected mouse faeces using a direct 
plating method. 
  
CCFA CCEY ChromID 
C. difficile 
TSA 
(5% sheep blood)  
Time (h) Recoverya Time (h) Recoverya Time (h) Recoverya Time (h) Recoverya 
104 72 0/1b 48 1 48 1/2d 72 0 
103 72 0 72 0/1c 72 0 72 0 
102 72 0 72 0/1b 72 0 72 0 
101 72 0 72 0 72 0 72 0 
a Recovery semi-quantified as 0 = no growth. 1 = 1st quadrant, 2 = 2nd quadrant, 3 = 3rd quadrant, 4 = 4th quadrant. 
b Recovery was semi-quantified as 0 on two plates and 1 on one plate. 
c Recovery was semi-quantified as 1 on two plates and 0 on one plate. 





Figure 5-3: An example of comparison plates when identifying C. difficile from the best 
performing media.  Each plate was inoculated with an identical clinical sample.  (A) CCEY; 
(B) CCEY with 1% Neutral Red; (C) ChromID C. difficile. 
 
The ability to identify C. difficile in mixed faecal flora is important to prevent laborious 
identification steps.  The two best performing solid media were trialled using four different 
clinical samples (kindly provided by Dr Steve Michell, University of Exeter).  After 
emulsification in PBS at a 1:1 ratio samples were heat shocked and centrifuged as before 
and 50 μL supernatant was plated on either ChromID C. difficile and CCEY agar, with and 
without 1% Neutral Red (to act as a pH indicator).  CCEY, with and without 1% Neutral 
Red, gave a typical flat grey colony appearance (Figure 5-3A) although plates containing 
1% Neutral Red produced a slight yellow shade (Figure 5-3B). The addition of the 1% 
Neutral Red did not give an adequate colour change to be considered an indicator of C. 
difficile. The ChromID agar, C. difficile generated the expected black colonies due to the 
chromogen integrated into the media (Figure 5-3C). No other faecal flora was detected in 
any of the samples. 
Due to these data, it was decided to use a 1:1 ratio where possible of stool to PBS.  Stool 
PBS mixtures were homogenised, heat shocked and then centrifuged.  50 μL sample 




5.2.2 Isolation of Clostridium difficile strains from patients within the University of Nottingham 
Hospitals Trust 
During the period 1st November 2013 to 30th September 2014 patients who were clinically 
diagnosed with CDI were considered for this study if they had not had an episode of CDI 
within the previous six months.  Patients were followed up for at least three months after 
their index episode of CDI to identify any recurrence events.  During this period, there were 
235 reported incidents of CDI combining both community / hospital acquisition and 
recurrence episodes.   
Isolation of C. difficile from stool was performed as described above.  Briefly stool samples 
were mixed in PBS 1:1 dilution, heat shocked (10 min at 80°C), centrifuged and 50 μL 
supernatant was plated using a four-quadrant streak, plates were incubated for 48 h.  After 
initial incubation, plates were inspected for the presence of C. difficile and up to 20 
individual isolates per sample were picked and resuspended in 200 μL BHIS broth in a 96 
well microtiter plate and allowed to incubate overnight.  After which, a 1:10 dilution of cell 
suspension was made in PCR grade H2O in a separate 96 well microtiter plate to act as a 
ribotyping template.  One drop of glycerol was added to each well of the 96 well microtiter 
plate containing the C. difficile suspensions and stored at -80°C until further use.  The PCR 
template 96 well microtiter plate was stored a -20°C.   
If C. difficile was not recovered from the index sample the patient was disregarded from 
the study.  This occurred on five occasions resulting in a recovery rate of 95.9% (n=122). 
5.2.3 Statistical analysis of patient demographics and recurrence cases. 
The data presented in Table 5-3 represents the clinical information collected at the index 
sample, these data were then analysed further to assess if the patient went onto suffer a 
relapse episode.  The patient demographics recorded at this time were sex, age, location of 
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CDI acquisition, co-infection, initial CDI therapy, if additional antibiotics given during 
CDI therapy, regular prescriptions of proton pump inhibitors during or after CDI therapy 
and CRP levels at the time of stool collection (Table 5-3).  Statistical analysis of these data 
in relation to the likelihood of a recurrence episode was performed using Fisher’s exact 
test.  These data show that 70% of patients in this study were ≥ 65 years of age and 59% of 
cases were female.  None of these demographics were deemed statistically significant, 
however, of these it is interesting to note that 10/11 patients who relapsed were ≥ 65 years 
of age.  Acquisition of CDI occurred in hospital for 88% of patients, of the 12% that 
acquired their CDI in the community two patient’s relapsed.  Co-infection occurred in 12% 
patients and although not statistically significant only one suffered relapse.  Initial CDI 
therapy included metronidazole, vancomycin, fidaxomicin, a combination of the previous 
antibiotics, no treatment or unknown.  Statistical analysis of metronidazole or vancomycin 
when compared to fidaxomicin showed no statistical significance (Table 5-3) but it is 
interesting to note that none of the patients who received fidaxomicin suffered a relapse 
episode (n=5).  The use of additional antibiotics during CDI therapy were recorded in 37% 
of patients, 44% were not given additional antibiotics and in 19% it was unknown if they 
had received additional antibiotics.  There was no statistical significance seen between the 
use of additional antibiotics or not with regards to relapse.  A regular prescription of proton 
pump inhibitors during or after CDI therapy was recorded in 22% of patients of which 4 
(18%) relapsed, 59% of patents did not receive proton pump inhibitors during or after CDI 
therapy of which 5 (8%) relapsed.  Although not statistically significant a higher percentage 
of patients relapsed if they were receiving proton pump inhibitors.  CRP levels were found 
to be >85mg/L in 40% of patients, <85mg/L in 36% of patients and untested in 24% 




5.2.4 Ribotype analysis of Clostridium difficile strains 
Twenty individual isolates of C. difficile were isolated from 75% of stool samples within 
this study (range 3 – 20).  All isolates were identified as C. difficile except for two; patient 
05 had a mixture of Clostridium glycocellium and C. difficile RT005 and patient 98 had a 
mixture of Clostridium butyricum and C. difficile RT078.  Co-infecting strains of C. 
difficile were found in 12% of samples and no combinations of ribotypes were detected 
more than once.  Of the 13 patients who were co-infected with multiple strains of C. difficile 
only two suffered recurrence episodes.  Patient 10 had RT062 and RT023 in their index 
sample and RT023 in their recurrence sample and patient 39 had RT001 in their index 
sample and RT001 and RT070 in their recurrence sample.  Although it cannot be said for 
certain that both ribotypes were not present in all samples.  A total of 41 different ribotypes 




Table 5-3: Patient demographic statistics taken at the index episode of Clostridium difficile 
infection. 


















Age <65 y 

































































































aMultiple antibiotics were used for initial CDI treatment were vancomycin / metronidazole 
(n=7) and vancomycin / fidaxomicin (n=2) 
bP value calculated by Fishers exact test. 
cUnknown results were excluded from statistical calculations. 
dWhen analysed against Fidaxomicin. 
 
5.2.5 Minimum inhibitory concentration analysis 
The minimum inhibitory concentrations for all C. difficile isolates were determined by 
minimum inhibitory concentrations evaluators (MICE).  Antibiotics assayed were 
vancomycin and metronidazole, resistance for both antibiotics is defined as an MIC >2 
mg/L.  Each isolate was tested once unless an MIC of resistance was recorded after which 
the result was confirmed in triplicate.  All isolates in this study were sensitive to both 
antibiotics (MIC data shown in Appendix Five).  The MIC90 was calculated as 1 mg/L for 
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both metronidazole and vancomycin.  The MIC50 was calculated as 1 mg/L for vancomycin 
and 0.5 mg/L for metronidazole. 
 
Figure 5-4: The 14 most prevalent ribotypes isolated in this study.  Figure legend; blue bars 
indicate Hospital Acquired CDI and red bars indicate Community Acquired CDI. 
 
5.2.6 Whole genome sequencing, global alignment and single nucleotide polymorphism analysis 
of Clostridium difficile strains from patients with recurrent infection 
C. difficile strains isolated from patients with recurrent infection were whole genome 
sequenced.  To serve as a control, one isolate of a corresponding ribotype isolated from a 
non-relapse patient was also sequenced (Table 5-5).  The hypothesis being that the isolates 
of the same ribotype isolated from both relapse and non-relapse patients should be 
genetically very similar and therefore differing genes and SNPs would be more indicative 
of providing a fitness benefit.   
Illumina MiSeq paired end short reads were adapter trimmed by the providing centres using 
their own methods.  Returned reads were quality checked using FastQC284 revealing 
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increased noise at both 5’ and 3’ ends.  Reads were further trimmed using CLC genomics 
workbench V8.5.3 (CLC) to remove this noise and filtered to remove broken pairs and 
reads <50bp.  Reads were then quality checked a second time using FastQC revealing an 
improvement in overall quality.  Figure 5-5 gives an example of FastQC output from the 
Illumina MiSeq reads received from isolate 01-01 before and after trimming.  Basic 
statistics for MiSeq paired end reads before and after trimming are presented in Table 5-4. 
 
Figure 5-5: FastQC analysis of Illumina MiSeq reads from 01-01.  Quality Scores across all 
bases (A) before and (B) after trimming.  Sequence content across all bases (C) before and 
(D) after trimming.  Showing a general improvement in quality score for bases and reduced 





Table 5-4: Statistics for the Illumina MiSeq reads after in-house filtering and trimming using 














34-01 NTU 920,240 911,644 240.1 211.8 
09-01 NTU 1,859,432 1,814,837 217.7 191.6 
01-01 NTU 1,219,978 1,207,351 238.8 210.6 
06-01 UoB 1,875,458 1,768,633 213.7 193.1 
69-01 NTU 1,122,342 1,101,270 226.7 199.9 
57-01 UoB 1,340,932 1,199,476 193.3 179.2 
96-01 UoB 4,314,276 4,033,025 211.3 192 
96-02 NTU 1,104,892 1,094,587 239.5 221.2 
96-03 NTU 1,298,572 1,283,042 236.6 208.7 
96-04 NTU 1,129,934 1,115,979 237.8 210 
39-01 NTU 1,629,804 1,596,732 220.7 194 
39-02(1) NTU 1,885,308 1,831,138 215.. 189.6 
05-01 NTU 909,882 900,816 232.3 204 
05-02 UoB 3,180,140 2,966,539 209.6 190.5 
19-01 NTU 1,463,294 1,442,126 231 203.5 
19-02 NTU 944,136 929,608 238.1 210.9 
42-01 NTU 1,230,402 1,219,387 235.6 207.2 
42-02 NTU 1,578,852 1,555,007 227.4 200.5 
45-01 NTU 1,051,788 1,043,009 238,5 210 
45-02 NTU 1,359,826 1,338,818 230.8 203.5 
85-01 NTU 1,528,166 1,509,706 235.9 208 
85-02 NTU 1,466,500 1,036,585 240.1 211.9 
10-01(2) NTU 1,019,070 1,004,758 231.8 204.3 
10-02 NTU 980,884 968,102 232.2 204.5 
12-01 NTU 1,227,136 1,210,203 229.1 201.5 
12-02 NTU 1,129,512 1,114,657 232.2 204.5 
55-01 NTU 1,475,640 1,451,743 229.6 202 
55-02 NTU 1,328,590 1,309,460 230.5 203 
61-01 UoB 1,858,536 1,724,740 206.4 187.8 
61-02 NTU 1,042,430 1,028,998 235.7 207.9 
61-03 UoB 2,471,980 2,255,276 200.3 184 
61-04 UoB 1,711,572 1,437,313 174.1 166.2 
61-05 UoB 1,854,494 1,739,055 210.9 191 




Sequence reads for the control strains and index samples for each of the relapse patients 
were assembled de novo in CLC genomics workbench using standard settings.  Assembled 
contigs for each genome were aligned to the CD630 reference genome map using 
Mauve’s120 move contigs feature.  Rearranged contigs were then annotated using the RAST 
pipeline121,122 and exported as one consensus .gbk file.  Further analysis of the relapsing 
strain genomes was performed in two ways.  Firstly, by using progressiveMauve to inspect 
the genome of the index strains for genetic regions not identified in CD630, R20291 and 
the control reference genome.  Secondly paired end reads of the relapsing strains were 
mapped to the index strain to identify single nucleotide variants (SNPs) as described in 
2.7.3.  Only SNPs that met specific read criteria were included; a minimum coverage of 20, 
count of 10, frequency of 90% and Phred score >30.  SNPs were manually validated in 
Artemis115, any located within 10 bases of a contig end were excluded. 
Each index strain from the relapse patient was compared to the control strain as described 
above to assess their relatedness by mapping the paired-end reads from each index sample 
to the corresponding control for their ribotype (Table 5-5).  These data are collected under 
the assumption that the more SNP differences between strains the more unrelated they 
are285.  High numbers of SNP within the same ribotype can be attributed to dense SNP 
clusters resulting from homologous recombination events285.  This has not been 
investigated here due to time limitations but it may explain the high SNP differences seen 
between the control strains for each tested ribotype and the test strains.  The largest SNP 
difference of all the isolates studied were the two RT001 strains isolated from the index 
sample of PT96 (relapsing strain) and PT34 (RT001 control strain) with 19,740 SNPs 
(Table 5-5).  The smallest SNP difference were seen in two RT054 strains isolated from 
the index sample of PT55 (relapsing strain) and PT69 (RT054 control strain) with 22 SNPs 
(Table 5-5).  These data suggest there were no transmission events between these patients.  
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However, this does not rule out transmission occurring between patients that were not 
included in the whole genome study.  The number of SNPs between index strain and 
relapsing strains to be classed as recurrent infection is ≤2261; this indicates that patients 
PT05, PT39 and PT45 all relapsed with a different strain of the same Ribotype (Table 5-5). 
Table 5-5: List of number of SNPs compared to a control strain and the index strain of all 
isolates taken from relapse patients.  
 




No. of SNPs 
compared to 
control strain 
No. of SNPs 
compared to index 





PT39 001 PT34 1,462 4 1 
PT96 001 PT34 19,740 1 – 2* 3 
PT05 005 PT09 906 79 1 
PT19 015 PT01 5,660 1 1 
PT42 015 PT01 5,589 0 1 
PT45 015 PT01 552 6 1 
PT85 015 PT01 5,509 0 1 
PT10 023 PT06 171 0 1 
PT12 023 PT06 688 0 1 
PT55 054 PT69 22 0 1 
PT61 076 PT57 189 0 4 
 *A second SNP was identified in the isolate from the isolate from the second relapse that 
was not present in the first or third. 
 
For each patient, clinical information was gathered (where possible) at the same time as 
their standard of care relapse stool sample was taken.  This combined with SNP, 
vancomycin/metronidazole MIC and the identification of unique strain genetic regions will 
be used to assess the likelihood of contributing to relapse.  Non-synonymous SNP changes 
will be analysed using PROVEAN (Protein Variation Effect Analyzer)286, this web based 
software utilises pairwise sequence alignments to assess homology between the original 
and the altered sequence.  A change in alignment score is interpreted as the impact of the 
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variation on protein function.  Briefly, the software clusters BLAST hits with an e-value 
cut-off of 0.1, the top 30 clusters are used for the delta alignment score and these scores are 
then averaged within and across clusters to generate the final score.  If this score is <-2.5 
the variation is predicted deleterious.  PHASTER (Phage Search Tool Enhanced Release)114 
was used to look for prophage regions within the genomes when unique locations were 
believed to contain phage related genes.  This web based software performs database 
comparisons using both GLIMMER (ORF prediction) and BLAST (protein identification) 










Sex Age Ribotype Date of 
sample 
No of days 
between episodes 
39-01 Male 93 001 23-03-14  
39-02(1)   001 19-05-14 57 
      
96-01 Female 55 001 01-08-14  
96-02 
  
001 20-08-14 19 
96-03 
  
001 25-09-14 36 
96-04 
  
001 03-11-14 39    




05-01 Female 90 005 05-11-13  
05-02 
  




19-01 Female 79 015 08-01-14  
19-02 
  




42-01 Female 96 015 30-03-14  
42-02 
  




45-01 Male 95 015 03-04-14  
45-02 
  




85-01 Male 66 015 16-07-14  
85-02 
  




10-01(2) Female 69 023 10-12-13  
10-02 
  




12-01 Male 85 023 13-12-13  
12-02 
  




55-01 Male 79 054 23-05-14  
55-02 
  




61-01 Female 69 076 03-06-14  
61-02 
  
076 30-06-14 27 
61-03 
  
076 19-07-14 19 
61-04 
  
076 07-09-14 50 
61-05 
  
076 03-12-14 87      
183a 




RT001 was the causative agent of CDI in two patients who suffered recurrent CDI.   
Patient 39; a male 93 years of age had one relapse episode 57 days after initial diagnosis 
(Table 5-6).  The index episode for this patient was determined to be hospital acquired and 
the relapse was classified as occurring in the community (Table 5-7).  The recurrence 
sample was shown to have two distinct ribotypes; RT001 and RT070 both were sensitive 
to vancomycin and metronidazole in vitro.  There were no recorded additional antibiotic 
treatments except for the CDI therapy which was vancomycin and fidaxomicin.  The proton 
pump inhibitor omeprazole was prescribed during CDI therapy for the index infection, this 
is a risk factor for relapse.  The CRP level was not raised to a level indicative of a risk of 
relapse.  Only isolate 39-02(1) (RT001) was chosen for further genetic analysis. 
Table 5-7: Clinical information for patient 39 gathered at each sample collection. 
 
Sample Date 23/03/14 19/05/14 




Co-infected No Yes (RT070) 
CDI Treatment Vancomycin then 
Fidaxomicin  
Fidaxomicin  
Use of antibiotics other 
than CDI therapy 
during the treatment 
course 
None None 
Regular prescription of 
proton pump inhibitors 
during or after CDI 
therapy 
Omeprazole None 
CRP >85mg/L 81mg/L Unknown 
Vancomycin minimum 
inhibitory 
concentration (≤2 mg/L 
= sensitive) 
1 mg/L RT001 – 1 mg/L 
RT070 – 0.5 mg/L 
Metronidazole 
minimum inhibitory 
concentration (≤2 mg/L 
= sensitive) 
0.25 mg/L RT001 – 0.5 mg/L 




Genome analysis revealed four SNPs unique to sample 39-02(1) when compared to the 
control strain 34-01 (Table 5-5), one ambiguous and three non-synonymous (NS).  The 
ambiguous SNP is located 28bp upstream of a hypothetical protein.  The first NS SNP is 
in PT3902_478 a diguanylate cyclase domain protein where an 841C>T a transition 
substitution results in a His281Tyr.  The second NS SNP is in PT3902_1837 a putative 
ABC transporter permease protein where an 719T>G a transversion substitution results in 
a Val240Gly.  The third NS SNP is in PT3902_2026 a hypothetical protein where a 
140A>G a transition substitution results in Tyr47Cys.  All of which were shown to be a 
tolerated substitution by PROVEAN suggesting these SNPs are not providing a fitness 
benefit for this strain. 
Whole genome alignment of 39-01 to 630, R20291 and 34-01 showed two unique phage 
regions in 39-01 at 62.8kb (position 1,088,587) and 107.5kb (position 3,398,363) in length, 
analysis by PHASTER showed they resemble C. difficile bacteriophages ΦMMP02 and 
ΦCD211 respectively.  These regions include phage related genes, hypothetical proteins, 
transcriptional regulators, spore related proteins and transposases.  A third unique region 
shares 99% identity and 100% coverage with Tn6218 (accession number HG002386) 
located in RT001 strain Ox746b presented in a study by Dingle et al 287.  The insertion has 
occurred ~6kb upstream of the flagella operon F3 at position 294,535 in strain PT39-01 





Figure 5-6: A Mauve alignment between Clostridium difficile strains 630, R20291, 34-01 (RT001 control strain) and 39-01 the index strain from the 
relapsing patient PT39.  The red checked lines indicate an insertion of Tn6218 containing MATE family of multi drug resistance (MDR) efflux pumps 
(purple box) at position 294,535 in 39-01 (7,879bp in length).  The green arrow indicates the last gene in the F3 flagella operon ~6kb downstream of 
the insertion site.  This region appears highly conserved between 630, R20291 and 34-01 but the insertion.  This insertion is located within a 240,846bp 
contig reducing the chances of an assembly error.  
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Patient 96; a female 55 years of age had four distinct episodes of CDI totalling a period of 
94 days (Table 5-6).  The index case was clinically determined to be hospital acquired along 
with the first two relapse episodes, the final recorded relapse was classified as occurring in 
the community (Table 5-8).  The clinical information gathered at the time of each CDI 
episode showed no risk factor for recurrence of CDI and it appears that the patient only 
received treatment for her infection after identification of the index episode and not for the 
relapse episodes.  In vitro MIC analysis of C. difficile strains showed sensitivity to both 
metronidazole and vancomycin.  
When comparing strain 96-01 to 34-01 (RT001 control strain), analysis revealed one SNP 
C>T a transition substitution present in all recurrence strains located in a 58bp intergenic 
region between tRNA and rRNA genes (Table 5-5).  There was also one NS SNP found in 
gene PT9603_3091, a hypoxanthine-guanine phosphoribosyl transferase, where a 425T>C 
a transition substitution results in Val142Ala.  This was shown to be a tolerated substitution 
by PROVEAN. 
Table 5-8: Clinical information for patient 96 gathered at each sample collection. 
 
Sample Date 01/08/14 19/08/14 25/09/14 03/11/14 
Hospital Acquired CDI 
Community Acquired 
CDI 
Hospital Hospital Hospital Community 
Co-infected No No No No 
CDI Treatment Metronidazole None None None 
Use of antibiotics other 
than CDI therapy during 
the treatment course 
None None None None 
Regular prescription of 
proton pump inhibitors 
during or after CDI 
therapy 
None None None None 
CRP >85mg/L 11 mg/L 10 mg/L 32 mg/L Unknown 
Vancomycin minimum 
inhibitory concentration 
(≤2 mg/L = sensitive) 
1 mg/L 0.5 mg/L 0.5 mg/L 1 mg/L 
Metronidazole minimum 
inhibitory concentration 
(≤2 mg/L = sensitive) 
1 mg/L 0.5 mg/L 0.5 mg/L 0.5 mg/L 
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Whole genome alignment of 96-01 to 630, R20291 and 34-01 showed one unique phage 
region of ~33kb, analysis by PHASTER showed it resembles C. difficile bacteriophage 
ΦMMP02 although it is incomplete.  When compared to 630, R20291 and 34-01 there is 
evidence of a unique 25kb Tn916-like element containing hypothetical proteins, 
conjugation proteins, membrane proteins, IAA acetyltransferase and β-ketoadipate enol-
lactone hydrolase (Figure 5-7).  The Tn6218 element identified in 39-01 was similarly 
found in this strain (position 3,829,473), it is however in a different location (Figure 5-8).  
This may be due to an assembly error that occurred during de novo process however both 
regions are located within longer contigs (240,846bp contig in PT39 and 124,615 contig in 
PT96).  This transposon element has been shown to be located in different regions within 
different ribotypes but this has yet to be seen within the same ribotype287.  Sanger 
sequencing or long read sequencing technologies could be used to identify if these are the 




Figure 5-7: A Mauve alignment between Clostridium difficile strains 630, R20291, 34-01 (RT001 control strain) and 96-01 the index strain from the 
relapsing patient PT96.  The red checked lines indicate a unique insertion of Tn916-like element containing hypothetical proteins, conjugation proteins, 
membrane proteins, IAA acetyltransferase and β-ketoadipate enol-lactone hydrolase at position 382,468 in 96-01 (25,243bp in length).  This insertion 
comprises of one contig which does not span any locally collinear blocks so misassembly cannot be discounted. This region appears to have a lot of 





Figure 5-8: A Mauve alignment of Clostridium difficile strains 39-01 and 96-01 both RT001.  Red boxes indicate the locations of a Tn6218 element, 
previously identified in Ox746b287.  Both are located in different regions (294,535 in 39-01 and 3,829,473 in 96-01) but within much larger contigs 
(240,846bp contig in 39-01 and 124,615 contig in 96-01) reducing the likelihood of misalignment.  Similar locally collinear blocks between strains are 





RT005 was the causative agent of CDI in one patient who suffered recurrent CDI.   
Patient 05; a female 90 years of age who had a relapse episode 44 days after initial 
diagnosis (Table 5-6).  Both index and relapse episodes were categorised as community 
acquired infections (Table 5-9).  Due to this limited clinical information was available only 
treatment notes were recorded; these were metronidazole for initial CDI therapy and 
vancomycin during the relapse episode.  In vitro MIC analysis of C. difficile strains showed 
sensitivity to both metronidazole and vancomycin (Table 5-9). 
Table 5-9: Clinical information for patient 05 gathered at each sample collection. 
 
Sample Date 05/11/13 19/12/13 




Co-infected No No 
Initial CDI 
Treatment 
Metronidazole  Vancomycin 
Use of antibiotics other 
than CDI therapy 
during the treatment 
course 
Unknown Unknown 
Regular prescription of 
proton pump inhibitors 
during or after CDI 
therapy 
Unknown Unknown 
CRP >85mg/L Unknown Unknown 
Vancomycin minimum 
inhibitory 
concentration (≤2 mg/L 
= sensitive) 
0.25 mg/L 0.25 mg/L 
Metronidazole 
minimum inhibitory 
concentration (≤2 mg/L 
= sensitive) 
1 mg/L 1 mg/L 
 
Mapping of Illimina MiSeq reads from 05-02 (relapse strain) to 05-01 (index strain) 
revealed 88 differences; 79 SNPs unique to 05-02 of which 56 are ambiguous (in a non-
coding region), 4 synonymous, 19 non-synonymous, two multiple nucleotide variants 
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(MNV) and seven indels.  Further analysis of SNPs were not performed as this is indicative 
of reinfection rather than relapse.   
Whole genome alignment of 05-01 to 630, R20291 and 09-01 (the RT005 control strain) 
revealed two interesting regions, the first located at position 400,234 is ~23kb and contains 
hypothetical proteins, transcriptional regulators, thiamine biosynthesis protein, lantibiotic 
transport permease protein, lantibiotic transport ATP-binding protein and a putative Tn916 
transcriptional regulator (Figure 5-9). 
A second unique region to PT05 index strain 05-01 contained ten hypothetical proteins and 
a macrolide-efflux protein (Figure 5-10).  Although there was no record of a macrolide 
class of antibiotic being prescribed in this case, fidaxomicin may not have been effective if 





Figure 5-9: A Mauve 
alignment between 
Clostridium difficile strains 
630, R20291, 09-01 (RT005 
control strain) and 05-01 the 
index strain from the 
relapsing patient PT96.  The 
red checked lines indicate a 
unique insertion of Tn916-like 
element at position 400,234  in 
05-01 (23,433bp in length), 
green box indicates lantibiotic 
related proteins.  The 
insertion is located within a 
contig of 34,012bp which 
overlaps the purple locally 
collinear blocks suggesting an 
accurate assembly. Similar 
locally collinear blocks 
between strains are linked by 





Figure 5-10: A Mauve alignment of Clostridium difficile strains 09-01 and 05-01 both RT005.  The green locally collinear blocks shown were not found 
in 630 or R20291.  The Red dashed lines indicate a unique genomic region to PT05 at position 50,5757 in 05-01 (7,531bp in length); Purple box indicates 
the location of a macrolide-efflux protein.  It is possible that there have been issues with the assembly of the contigs in these genomes as the location of 
the green locally collinear blocks begin at either end of the genomes (position 4,174,169 in 09-01 and 480,408 in 05-01).  However, this unique region is 





RT015 was the causative agent of CDI in four patients who suffered recurrent CDI.   
Patient 19; a female 79 years of age had one recurrence episode 97 days after initial 
diagnosis (Table 5-6).  The index episode for this patient was determined to be hospital 
acquired and the relapse was classified as occurring in the community (Table 5-10).  PT19 
index case was initially treated with vancomycin but there is a record of Tazocin and co-
amoxiclav also having been prescribed at around the time of initial symptoms of CDI, a 
risk factor for relapse.  Although in this case CRP was not elevated.  No clinical information 
was available for collection during the relapse episode.  In vitro MIC analysis of C. difficile 
strains showed sensitivity to both metronidazole and vancomycin. 
Genome analysis revealed one ambiguous SNP unique to 19-02 when compared to 01-01 
at position 519206 with a C>A a transversion substitution (Table 5-5).  This is located ~300 
bases upstream of a predicted amidohydrolase on the anti-sense strand and ~30bp 
downstream of a quaternary ammonium compound-resistance protein.  Whole genome 
alignment revealed that all four strains were very similar except for a ~56kb region unique 
to 19-01 which contains hypothetical proteins, peptidoglycan bound protein, a putative 
Tn916 regulator, iron acquisition yersiniabactin synthesis enzyme, various transport and 




Table 5-10: Clinical information for patient 19 gathered at each sample collection. 
 
Sample Date 08/01/14 15/04/14 








Use of antibiotics other 
than CDI therapy 
during the treatment 
course 




Regular prescription of 
proton pump inhibitors 
during or after CDI 
therapy 
No Unknown 
CRP >85mg/L 14 mg/L Unknown 
Vancomycin minimum 
inhibitory 
concentration (≤2 mg/L 
= sensitive) 
0.25 mg/L 0.5 mg/L 
Metronidazole 
minimum inhibitory 
concentration (≤2 mg/L 
= sensitive) 






Figure 5-11: A Mauve alignment of Clostridium difficile strains 630, R2091, 01-01 (RT015 control strain) and 19-01 the index strain from the relapsing 
patient PT19.  Red box indicates a unique insertion which contains hypothetical proteins, peptidoglycan bound protein, a putative Tn916 regulator, 
iron acquisition yersiniabactin synthesis enzyme, various transport and transcriptional proteins at position 408,567 in 19-01 (56,834bp in length).  
However, this unique region is within the longer contig of 231,116bp suggesting that it is present within this region.  The comparison of the genomes 
in general shows they are very similar as defined by the large locally collinear blocks of the same colour. Similar locally collinear blocks between 




Patient 42, a female 96 years of age had one recurrent episode 26 days after initial 
diagnosis (Table 5-6).    The index episode for this patient was determined to be hospital 
acquired and the relapse was classified as occurring in the community (Table 5-11).  From 
the acquired data, there were no indications of risk factors for relapse episodes occurring.  
The patient’s initial CDI therapy was both metronidazole and vancomycin which the C. 
difficile strain was determined to be sensitive to in vitro.  During the relapse episode 
fidaxomicin was given as CDI therapy.  There was no recorded third episode within the 
study period.   
Table 5-11: Clinical information for patient 42 gathered at each sample collection. 
 
Sample Date 30/03/14 25/04/14 




Co-infected No No 
Initial CDI Treatment Metronidazole then 
Vancomycin  
Fidaxomicin  
Use of antibiotics other 
than CDI therapy during 
the treatment course 
No No 
Regular prescription of 
proton pump inhibitors 
during or after CDI 
therapy 
No No 
CRP >85mg/L 69 mg/L Unknown 
Vancomycin minimum 
inhibitory concentration 
(≤2 mg/L = sensitive) 
1 mg/L 1 mg/L 
Metronidazole minimum 
inhibitory concentration 
(≤2 mg/L = sensitive) 
0.25 mg/L 0.5 mg/L 
 
There were no SNPs identified between 42-01 and 42-02 (Table 5-5). Whole genome 
alignment of 42-01 revealed a unique Tn619-like region that contains two teicoplanin 
resistance genes and one tetracycline resistance protein (Figure 5-12).   Lastly a Tn6218-
like region containing hypothetical proteins, regulatory proteins and Multi antimicrobial 
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extrusion protein MATE family of MDR efflux pumps is located at position 3,003,729.  
This appears like the Tn6218 elements found in RT001 strains.   
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Figure 5-12: A Mauve alignment between Clostridium difficile strains 630, R20291, 01-01 (RT015 control strain) and 42-01 the index strain from the 
relapsing patient PT42.  The red checked lines indicate a unique insertion of Tn916-like element, green arrows indicate teicoplanin resistance genes 
and purple arrow indicates tetracycline resistance gene at position 3,451,408 in 42-01 (43,592bp in length).  The unique region is within the longer 




Patient 45, a male 95 years of age had one recurrent episode 87 days after initial diagnosis 
(Table 5-6).  The index episode was clinically indicated as occurring in the community and 
the relapse episode as hospital acquired (Table 5-12).  The index episode was treated with 
metronidazole which the C. difficile strain was determined to be sensitive to in vitro.  
During the relapse episode fidaxomicin was given as CDI therapy.  There was no recorded 
third episode within the study period.  In vitro MIC analysis of C. difficile strains showed 
sensitivity to vancomycin.  At the time of the relapse episode the patient was receiving the 
proton pump inhibitory lansoprazole and had an elevated CRP (90 mg/L) which are both 
risk factors for relapse.   
Table 5-12: Clinical information for patient 45 gathered at each sample collection. 
 
Sample Date 03/04/14 29/06/14 








Use of antibiotics other 
than CDI therapy 
during the treatment 
course 
Unknown No 
Regular prescription of 
proton pump inhibitors 
during or after CDI 
therapy 
Unknown Lansoprazole 
CRP >85mg/L Unknown 90 mg/L 
Vancomycin minimum 
inhibitory 
concentration (≤2 mg/L 
= sensitive) 
0.5 mg/L 0.5 mg/L 
Metronidazole 
minimum inhibitory 
concentration (≤2 mg/L 
= sensitive) 
0.5 mg/L 0.5 mg/L 
 
Mapping of Illimina MiSeq reads from 45-02 to 45-01 revealed six SNPs unique to sample 
45-02 (Table 5-5), one ambiguous and five NS.  The ambiguous SNP is located 143bp 
downstream of PT45_398 a hypothetical protein and 300bp downstream PT45_399 a 
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partial integrase.  The first NS SNP is in PT45_2600 a 2,4-dienoyl-CoA reductase 
(NADPH) where a 389G>A a transition substitution results in Gly130Asp.  This is deemed 
a tolerated substitution by PROVEAN.  The second NS SNP is in PT45_1933 a RNA 
methyltransferase, TrmA family were an 585G>T a transversion substitution results in a 
Leu195Phe.  The third NS SNP is in PT45_434 a putative aldo/keto reductase were an 
585G>A a transition substitution results in Gly180Arg.  The fourth NS SNP is in 
PT45_3493 a hypothetical protein where a 12A>C a transversion substitution results in 
Arg4Ser.  The sixth NS SNP is in PT45_ 2351 a Stage V sporulation protein D where a 
1442A>T a transversion substitution results in Asp481Val.  Analyses of these substitutions 
were all determined as deleterious by PROVEAN.   
Whole genome alignment of 45-01 only revealed one unique region ~31kb that contains a 
lantibiotic transport permease protein, lantibiotic transport ATP-binding protein and a 




Figure 5-13: A Mauve alignment between Clostridium difficile strains 630, R20291, 01-01 (RT015 control strain) and 45-01 the index strain from the 
relapsing patient PT45.  The red checked lines indicate a unique insertion of Tn916-like element at position 409,131 in 45-01 (31,243bp in length), 
green box indicates lantibiotic related proteins.  This insertion comprises of three contigs so misassembly cannot be discounted however the longest of 




Patent 85, a male 66 years of age suffered one recurrent episode 26 days after initial 
diagnosis (Table 5-6).  The index episode for this patient was clinically determined to be 
hospital acquired and the relapse was classified as occurring in the community (Table 
5-13).  The index episode was treated with metronidazole which the C. difficile strain was 
determined to be sensitive to in vitro.  There was no record of treatment was given as CDI 
therapy during the relapse episode.  During the treatment period for the index episode both 
Tazocin and omeprazole were given, both count as risk factors for relapse.  The patient also 
had a CRP level of 104 mg/L another risk factor for relapse.  It is not known if any other 
treatments were being given during the relapse episode. 
Table 5-13: Clinical information for patient 85 gathered at each sample collection. 
 
Sample Date 16/07/14 11/08/14 
Hospital Acquired CDI 
Community Acquired CDI 
Hospital Community 
Co-infected No No 
Initial CDI Treatment Metronidazole Unknown 
Use of antibiotics other than 
CDI therapy during the 
treatment course 
Tazocin Unknown 
Regular prescription of 
proton pump inhibitors 




CRP >85mg/L 104 mg/L Unknown 
Vancomycin minimum 
inhibitory concentration (≤2 
mg/L = sensitive) 
1 mg/L 0.5 mg/L 
Metronidazole minimum 
inhibitory concentration (≤2 
mg/L = sensitive) 
0.5 mg/L 1 mg/L 
 
Genome analysis revealed no SNPs unique to sample 85-02 compared to the index strain 
(Table 5-5). Whole genome alignment revealed that all four strains were very similar except 
for a ~56kb region unique to 85-01 which contains hypothetical proteins, peptidoglycan 
bound protein, a putative Tn916 regulator, iron acquisition yersiniabactin synthesis 
enzyme, various transport and transcriptional proteins (Figure 5-14).  This sequence shows 




Figure 5-14: A Mauve alignment between Clostridium difficile strains 630, R2091, 01-01 (RT015 control strain) and 85-01 the index strain from the 
relapsing patient PT85  Red box indicates a unique insertion containing hypothetical proteins, peptidoglycan bound protein, a putative Tn916 
regulator, iron acquisition yersiniabactin synthesis enzyme, various transport and transcriptional proteins at position 401,317 in 85-01 (55,153bp in 
length.  This insertion comprises of two contigs however both the upstream and the downstream regions span locally collinear blocks.  Similar locally 





RT023 was the causative agent of CDI in two patients who suffered recurrent infection.   
Patient 10, a female 69 years of age had one recurrent episode 83 days after initial 
diagnosis (Table 5-6).   Both index and relapse episodes were classed clinically as hospital 
acquired (Table 5-14).   The index sample was shown to have two distinct ribotypes; RT023 
and RT062 both were sensitive to vancomycin and metronidazole in vitro.  The relapse 
isolate was also sensitive to vancomycin and metronidazole in vitro.  The patient had 
multiple risk factors for relapse such as taking meropenem, they also had an elevated CRP 
of 367 mg/L.  During their relapse episode both vancomycin and metronidazole were given 
for CDI therapy.  No other antibiotics or proton pump inhibitors were given at this time.  
There was no recorded third episode of relapse during the study period even though the 
patient had a raised CRP of 244 mg/L. 
Genome analysis revealed no SNP unique to sample 10-02 (Table 5-5).  Whole genome 
alignment did not reveal any unique genetic regions when compared to 630, R20291 and 
06-01.  There was evidence of the insertion previously described within the PaLoc in both 




Table 5-14: Clinical information for patient 10 gathered at each sample collection. 
 
Sample Date 10/12/13 03/03/14 




Co-infected Yes (RT062) No 
Initial CDI 
Treatment 
Vancomycin Vancomycin and Metronidazole 
Use of antibiotics other 
than CDI therapy 
during the treatment 
course 
Meropenem None 
Regular prescription of 
proton pump inhibitors 
during or after CDI 
therapy 
No None 
CRP >85mg/L 367 mg/L 244 mg/L 
Vancomycin minimum 
inhibitory 
concentration (≤2 mg/L 
= sensitive) 
RT023 – 1 mg/L 




concentration (≤2 mg/L 
= sensitive) 
RT023 – 1 mg/L 
RT062 – 1 mg/L 
1 mg/L 
 
Patient 12, a male 85 years of age had one recurrent episode 38 days after initial infection 
(Table 5-6).  Both index and relapse episodes were classed clinically as hospital acquired 
(Table 5-15).  No other antibiotics were given during CDI therapy in either the index or the 
relapse cases.  The proton pump inhibitor omeprazole was given during both CDI episodes.  
The patient did not have a CRP level indicative of relapse during the index episode of CDI 
but it was raised during the relapse at 171 mg/L.  Both strains were shown to be sensitive 
to vancomycin and metronidazole in vitro.   
No SNP were identified during analysis of the relapse strain (Table 5-5).  As with strain 




Table 5-15: Clinical information for patient 12 gathered at each sample collection. 
 
Sample Date 13/12/13 20/01/14 








Use of antibiotics other 
than CDI therapy 
during the treatment 
course 
None None 
Regular prescription of 
proton pump inhibitors 
during or after CDI 
therapy 
Omeprazole  Omeprazole 
CRP >85 mg/L 28 mg/L 171 mg/L 
Vancomycin minimum 
inhibitory 
concentration (≤2 mg/L 
= sensitive) 
0.25 mg/L 0.12 mg/L 
Metronidazole 
minimum inhibitory 
concentration (≤2 mg/L 
= sensitive) 
1 mg/L 1 mg/L 
 
5.2.7.5 RT054 
RT054 was the causative agent of CDI in one patient who suffered recurrent infection.   
Patient 55, a male 77 years of age had one recurrent episode 30 days after initial diagnosis 
(Table 5-6).   Both index and relapse episodes were classed clinically as hospital acquired 
(Table 5-16).  Vancomycin was prescribed as the initial CDI therapy, the strains isolated at 
both index and relapse episodes were deemed sensitive to this antibiotic in vitro as was 
metronidazole.  During the index episode, there was no recorded administration of either 
alternative antibiotics or proton pump inhibitors and the CRP level was unknown.  All three 




Table 5-16: Clinical information for patient 55 gathered at each sample collection. 
 
Sample Date 23/05/14 22/06/14 








Use of antibiotics other 
than CDI therapy 
during the treatment 
course 
None Unknown 
Regular prescription of 
proton pump inhibitors 
during or after CDI 
therapy 
None Unknown 
CRP >85 mg/L Unknown Unknown 
Vancomycin minimum 
inhibitory 
concentration (≤2 mg/L 
= sensitive) 
0.5 mg/L 1 mg/L 
Metronidazole 
minimum inhibitory 
concentration (≤2 mg/L 
= sensitive) 
0.25 mg/L 0.5 mg/L 
 
No SNP were identified during analysis when comparing 55-02 to 55-01 (Table 5-5).  
Whole genome analysis between 630, R20291, 69-01 and 55-01 showed two unique 
regions.  One with a Tn916-like element containing ParA/B, a recombinase, threonine 
dehydrogenase and hypothetical proteins (Figure 5-15).  The second region contains phage 
related genes, hypothetical proteins, a lipoprotein, TrsK and TrsE-like genes and resembles 




Figure 5-15: A Mauve alignment between Clostridium difficile strains 630, R20291, 69-01 (RT054 control strain) and 55-01 the index strain from the 
relapsing patient PT55.  The red checked lines indicate a unique insertion of a Tn916-like element containing ParA/B, a recombinase, threonine 
dehydrogenase and hypothetical proteins at position 356,396 in 55-01 (25,415bp in length).  This insertion comprises of nine contigs so misassembly 




RT076 was the causative agent of CDI in one patient who suffered recurrent infection.   
Patient 61, a male 69 years of age had five distinct episodes of CDI totalling a period of 
183 days (Table 5-6).  The first four episodes were classed clinically as hospital acquired 
with the fifth occurring in the community (Table 5-17).  During the index episode, the 
patient was treated with both metronidazole and vancomycin which the isolates were shown 
to be sensitivity to in vitro.  The patient was also prescribed omeprazole during this time 
and had a raised CRP of 228 mg/L, both are risk factors for relapse.  During the second and 
third episodes, the patient was treated with fidaxomicin but this was unsuccessful in 
preventing future relapses.  It was not recorded if the patient was receiving any other 
treatments at this time or if his CRP level was raised.  For the fourth and fifth episodes, the 
patient received vancomycin alone as CDI therapy.  At the fourth episode, the patient again 
had a raised CRP level of 169 mg/L.  There was not a sixth relapse during the study period.  
SNP analysis of all four recurrence strains revealed no differences between the strains 
(Table 5-5).  Whole genome analysis of 61-01 compared to 630, R20291 and 57-01 (RT076 
control strain) showed a single unique region containing a Tn916-like element, region that 
shares 90% coverage with QCD23M63288 and contains a mobile element protein, 
hypothetical proteins, ABC transporter Vex, DltR, sensor histidine kinase and 




Table 5-17: Clinical information for patient 61 gathered at each sample collection. 
 





Hospital Hospital Hospital Hospital Community 






















Omeprazole Unknown Unknown None Unknown 
CRP >85 
mg/L 





(≤2 mg/L = 
sensitive) 





(≤2 mg/L = 
sensitive) 





Figure 5-16: A Mauve alignment between Clostridium difficile strains 630, R20291, 57-01 (RT075 control strain) and 61-01 the index strain from the 
relapsing patient PT61.  The red checked lines indicate a unique insertion of a Tn916-like element containing a region that shares 90% coverage with 
QCD23M63288 and contains a mobile element protein, hypothetical proteins, ABC transporter Vex, DltR, sensor histidine kinase and transcriptional 
regulators at position 2,913,503 in 61-01 (29,363bp in length).  Green box indicates Vex related genes and a blue arrow indicates the DltR gene.  This 




The aim of this study was to identify if risk factors, co-infection and / or host evolution of 
strains are associated with recurrent CDI.   To achieve this, we studied a cohort of patients 
from Nottingham University Hospitals NHS Trust between November 2013 and November 
2014 whom were suffering from their first episode of CDI within the past six months.   
There are many studies investigating the isolation of C. difficile from both stool277–280 and 
the environment281 however, they often rely on expensive commercially made chromogenic 
media which is often not affordable in the research setting.  As one of our interests was the 
rate of co-infection and its effect on recurrent CDI we wanted to develop a cost effective 
and robust method of C. difficile isolation of multiple colonies in small stool samples. 
We first looked at a broth enrichment step which revealed that CCFB could recover spores 
from faecal samples of hamsters infected with either CD630 or R20291.  CCMB-TAL was 
only able to recover spores from faeces containing spores from R20291 and this was after 
an additional 24 h incubation, when compared to CCFB, in all cases.  Whereas spores from 
both R20291 and CD630 were recoverable in CCFB after an overnight incubation. These 
findings suggest that fructose is a preferable carbon source over mannitol.  CCMB-TAL 
had an improved recovery rate over CCFB, which appears to correlate with previous 
findings where lysozyme increased the recovery rate of C. difficile283.  We assessed if the 
addition of lysozyme would enhance recovery in CCFB when tested against the faecal 
samples previously used.  In our case, there was no observed difference.  However, this 
sample size was small and may not be reliable.  CCFB was the chosen broth for future 
studies as sensitivity rather than recovery is more important in this case. 
The next stage of the C. difficile culture comparison study was to assess which of four solid 
media (CCFA, CCEY, ChromID C. difficile and TSA (5% sheep blood)) exhibited superior 
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performance.  This was assessed in two steps, firstly with a broth enrichment step followed 
by direct plating onto the solid media.  Secondly, plating stool supernatants directly onto 
the solid media.  Our findings were that only broths containing 104 spore/faecal mixtures 
gave a positive reaction when a broth enrichment step was utilised.   A recently published 
study stated that up to 10 CFU/mL C. difficile can be recovered after broth enrichment 
using CCMB-TAL289, although not directly comparable as different broths were utilised, 
our findings are contradictory.  It appears that Hink et al. may not have taken into account 
the number of spores within the spiked stool sample.  The medium used for calculating the 
number of CFU/mL used for spiking did not contain germinant therefore only vegetative 
cells would be enumerated.  However, the medium used in the experimental procedure 
contains taurocholate allowing spores to germinate and altering the CFU/mL in each 
sample by an undetermined amount. Therefore, the 10 CFU/mL value may be 
overestimated. 
The direct plating of stools onto the four chosen media showed that CCEY was the most 
sensitive being able to recover up to 102 spores but ChromID C. difficile had the best 
recovery rate.  In this study sensitivity is more important than recovery rate for recovering 
C. difficile from stool samples, especially in samples from patients where antibiotic 
treatment for CDI may have commenced. Consequently, we suggest a method of direct 
plating onto CCEY without a broth enrichment step.  Also by removing the broth 
enrichment step we eliminate the risk of selecting out a dominant ribotype through growth 
competition. 
Lastly we looked at using Neutral Red as an indicator to aid identification of growth of C. 
difficile on solid media.  We incorporated 1% Neutral Red into the recipe for CCEY and 
compared it to ChromID C. difficile.  For this we wanted to use clinical samples as even 
though the addition of cycloserine and cefoxitin is used to inhibit growth of faecal flora 
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there can be breakthrough of other organisms.  It is clear that the black pigmentation 
produced by ChromID C. difficile makes the identification of C. difficile easy.  It has been 
reported that not all C. difficile strains yield this pigment.  One study found that 3% and 
1% of samples did not produce the expected black pigment after 24 h and 48 h, 
respectively280 and this should be taken into account.   We found that no other faecal flora 
was cultivated from these samples and that the addition of the 1% neutral red did not give 
a necessary colour change to be used as an indicator of C. difficile growth.   
Overall direct plating of faecal supernatants onto CCEY provided a 95.9% recovery rate in 
this study when applied to the clinical samples, comparable to that of the CDRN252.   
Selection of patients into the study was based on them not having had a previous episode 
of CDI within the previous six months and that we were able to isolate C. difficile from the 
stool samples provided to the clinical microbiology department as part of their standard of 
care treatment.  The patient cohort was 59% female (59/100), 70% were 65 or over (70/100) 
and 15% were classified as community acquired cases of CDI (15/100).  There are reports 
of CA-CDI being more severe and affecting patients with no risk factors256,290,291.  Fifteen 
of the index strains were acquired in the community and of these five went on to relapse 
which agrees with other reports that CDI in no longer merely a nosocomial infection.  
Although there were no statistically significant findings when analysing the clinical 
information from the patient cohort there are some interesting results.  In this cohort almost 
all (10/11) patients who relapsed were ≥65 years of age and no one who received 
fidaxomicin for treatment of their index episode of CDI went on to relapse (5/5).   
There might have been a statistical significance for the risk factors i.e. additional 
antibiotics, use of PPI and raised CRP, if we were able to collect full clinical information.  
However, the number of unknowns in these categories may have affected these data. 
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The nature of this study was not one of epidemiological value due to a lack of patient 
location data, however, from the ribotype data gathered from the index episodes of CDI it 
can be seen that RT015 was the most prevalent within the hospital and community.  
According to CDRN data from December 2013 – December 2014 RT015 was the most 
prevalent throughout the East Midlands252.  Other ribotypes that are seen as emergent 
throughout the UK are RT002, RT078, RT014, RT005 and RT020 which were seen in 
12.21%, 7.63%, 6.87%, 6.11%, 5.34% and 3.82% of cases respectively.  Ribotypes that 
were seen more frequently but not yet classed as emergent were RT023 and RT076 with 
9.16% and 5.34% of cases respectively.  There has been much debate on whether lineage 
determines host specific outcome but as increasing evidence becomes available it appears 
likely that biomarkers and clinical scores are more accurate methods of prediction245,263,292–
296.   
In two patient samples, colonies originally thought to be C. difficile were revealed to be C. 
butyricum (PT98) and C. glycolicum (PT05).  These findings are interesting in themselves 
as although C. butyricum are known as a common commensal of the human and animal 
gut, subtype E1 can produce botulinum neurotoxin (BoNT).  This is due to a chromosomal 
insertion of an operon that has high similarity to BoNT carried by group II type E toxin-
producing C. botulinum297.  C. butyricum is also implicated in necrotizing enterocolitis in 
infants297 and antibiotic associated diarrhoea298.  C. glycolicum is also a common 
commensal of the human and animal gut although compared to C. butyricum there are few 
clinical cases demonstrating pathogenicity299.  To clarify if these organisms contributed to 
the clinical presentations in these cases further analysis of strains and a clinical history 
would be required but was not performed. 
Co-infection has recently been a topic of conversation within the C. difficile community.  
A few recent studies have looked into the rates of co-infection although they are mainly to 
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assess the levels for epidemiological reasons271–273,300.  Only one study has looked at co-
infection and its relationship with relapse270, they found that 9% of co-infected patients 
relapsed, although the study number was small (25 relapse patients). 
In our study cohort 13 out of 100 patients were found to be co-infected with two different 
ribotypes.  This value may be under representative due to the relatively insensitive nature 
of ribotyping and that only 20 colonies were used for downstream analysis. The level of 
co-infection might have been higher if either more colonies were studies or another typing 
method was used i.e. MLVA or whole genome sequencing271.  This is supported by the 
number of SNPs seen in this study between isolates of the same ribotype (Table 5-5). Two 
patients who suffered relapse episodes were also co-infected in either their index sample 
(PT10) or their relapse sample (PT39).  The method of screening used in our study is likely 
not sensitive enough to conclusively state that both ribotypes were not present in all 
samples for each patient.  Mixed colonisation may be due to two or more separate 
transmission events or possibly from a carrier whom is also colonised with more than one 
lineage which are transmitted simultaneously301.  This has been described in patients 
colonised with Staphylococcus aureus using VNTR302 and either scenario cannot be ruled 
out in these cases.  In this study co-infection was not statistically significant as a predictor 
of recurrent CDI although this might change if a more sensitive method of typing and / or 
more colonies were analysed from initial culture.  Therefore, this should be considered in 
future projects which employ more sensitive typing methods. 
Genome evolution can be a result of point mutation and is usually due to a beneficial 
modification such as adapting to environmental changes or avoiding host immune system.   
These mutations rates have been described in Helicobacter pylori as high as 30 mutations 
per year per genome303.  In C. difficile this rate has been estimated to be ~2 mutations per 
year per genome304.  These differences may be attributed to genome length and efficiency 
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of mismatch repair systems301.  On a larger scale horizontal gene transfer (HGT) speeds up 
diversification through the acquisition of multiple genes at one time.  Genomic plasticity is 
a widely accepted concept within the C. difficile genetics with examples of transposons, 
bacteriophages and plasmids being described154,207,215,288,305.  Phase variation, although not 
directly linked to genome evolution may be responsible for adaptation to a specific 
environment i.e. repression of surface proteins to avoid detection by the host immune 
system in Neisseria meningitides306.  We used whole genome and SNP analysis to see if 
any C. difficile isolates from our patient cohort that suffered relapse had evolved during 
infection or if any HGT had occurred that provided a fitness benefit. 
There have been a small number of studies using whole genome sequencing to study 
recurrence episodes in CDI.  However, these were used to assess transmission of strains 
between patients and differentiation between patients34,261,269 and only one looked further 
in to the genetic locations of SNPs to speculate about increased fitness benefit261.   
SNPs were analysed in strains isolated from the 11 patients suffering recurrence episodes 
to assess the level of within host evolution.  Unique genomic regions were also assessed, 
when compared to CD630, R20291 and the control strain of the same ribotype, to identify 
genes that may provide a fitness benefit.  A common definition of 8 weeks (56 days) is 
generally used to associate a recurrence episode261.  In two patients PT85 (RT015) and 
PT12 (RT023) there were no SNPs detected between the index and the recurrence 
suggesting relapse in both cases.  The length of time between index and relapse was 26 and 
38 days respectively.  Whole genome comparison of RT015 from PT85 showed a ~15kb 
region containing a number of genes but most interestingly a putative pilin which although 
not demonstrated experimentally, could provide a fitness benefit for adherence within the 
gut307.  Whole genome comparison of RT023 from PT12 revealed a unique phage region 
with similarity to ΦMMP02 although the genes within this region do not appear to confer 
205 
 
a fitness benefit.  SNP analysis of RT001 from PT39 had four tolerated SNPs and two 
unique phage regions with similarity to ΦMMP03 and ΦCD211.  As with RT023 from 
PT12 these regions do not appear to provide a fitness benefit. 
There were three patients who suffered one relapse more than 80 days after their index 
episode.  C. difficile ribotypes from PT19 and PT45 were RT015 and the ribotype from 
PT10 was RT023.  Both the C. difficile strains isolated from PT19 and PT10 had one 
ambiguous SNP and no unique genetic regions that appear to give a fitness benefit, these 
data do not provide an insight as to why the strains were able to persist in these patients for 
extended periods of time.  In the recurrence strain for PT45 there were six SNPs in total, 
one ambiguous, one tolerated substitution and four deleterious substitutions.  These were 
located in a RNA methyltransferase, a putative aldo/keto reductase, a hypothetical protein 
and a stage V sporulation protein.  It would only be speculation to suggest that these SNPs 
had an effect on recurrence or length of carriage.  However, the most interesting fact about 
these three patients is that they appear to have been colonised with the same strain of C. 
difficile for many weeks.  Previously, Lawley et al. demonstrated that in immunocompetent 
mice colonisation of C. difficile can occur and in this state a low level of spores are shed 
into the environment, and after treatment with antibiotics these mice became super 
shedders93.  Although only supposition it would be interesting to look into these patients in 
more detail to see if any transmission events occurred during this time to other patients 
within this study.  We have grouped PT45 in this category, however, studies suggest that 2 
– 10 SNP differences between genomes should be classed as intermediate and therefor 
indistinguishable between the same strain and a highly related strain308.  Meaning that this 
patient could have acquired a new strain. 
PT96s (RT001) length of carriage lasted 94 days with four distinct episodes of CDI.   There 
was one ambiguous SNP present in all four relapse samples and a tolerated SNP in a 
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hypoxanthine-guanine phosphoribosyl transferase found in PT96-03, which likely 
demonstrates heterogeneity of the population.  PT42 (RT015) had a 26-day length of 
carriage and no SNP were present in the recurrence genome.  The interesting observation 
in these two strains is there are multi antimicrobial extrusion protein MATE family of MDR 
efflux pump genes found in both that are unique to each strain.  Again one can only 
hypothesise that these genes may have a role in an increasing fitness benefit, but these 
genes are known to transport antibiotics out of bacterial cells in other organisms309 and 
although these isolates were found to be vancomycin and metronidazole sensitive in vitro 
this may not be the case in vivo.  There have also been studies identifying phase variation 
in both Staphylococci310 and Neisseria gonorrhoae311 where phase variation has been 
attributed to resistance to antimicrobials when under selective pressure. 
PT59 (RT076) length of carriage lasted 183 days with five distinct episodes of CDI.   No 
SNPs were detected in any of the relapse isolates suggesting the same strain of C. difficile 
was present throughout the whole period.  Whole genome analysis showed a Tn6073-like 
region which contains three Vex-like ABC transporter genes.  These genes along with a 
Pep27 (cell – cell signalling peptide) and VncR/S (subunits of a two-component signal 
transduction system) in have been demonstrated in Streptococcus pneumoniae to infer 
vancomycin tolerance312.  This patient was initially treated with vancomycin and 
metronidazole, then with fidaxomicin during their second and third episodes and finally 
with vancomycin during their fourth and fifth episodes.  So these genes alone would not 
likely explain the multiple recurrence episodes, it is however a curious correlation.   
Lastly PT05 (RT005) is the only patient identified as a re-infection through whole genome 
sequencing.  Even though both strains were of the same ribotype there were 61 SNPs 
identified between the index and the recurrence strain which is deemed an indicator of re-
infection34.  This is an interesting finding which suggests that low sensitive typing methods 
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are most likely under estimating the number of re-infections and labelling them relapse 
episodes34,261. 
There are some limitations to this study; the patient reference sequences may be deemed 
low quality due to the nature of de novo assembly of short reads.  This would be improved 
by using a third-generation sequencing technology such as SMRT or MinION sequencing.  
The method used in this study may not have given enough resolution to identify the 
locations of the unique regions and these may have been “dumped” at the end of the 
sequence during the move contigs step when using Mauve.  Also, we are not able to 
determine if the unique genes found in the whole genome alignment are not present in all 
the strains found in the non-relapse patients sharing the same ribotype as these were not 
analysed.  Using ribotyping as a method of assessing co-infection might have 
underestimated the level of co-infection within our study cohort.  It is not possible to state 
if the patients with apparent long-term carriage were indeed colonised for the whole period 
or if they re-acquired the same strain from an environmental source at a later date.  This 
could be resolved by collecting follow up stool samples after successful treatment in future 
studies.   
Although there are some limitations to this study we have identified a cost effective and 
sensitive method of isolating C. difficile from stool samples.  RT015 was the dominant 
circulating ribotype at the time but these data suggest that they may not be highly related 
at all and therefore questions are raised on how epidemiologically relevant this typing 
method is.  The sequencing data has also revealed that many of the relapse patients were 
potentially colonised for longer periods of time than the standard 8 weeks of classification 
for a relapse261.  This suggests two things; some of the C. difficile strains analysed in this 
study are not under short term selection pressure and these data suggests the commonly 
used classification of relapse should be redefined.  We also identified a number of genes 
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and SNPs that appear unique to the relapse strains which may infer a fitness benefit.  
However, this would require verifying experimentally before any conclusions could be 
made. 
5.4 Key Outcomes 
• A cost effective and sensitive method for the isolation of Clostridium difficile from 
stool samples. 
• CA-CDI is a significant risk factor for recurrent episodes of infection. 
• Co-infection was not a risk factor for recurrent CDI in this study cohort. 
• Carriage of the same C. difficile strain was seen for periods of time longer than the 
standard 8 weeks of classification for a relapse. 
• A number of genes and SNPs were identified as potential candidates for increased 
fitness benefit within relapsing strains. 
5.5 Future Work 
• Collect stool samples from non-relapse cases and assess the length of carriage over 
time. 
• Use whole genome sequencing on the non-relapse strains to confirm the uniqueness of 
genes found in strains from relapse cases of the same ribotype. 
















The aim of the first part of this thesis was to try and improve our knowledge of TcdA and 
TcdB regulation within C. difficile.  The role of TcdR in this process has been studied 
previously75,128 but our group are the first to create a clean deletion of this gene.  Earlier 
work as relied on fusion reporter systems and insertional gene inactivation, but we hoped 
that our study would more reflect the natural environment.  We were able to show that NM-
R20291∆tcdR had significantly less TcdA and TcdB in supernatants at 12, 24 and 48 h 
when compared to the wild-type and complemented strain.  These data further confirm the 
previous findings of Mani et al. in demonstrating that TcdR is a positive regulator of TcdA 
and TcdB transcription. 
It has been shown previously that over 50% of the CDS in C. difficile 630 have unknown 
functions175.  This hinders the understanding of regulatory networks when using reverse 
genetic analysis.  The use of forward genetic analysis allows us to randomly look for altered 
phenotypes and then identify candidate genes that are involved in these networks either 
directly or indirectly.  This is reliant on a robust and rapid screening method.  To overcome 
the laborious nature of measuring toxin in supernatants of C. difficile cultures a “reporter” 
strain was developed in which tcdB was replaced with licB a lichenase gene.  The lichenase 
breaks down lichenan which could be utilised in a plate assay and was believed to be 
comparative to the amount of toxin produced.  A random mutant library was produced 
using the mariner-transposon system which revealed a number of interesting phenotypes 
upon screening.  The most striking resulted from a double insertion where two genes were 
interrupted, R20291::2908 and R20291::jag.  R20291::2908 is thought to be involved in a 
programmed cell-death system and / or Type I restriction modification systems177 and 
R20291::jag in sporulation178.  ClosTron mutagenesis was employed to disrupt each of 
these genes individually to confirm the phenotypes seen in the transposon mutants.  Initially 
measurements of toxin in supernatants revealed that NM-R20291::2908(ermB) had reduced 
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concentrations when compared to wild-type.  However, these finding were not reproducible 
during complementation studies which was attributed to user error.  Current literature 
would also suggest that a gene involved in sporulation would more likely alter toxin 
production when disrupted.  Unfortunately, time constraints did not allow resolution of this 
issue. 
Even though through using the plate screening method we were able to identify altered 
phenotypes we wanted to produce a semi-quantitative method.  This involved using culture 
supernatants containing lichenase and liquid media containing a known concentration of 
lichenan.  This system had been used previously in C. botulinum within our group but we 
found it unreproducible in C. difficile.  We surmised that this is due to differences in both 
growth and toxin regulation between the two strains.   
The second aim of this study was to produce a complete genome map for the high toxin 
producing strain VPI 10463, to investigate possible genetic factors that may support this 
phenotype.  Using PacBio RSII and Illumina MiSeq technologies we were able to produce 
a complete circular genome for VPI 10463.  Analysis of the genome revealed a large 
inversion that occurs in two lineage specific regions, the largest described within C. difficile 
strains to date.  This was confirmed through the mapping of the long PacBio reads back to 
the newly created genome map for VPI 10463 which showed sufficient coverage over the 
inversion sites to rule out assembly error. Analysis of VPI 10463s orthologues revealed a 
candidate gene for the increased toxin production seen in this strain.  A putative second 
holin like gene which is not present in either CD630 or R20291 was hypothesised to allow 
more TcdA and TcdB out of the cell.  We aimed to test this experimentally using ClosTron 
mutagenesis but were unable to get transposition of the intron into the target gene.   
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A number of studies have shown there to be a link between toxin regulation and the 
inactivation of numerous flagella related genes161,162.  Analysis of the flagella operons in 
VPI 10463 revealed a nonsense mutation in fliJ resulting in a truncated protein.  This 
mutation has resulted in a monotrichous phenotype and a reduced zone of motility.  The 
effect of this mutation hasn’t been studied experimentally here but it may play a part in the 
increased toxin production seen in this strain. 
One of the issues hindering basic research of C. difficile is the low level of DNA transfer 
achievable within clinically relevant strains.  This means that most published studies where 
genetic manipulation occurs are focused on derivatives of CD630.  Recently there are 
examples of how making inferences from one strain to encompass the whole genus may 
result in inaccuracies313.  This being said we wanted to improve DNA transfer into VPI 
10463 and potentially other strains, so a broader knowledge can be gained from genetic 
studies.  Strains VPI 10463 and R20291 were found to have two and one type I restriction 
modification systems respectively.  ClosTron mutants were created to interrupt one of the 
restriction subunits (hsdR) in each strain.  We demonstrated that this insertional inactivation 
increased conjugation frequency in both strains.   
The last body of work presented here involved a study of patients within the University of 
Nottingham Hospitals NHS Trust.  The first part of this study was to develop an 
inexpensive and reliable method to isolate C. difficile from stool samples.  It was 
determined that direct plating of faecal supernatants onto CCEY after heat shock was 
sufficient to isolate C. difficile in 95.9% of cases.   
The overall aim of this study was to identify if risk factors, co-infection and / or host 
evolution of strains are associated with recurrent CDI.  The study included 100 patients 
suffering an episode of CDI if they had not had an episode within the previous six months.  
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Both co-infection and recurrence was found to be at 11% within this cohort although co-
infection was shown not a risk factor for recurrence.  None of the clinical information 
gathered for these patients were found to be statistically significant, although 90.9% of 
patients who relapsed were ≥65 years of age and if the patient received fidaxomicin for 
treatment of their index episode they did not suffer recurrence.   
Ribotype analysis of the infecting strains showed that the pattern observed in this patient 
cohort followed the trend reported by the CDRN for the East Midlands.  Interestingly, two 
isolates initially believed to be C. difficile were later found to be C. butyricum (PT98) and 
C. glycolicum (PT05).  Their involvement in the infection of these patients was not 
experimentally demonstrated here but has been shown to be pathogenic previously297,299.   
Whole genome sequencing of the isolates recovered from patients with recurrent CDI 
showed potential SNPs and unique genomic regions that could infer a fitness benefit in 
these strains.  Unique genes include a unique putative pilin which could increase adherence 
of this strain in the gut307, multi antimicrobial extrusion protein MATE family of MDR 
efflux pump genes which have been shown to increase resistance to antimicrobials when 
under selective pressure309 and Vex-like ABC transporter genes shown to infer vancomycin 
tolerance in Streptococcus pneumoniae312. 
Two patients had more than one recurrence episode, PT96 was 94 days with four episodes 
and PT59 was 183 days with five episodes and were found to have a MATE family of MDR 
efflux pump and a Vex-like ABC transporter gene respectively.   
The most common definition of time to recurrences is eight weeks (56 days), however in 
this study three patients relapsed strain >80 days after their index episode two of these 
patients with a genetically indistinct (one SNP difference) strain.  This suggests that there 
may be colonisation within the gut for much longer than we originally believed.   
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Only one patient who had a recurrence episode was shown to have re-infection through a 
different strain.  The index strain from PT05 was shown to be RT005, this patients 
recurrence strain was also shown to be RT005 however, there were 61 SNP identified 
between the two strains.  This number of SNP has been defined as indicative of a re-
infection34.  These findings show that routine typing methods may falsely define a 
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These data were kindly provided by Jorge Montfort-Gardeazabal and form part of his Ph.D. 
thesis. 
A number of SNPs have been identified in two different stock collections of C. difficile 
strain R20291 compared to the published sequence.  These strains are one from our 
laboratory in the Synthetic Biology Research Centre, University of Nottingham (NM-
R20291) and one from the London school of Hygiene and Tropical medicine laboratory 
(BW-R20291).  Table A1-0-1 shows a list of SNPs that are either found in both strains 
(yellow) compared to the reference strain sequence or SNPs only found in NM-R20291 
(green).  Yellow SNPs may be due to mistakes in the reference sequence.  SNPs found in 
NM-R20291 include a SNP in both rsbW (anti-sigma-B factor) and vncR (a two-component 
response regulator) resulting in missense mutations.  Deletions in rbsK (a ribokinase 
belonging to the pfkB family) and R20291_2456 (putative two-component sensor histidine 
kinase) resulting in transcription of incomplete proteins.   
It is believed that the SNPs in NM-R20291 have led to a number of phenotypic changes as 
BW-R20291 is genetically more identical to the ancestral strain. The phenotypic changes 
identified in NM-R20291 include improved growth kinetics when grown in either BHIS 
broth or minimal media containing glucose, fructose and mannitol.  NM-R20291 
demonstrated a reduced motility and was found to be monotrichous by TEM compared to 
BW-R20291, which is peritrichously flagellated.  NM-R20291 produces more toxin, 
sporulation occurs later and is able to form biofilms better than BW-R20291 (data from 




Table A1-0-1: Single nucleotide polymorphisms found in two R20291 strains compared to the 
reference sequence.  Yellow indicates SNPs identified in both strains and green indicates SNPs 









































































9694 SNP 1 G T 99.34211 rsbW Gly82Val 
132924 Insertion 1 - A 100   
132939 SNP 1 G T 100 CDR20291_t40  
132955 SNP 1 C A 100 CDR20291_t40  
132958 SNP 1 T G 100 CDR20291_t40  
132959 SNP 1 T C 100 CDR20291_t40  
143465 Insertion 1 - A 97.56098 
similar to 16S 
ribosomal RNA  
206403 Insertion 1 - A 97.22222   
358264 Deletion 1 A - 98.07692 rbsK Met57fs 
581484 Insertion 1 - A 94.94382   
581491 Insertion 1 - A 97.74011   
581498 Insertion 1 - A 94.47514   
1564437 Deletion 1 A - 96.79487   
1568676 SNP 1 C A 100 CDR20291_1323 Gln138Lys 
1578174 Deletion 1 T - 96.32353   
1578209 Insertion 1 - A 94.28571   
1592813 SNP 1 A T 100   
1864421 Insertion 1 - T 97.82609 CDR20291_1576  
1899604 Deletion 1 A - 94.57364   
2077305 Deletion 1 C - 100   
2120669 SNP 1 A G 99.43182 vncR Asp202Gly 
2235743 Deletion 1 T - 99.29078 CDR20291_1913 Lys81fs 
2262066 Insertion 1 - A 94.81481   
2264191 Deletion 1 T - 98.78049   
2298116 Insertion 1 - T 95.41985   
2361948 SNP 1 C A 100   
2361961 Insertion 1 - A 97.91667   
2367948 Insertion 1 - T 97.94521   
2578164 Deletion 1 T - 99.35484   
2674749 Deletion 1 T - 99.35484   
2680792 Insertion 1 - T 96.20253   
2772184 Deletion 1 T - 97.59615 CDR20291_2368  
2881470 Deletion 1 T - 98.21429 CDR20291_2456 Leu434fs 
3077994 Deletion 1 A - 98.77301   
3162105 Deletion 1 T - 96.7033   













In-house Whole Genome Analysis Pipeline 
 
De novo sequence assembly -  
 





canu [-correct | -trim | -assemble | -trim-assemble]  
-p <assembly-prefix>  
-d <assembly-directory>  
genomeSize=<number>[g|m|k]  
[other-options]  [-pacbio-raw | -pacbio-corrected | -nanopore-raw | -nanopore-
corrected] *fastq 
 
Mapping sequence reads to De novo sequence assembly - 
 
Indexing a reference file 
 
$ bwa index reference.fasta  
 
Aligning reads to reference 
 




-x Sequence data type 
-t Number of threads 
>output.sam output is SAM 
 
Generating a Bam File 
 
$ samtools view -S -b -o file.bam file.sam 
 
 Options Evoked 
 
 -b output is BAM 
-S input is SAM 
-o  output file name 
 
Sorting the Bam File 
 
$ samtools sort file.bam file_sorted 
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Table A3-0-1: Settings utilised for fixed ploidy variant detection in CLC genomics workbench 
V8.5.3 
 
Fixed Ploidy Variant Detection   
Ploidy 1 
Required variant probability (%) 90 
Ignore positions with coverage above 100000 
Minimum coverage 20 
Minimum count 10 
Minimum frequency (%) 90 
Restrict calling to target regions False  
Ignore broken pairs True 
Ignore non-specific matches Reads 
Minimum read length 20 
Base quality filter True 
Neighborhood radius 10 
Minimum central quality 30 
Minimum neighborhood quality 25 
Read direction filter True 
Direction frequency (%) 5 
Relative read direction filter True 
Significance (%) 1 
Read position filter True 
Significance (%) 1 
Remove pyro-error variants False 
In homopolymer regions with minimum length 3 



















Table A4-0-1: List of genes unique to C. difficile strain VPI 10463 after comparison to 630 
and R20291 
 
Gene Name Product 
Ga0114281_113664 chromosomal replication initiator protein DnaA 
Ga0114281_113570 putative transposase 
Ga0114281_113569 putative transposase 
Ga0114281_113566 glycoside/pentoside/hexuronide:cation symporter, GPH family 
Ga0114281_113565 glycoside/pentoside/hexuronide:cation symporter, GPH family 
Ga0114281_113456 aspartate aminotransferase 
Ga0114281_113455 ribonucleoside-triphosphate reductase class III catalytic subunit 
Ga0114281_113454 anaerobic ribonucleoside-triphosphate reductase activating protein 
Ga0114281_113396 hypothetical protein 
Ga0114281_113382 ParB/RepB/Spo0J family partition protein 
Ga0114281_113381 hypothetical protein 
Ga0114281_113380 hypothetical protein 
Ga0114281_113379 Antirestriction protein (ArdA) 
Ga0114281_113378 hypothetical protein 
Ga0114281_113377 Protein of unknown function (DUF3801) 
Ga0114281_113376 type IV secretion system protein VirD4 
Ga0114281_113375 cAMP-binding domain of CRP or a regulatory subunit of cAMP-dependent protein kinases 
Ga0114281_113374 hypothetical protein 
Ga0114281_113373 RNA polymerase sigma factor, sigma-70 family 
Ga0114281_113372 RNA polymerase sigma-70 factor, ECF subfamily 
Ga0114281_113371 plasmid mobilization system relaxase 
Ga0114281_113370 Cysteine-rich VLP 
Ga0114281_113369 phage replisome organizer, putative, N-terminal region 
Ga0114281_113368 phage DNA replication protein (predicted replicative helicase loader) 
Ga0114281_113367 Site-specific DNA recombinase 
Ga0114281_113366 hypothetical protein 
Ga0114281_113365 stage V sporulation protein G 
Ga0114281_113364 hypothetical protein 
Ga0114281_113363 PrgI family protein 
Ga0114281_113362 Type IV secretory pathway, VirB4 component 
Ga0114281_113361 NlpC/P60 family protein 
Ga0114281_113360 protein of unknown function (DUF4366) 
Ga0114281_113359 hypothetical protein 
Ga0114281_113358 hypothetical protein 
Ga0114281_113357 hypothetical protein 
Ga0114281_113356 Relaxase/Mobilisation nuclease domain-containing protein 
Ga0114281_113355 DNA-binding transcriptional regulator, XRE-family HTH domain 
Ga0114281_113354 His Kinase A (phospho-acceptor) domain-containing protein 
Ga0114281_113353 DNA-binding response regulator, OmpR family, contains REC and winged-helix (wHTH) domain 
Ga0114281_113352 bacitracin transport system ATP-binding protein 
Ga0114281_113351 ABC-2 type transport system permease protein/bacitracin transport system permease protein 
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Ga0114281_113350 ABC-2 type transport system permease protein 
Ga0114281_113349 conserved hypothetical protein TIGR01655 
Ga0114281_113348 hypothetical protein 
Ga0114281_113347 Site-specific DNA recombinase 
Ga0114281_113344 hypothetical protein 
Ga0114281_113342 putative ABC transport system ATP-binding protein 
Ga0114281_113341 ABC-type transport system, involved in lipoprotein release, permease component 
Ga0114281_113340 hypothetical protein 
Ga0114281_113339 DNA-binding response regulator, OmpR family, contains REC and winged-helix (wHTH) domain 
Ga0114281_113338 Signal transduction histidine kinase 
Ga0114281_113337 putative ABC transport system ATP-binding protein 
Ga0114281_113336 putative ABC transport system permease protein 
Ga0114281_113335 hypothetical protein 
Ga0114281_113298 Site-specific recombinase XerD 
Ga0114281_113297 Helix-turn-helix domain-containing protein 
Ga0114281_113296 hypothetical protein 
Ga0114281_113295 DNA-binding transcriptional regulator, XRE-family HTH domain 
Ga0114281_113294 putative transcriptional regulator 
Ga0114281_113293 hypothetical protein 
Ga0114281_113292 Arc-like DNA binding domain-containing protein 
Ga0114281_113291 hypothetical protein 
Ga0114281_113290 anti-repressor protein 
Ga0114281_113289 hypothetical protein 
Ga0114281_113288 DeoR-like helix-turn-helix domain-containing protein 
Ga0114281_113287 hypothetical protein 
Ga0114281_113286 hypothetical protein 
Ga0114281_113285 virus Gp157 
Ga0114281_113284 ERF superfamily protein 
Ga0114281_113283 DnaD and phage-associated domain-containing protein 
Ga0114281_113282 hypothetical protein 
Ga0114281_113281 single-strand DNA-binding protein 
Ga0114281_113280 phage uncharacterized protein TIGR01671 
Ga0114281_113279 hypothetical protein 
Ga0114281_113278 hypothetical protein 
Ga0114281_113277 iron(III) transport system ATP-binding protein 
Ga0114281_113276 hypothetical protein 
Ga0114281_113275 hypothetical protein 
Ga0114281_113274 hypothetical protein 
Ga0114281_113273 hypothetical protein 
Ga0114281_113272 hypothetical protein 
Ga0114281_113271 3'-phosphoadenosine 5'-phosphosulfate sulfotransferase (PAPS reductase)/FAD synthetase 
Ga0114281_113270 hypothetical protein 
Ga0114281_113269 hypothetical protein 
Ga0114281_113268 hypothetical protein 
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Ga0114281_113267 hypothetical protein 
Ga0114281_113266 hypothetical protein 
Ga0114281_113265 Holliday junction resolvase RusA (prophage-encoded endonuclease) 
Ga0114281_113264 ORF6N domain-containing protein 
Ga0114281_113263 hypothetical protein 
Ga0114281_113262 iron(III) transport system ATP-binding protein 
Ga0114281_113261 hypothetical protein 
Ga0114281_113260 iron(III) transport system ATP-binding protein 
Ga0114281_113259 hypothetical protein 
Ga0114281_113258 hypothetical protein 
Ga0114281_113257 Uncharacterized protein YjcR 
Ga0114281_113256 phage terminase large subunit 
Ga0114281_113255 phage portal protein, SPP1 family 
Ga0114281_113254 phage putative head morphogenesis protein, SPP1 gp7 family 
Ga0114281_113253 hypothetical protein 
Ga0114281_113252 Phage minor structural protein GP20 
Ga0114281_113251 hypothetical protein 
Ga0114281_113250 hypothetical protein 
Ga0114281_113249 hypothetical protein 
Ga0114281_113248 hypothetical protein 
Ga0114281_113247 Bacteriophage HK97-gp10, putative tail-component 
Ga0114281_113246 hypothetical protein 
Ga0114281_113245 hypothetical protein 
Ga0114281_113244 Phage tail sheath protein 
Ga0114281_113243 Phage tail tube protein 
Ga0114281_113242 hypothetical protein 
Ga0114281_113241 Phage XkdN-like tail assembly chaperone protein, TAC 
Ga0114281_113240 hypothetical protein 
Ga0114281_113239 tape measure domain-containing protein 
Ga0114281_113238 LysM domain-containing protein 
Ga0114281_113237 NlpC/P60 family protein 
Ga0114281_113236 Protein of unknown function (DUF2577) 
Ga0114281_113235 Protein of unknown function (DUF2634) 
Ga0114281_113234 Uncharacterized phage protein gp47/JayE 
Ga0114281_113233 hypothetical protein (DUF2313) 
Ga0114281_113232 Phage tail-collar fibre protein 
Ga0114281_113231 Glycine rich protein 
Ga0114281_113230 hypothetical protein 
Ga0114281_113229 hypothetical protein 
Ga0114281_113228 hypothetical protein 
Ga0114281_113227 hypothetical protein 
Ga0114281_113226 Haemolysin XhlA 
Ga0114281_113225 Phage holin family Hol44, holin superfamily V 
Ga0114281_113224 N-acetylmuramoyl-L-alanine amidase 
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Ga0114281_113223 hypothetical protein 
Ga0114281_113222 hypothetical protein 
Ga0114281_113221 hypothetical protein 
Ga0114281_113220 Zn-dependent peptidase ImmA, M78 family 
Ga0114281_113219 hypothetical protein 
Ga0114281_113218 hypothetical protein 
Ga0114281_113217 hypothetical protein 
Ga0114281_113215 Predicted transcriptional regulator 
Ga0114281_113214 Predicted transcriptional regulator 
Ga0114281_113092 hypothetical protein 
Ga0114281_113091 Phage integrase family protein 
Ga0114281_113090 hypothetical protein 
Ga0114281_113089 Helix-turn-helix 
Ga0114281_113088 hypothetical protein 
Ga0114281_113087 hypothetical protein 
Ga0114281_113086 hypothetical protein 
Ga0114281_113085 hypothetical protein 
Ga0114281_113084 hypothetical protein 
Ga0114281_113083 hypothetical protein 
Ga0114281_113082 toxin secretion/phage lysis holin 
Ga0114281_113081 N-acetylmuramoyl-L-alanine amidase 
Ga0114281_113080 hypothetical protein 
Ga0114281_113079 hypothetical protein 
Ga0114281_113078 hypothetical protein 
Ga0114281_113077 type I restriction enzyme M protein 
Ga0114281_113076 type I restriction enzyme, S subunit 
Ga0114281_113075 hypothetical protein 
Ga0114281_113074 hypothetical protein 
Ga0114281_113073 hypothetical protein 
Ga0114281_113072 type I restriction enzyme, R subunit 
Ga0114281_113071 hypothetical protein 
Ga0114281_113070 hypothetical protein 
Ga0114281_113069 DNA repair protein RadC 
Ga0114281_113068 protein of unknown function (DUF960) 
Ga0114281_113067 hypothetical protein 
Ga0114281_113066 hypothetical protein 
Ga0114281_113065 hypothetical protein 
Ga0114281_113064 hypothetical protein 
Ga0114281_113063 hypothetical protein 
Ga0114281_113062 hypothetical protein 
Ga0114281_113061 hypothetical protein 
Ga0114281_113060 hypothetical protein 
Ga0114281_113059 hypothetical protein 
Ga0114281_113058 hypothetical protein 
255 
 
Ga0114281_113057 hypothetical protein 
Ga0114281_113056 hypothetical protein 
Ga0114281_113055 hypothetical protein 
Ga0114281_113054 hypothetical protein 
Ga0114281_113053 hypothetical protein 
Ga0114281_113052 hypothetical protein 
Ga0114281_113051 hypothetical protein 
Ga0114281_113050 hypothetical protein 
Ga0114281_113049 site-specific DNA recombinase 
Ga0114281_113048 protein of unknown function (DUF4297) 
Ga0114281_113047 hypothetical protein 
Ga0114281_113046 hypothetical protein 
Ga0114281_113045 hypothetical protein 
Ga0114281_113044 transcriptional regulator, LytTR family 
Ga0114281_113043 hypothetical protein 
Ga0114281_113042 hypothetical protein 
Ga0114281_113041 hypothetical protein 
Ga0114281_113040 Protein of unknown function (DUF3139) 
Ga0114281_113039 putative ABC transport system permease protein 
Ga0114281_113038 putative ABC transport system ATP-binding protein 
Ga0114281_113029 iron(III) transport system permease protein 
Ga0114281_112987 6-phospho-beta-glucosidase 
Ga0114281_112964 type I restriction enzyme, S subunit 
Ga0114281_112963 hypothetical protein 
Ga0114281_112962 Predicted nucleotidyltransferase 
Ga0114281_112779 Ala-tRNA(Pro) deacylase 
Ga0114281_112708 hypothetical protein 
Ga0114281_112447 hypothetical protein 
Ga0114281_112446 Putative cell wall binding repeat 2 
Ga0114281_112445 hypothetical protein 
Ga0114281_112443 hypothetical protein 
Ga0114281_112328 hydrophobic/amphiphilic exporter-1, HAE1 family 
Ga0114281_112308 Putative peptidoglycan binding domain-containing protein 
Ga0114281_112307 transcriptional repressor, CopY family 
Ga0114281_112306 Signal transducer regulating beta-lactamase production, contains metallopeptidase domain 
Ga0114281_112305 Putative peptidoglycan binding domain-containing protein 
Ga0114281_112229 Response regulator receiver domain-containing protein 
Ga0114281_112226 ABC transporter 
Ga0114281_112214 putative transposase 
Ga0114281_112213 hypothetical protein 
Ga0114281_112212 hypothetical protein 
Ga0114281_112211 hypothetical protein 
Ga0114281_112210 hypothetical protein 
Ga0114281_112209 hypothetical protein 
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Ga0114281_112208 BRO family, N-terminal domain 
Ga0114281_112207 hypothetical protein 
Ga0114281_112206 hypothetical protein 
Ga0114281_112205 hypothetical protein 
Ga0114281_112204 hypothetical protein 
Ga0114281_112203 hypothetical protein 
Ga0114281_112202 hypothetical protein 
Ga0114281_112201 putative transcriptional regulator 
Ga0114281_112200 Predicted transcriptional regulator 
Ga0114281_112121 hypothetical protein 
Ga0114281_112077 Sodium:dicarboxylate symporter family protein 
Ga0114281_112032 hypothetical protein 
Ga0114281_112031 hypothetical protein 
Ga0114281_112006 MatE protein 
Ga0114281_112005 putative efflux protein, MATE family 
Ga0114281_111904 transcriptional regulator, TetR family 
Ga0114281_111903 Pimeloyl-ACP methyl ester carboxylesterase 
Ga0114281_111902 hypothetical protein 
Ga0114281_111901 hypothetical protein 
Ga0114281_111900 DNA-binding transcriptional regulator, MarR family 
Ga0114281_111899 putative efflux protein, MATE family 
Ga0114281_111898 hypothetical protein 
Ga0114281_111897 hypothetical protein 
Ga0114281_111875 hypothetical protein 
Ga0114281_111869 hypothetical protein 
Ga0114281_111771 hypothetical protein 
Ga0114281_111770 ABC-2 type transport system ATP-binding protein 
Ga0114281_111769 hypothetical protein 
Ga0114281_111768 RNA polymerase sigma-70 factor, ECF subfamily 
Ga0114281_111767 transcriptional regulator, PadR family 
Ga0114281_111766 protein of unknown function (DUF303) 
Ga0114281_111765 hypothetical protein 
Ga0114281_111764 transcriptional regulator, AraC family 
Ga0114281_111763 Site-specific DNA recombinase 
Ga0114281_111760 conserved repeat domain-containing protein 
Ga0114281_111715 Site-specific recombinase XerD 
Ga0114281_111714 Site-specific recombinase XerD 
Ga0114281_111713 hypothetical protein 
Ga0114281_111569 Transcriptional regulatory protein, C terminal 
Ga0114281_111568 Restriction endonuclease 
Ga0114281_111567 hypothetical protein 
Ga0114281_111566 hypothetical protein 
Ga0114281_111565 dGTPase 
Ga0114281_111564 N-acetylmuramoyl-L-alanine amidase 
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Ga0114281_111563 N-acetylmuramoyl-L-alanine amidase 
Ga0114281_111562 toxin secretion/phage lysis holin 
Ga0114281_111561 hypothetical protein 
Ga0114281_111560 hypothetical protein 
Ga0114281_111559 hypothetical protein 
Ga0114281_111558 phage uncharacterized protein, XkdX family 
Ga0114281_111557 hypothetical protein 
Ga0114281_111499 hypothetical protein 
Ga0114281_111453 Lysophospholipase, alpha-beta hydrolase superfamily 
Ga0114281_111449 hypothetical protein 
Ga0114281_111448 hypothetical protein 
Ga0114281_111447 Putative cell wall binding repeat 2 
Ga0114281_111443 Haemolysin XhlA 
Ga0114281_111442 hypothetical protein 
Ga0114281_111441 hypothetical protein 
Ga0114281_111440 hypothetical protein 
Ga0114281_111439 hypothetical protein 
Ga0114281_111438 hypothetical protein 
Ga0114281_111437 hypothetical protein 
Ga0114281_111436 hypothetical protein 
Ga0114281_111435 hypothetical protein 
Ga0114281_111432 Glycine rich protein 
Ga0114281_111431 Phage tail-collar fibre protein 
Ga0114281_111430 hypothetical protein (DUF2313) 
Ga0114281_111429 Uncharacterized phage protein gp47/JayE 
Ga0114281_111428 Protein of unknown function (DUF2634) 
Ga0114281_111427 Protein of unknown function (DUF2577) 
Ga0114281_111426 NlpC/P60 family protein 
Ga0114281_111424 tape measure domain-containing protein 
Ga0114281_111423 hypothetical protein 
Ga0114281_111422 hypothetical protein 
Ga0114281_111418 hypothetical protein 
Ga0114281_111416 Bacteriophage HK97-gp10, putative tail-component 
Ga0114281_111415 hypothetical protein 
Ga0114281_111414 hypothetical protein 
Ga0114281_111413 hypothetical protein 
Ga0114281_111410 hypothetical protein 
Ga0114281_111409 phage putative head morphogenesis protein, SPP1 gp7 family 
Ga0114281_111408 phage portal protein, SPP1 family 
Ga0114281_111407 phage terminase large subunit 
Ga0114281_111406 Uncharacterized protein YjcR 
Ga0114281_111405 hypothetical protein 
Ga0114281_111404 hypothetical protein 
Ga0114281_111403 protein of unknown function (DUF4868) 
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Ga0114281_111402 KTSC domain-containing protein 
Ga0114281_111401 hypothetical protein 
Ga0114281_111400 hypothetical protein 
Ga0114281_111397 VRR-NUC domain-containing protein 
Ga0114281_111396 hypothetical protein 
Ga0114281_111391 hypothetical protein 
Ga0114281_111388 hypothetical protein 
Ga0114281_111387 Helix-turn-helix domain-containing protein 
Ga0114281_111386 Cro/C1-type HTH DNA-binding domain-containing protein 
Ga0114281_111385 hypothetical protein 
Ga0114281_111384 hypothetical protein 
Ga0114281_111383 Phage antirepressor protein YoqD, KilAC domain 
Ga0114281_111382 hypothetical protein 
Ga0114281_111381 hypothetical protein 
Ga0114281_111380 hypothetical protein 
Ga0114281_111379 Arc-like DNA binding domain-containing protein 
Ga0114281_111378 phage regulatory protein, rha family 
Ga0114281_111377 putative transcriptional regulator 
Ga0114281_111376 Transcriptional regulator, contains XRE-family HTH domain 
Ga0114281_111375 SIR2-like domain-containing protein 
Ga0114281_111267 putative ABC transport system permease protein 
Ga0114281_111266 putative ABC transport system permease protein 
Ga0114281_111262 hypothetical protein 
Ga0114281_111261 GntR family transcriptional regulator 
Ga0114281_111121 PAS domain S-box-containing protein/diguanylate cyclase (GGDEF) domain-containing protein 
Ga0114281_111024 hypothetical protein 
Ga0114281_111020 hypothetical protein 
Ga0114281_111018 transposon Tn916 excisionase 
Ga0114281_111017 Helix-turn-helix domain-containing protein 
Ga0114281_111016 RNA polymerase sigma factor, sigma-70 family 
Ga0114281_111015 hypothetical protein 
Ga0114281_111014 protein of unknown function (DUF4177) 
Ga0114281_111013 Glycopeptide antibiotics resistance protein 
Ga0114281_111012 Cyclopropane fatty-acyl-phospholipid synthase 
Ga0114281_111011 transcriptional regulator, TetR family 
Ga0114281_111010 hypothetical protein 
Ga0114281_111003 Conjugative transposon protein TcpC 
Ga0114281_111002 NlpC/P60 family protein 
Ga0114281_111001 AraC family transcriptional regulator 
Ga0114281_111000 AraC family transcriptional regulator 
Ga0114281_11999 ribosomal-protein-alanine N-acetyltransferase 
Ga0114281_11998 tRNA-Thr(GGU) m(6)t(6)A37 methyltransferase TsaA 
Ga0114281_11997 DNA-binding transcriptional regulator, MerR family 
Ga0114281_11996 Conjugative transposon protein TcpC 
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Ga0114281_11995 Glycopeptide antibiotics resistance protein 
Ga0114281_11994 MFS transporter, DHA1 family, multidrug resistance protein 
Ga0114281_11993 pyruvate, water dikinase 
Ga0114281_11992 transcriptional regulator, TetR family 
Ga0114281_11987 TcpE family protein 
Ga0114281_11985 Antirestriction protein (ArdA) 
Ga0114281_11984 hypothetical protein 
Ga0114281_11983 Acetyltransferase (GNAT) domain-containing protein 
Ga0114281_11981 Protein of unknown function (DUF3789) 
Ga0114281_11976 hypothetical protein 
Ga0114281_11975 Protein of unknown function (DUF3788) 
Ga0114281_11974 Catechol 2,3-dioxygenase 
Ga0114281_11973 protein of unknown function (DUF961) 
Ga0114281_11967 Helix-turn-helix 
Ga0114281_11966 Peptidase propeptide and YPEB domain-containing protein 
Ga0114281_11965 Putative cell wall binding repeat 2 
Ga0114281_11964 hypothetical protein 
Ga0114281_11539 Acetyltransferase (isoleucine patch superfamily) 
Ga0114281_11538 DNA-binding transcriptional regulator, LysR family 
Ga0114281_11457 hypothetical protein 
Ga0114281_11435 hypothetical protein 
Ga0114281_11399 hypothetical protein 
Ga0114281_11394 hypothetical protein 
Ga0114281_11329 Putative cell wall binding repeat 2 
Ga0114281_11328 hypothetical protein 
Ga0114281_11327 Fic family protein 
Ga0114281_11309 ABC-2 type transport system ATP-binding protein 
Ga0114281_11308 hypothetical protein 
Ga0114281_11300 putative transposase 
Ga0114281_11291 regulatory protein, gntR family 
Ga0114281_11290 diguanylate cyclase (GGDEF) domain-containing protein 
Ga0114281_11289 hypothetical protein 
Ga0114281_11288 His Kinase A (phospho-acceptor) domain-containing protein 
Ga0114281_11273 Site-specific DNA recombinase 
Ga0114281_11272 hypothetical protein 
Ga0114281_11271 Helix-turn-helix domain-containing protein 
Ga0114281_11270 Sigma-70, region 4 
Ga0114281_11269 ATP-binding cassette, subfamily B 
Ga0114281_11268 ATP-binding cassette, subfamily B 
Ga0114281_11267 AraC-type DNA-binding protein 
Ga0114281_11266 energy-coupling factor transport system ATP-binding protein 
Ga0114281_11265 energy-coupling factor transport system permease protein 
Ga0114281_11264 energy-coupling factor transport system substrate-specific component 
Ga0114281_11263 thiazolinyl imide reductase 
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Ga0114281_11262 hypothetical protein 
Ga0114281_11261 pyochelin synthetase 
Ga0114281_11260 yersiniabactin nonribosomal peptide synthetase 
Ga0114281_11259 yersiniabactin salicyl-AMP ligase 
Ga0114281_11258 4'-phosphopantetheinyl transferase 
Ga0114281_11257 Surfactin synthase thioesterase subunit 
Ga0114281_11256 3-deoxy-D-arabinoheptulosonate-7-phosphate synthase 
Ga0114281_11255 salicylate synthetase/yersiniabactin salicyl-AMP ligase 
Ga0114281_11254 iron (metal) dependent repressor, DtxR family 
Ga0114281_11253 Conjugative transposon protein TcpC 
Ga0114281_11252 Cell wall-associated hydrolase, NlpC family 
Ga0114281_11251 hypothetical protein 
Ga0114281_11250 AAA-like domain-containing protein 
Ga0114281_11249 TcpE family protein 
Ga0114281_11248 hypothetical protein 
Ga0114281_11247 hypothetical protein 
Ga0114281_11246 hypothetical protein 
Ga0114281_11245 Antirestriction protein 
Ga0114281_11244 hypothetical protein 
Ga0114281_11243 hypothetical protein 
Ga0114281_11242 hypothetical protein 
Ga0114281_11241 phage replication initiation protein 
Ga0114281_11240 FtsK/SpoIIIE family protein 
Ga0114281_11239 protein of unknown function (DUF961) 
Ga0114281_11238 protein of unknown function (DUF961) 
Ga0114281_11237 LPXTG-motif cell wall anchor domain-containing protein 
Ga0114281_11236 TatD DNase family protein 
Ga0114281_11235 hypothetical protein 
Ga0114281_11234 hypothetical protein 
Ga0114281_11233 KAP family P-loop domain-containing protein 
Ga0114281_11228 hypothetical protein 
Ga0114281_11105 flagellar FliJ protein 
Ga0114281_11104 flagellar FliJ protein 
Ga0114281_1194 WxcM-like, C-terminal 
Ga0114281_1144 Predicted transcriptional regulator 
Ga0114281_1143 Predicted transcriptional regulator 
Ga0114281_1141 hypothetical protein 
Ga0114281_1140 hypothetical protein 
Ga0114281_1139 Zn-dependent peptidase ImmA, M78 family 
Ga0114281_1138 hypothetical protein 
Ga0114281_1137 hypothetical protein 
Ga0114281_1136 hypothetical protein 
Ga0114281_1135 N-acetylmuramoyl-L-alanine amidase 
Ga0114281_1134 holin, TcdE family 
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Ga0114281_1133 hypothetical protein 
Ga0114281_1132 hypothetical protein 
Ga0114281_1131 hypothetical protein 
Ga0114281_1130 Glycine rich protein 
Ga0114281_1129 Phage tail-collar fibre protein 
Ga0114281_1128 hypothetical protein (DUF2313) 
Ga0114281_1127 Uncharacterized phage protein gp47/JayE 
Ga0114281_1126 Protein of unknown function (DUF2634) 
Ga0114281_1125 Protein of unknown function (DUF2577) 
Ga0114281_1124 Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase 
Ga0114281_1123 LysM domain-containing protein 
Ga0114281_1122 tape measure domain-containing protein 
Ga0114281_1121 protein of unknown function (DUF4428) 
Ga0114281_1120 Phage XkdN-like tail assembly chaperone protein, TAC 
Ga0114281_1119 hypothetical protein 
Ga0114281_1118 Phage tail tube protein 
Ga0114281_1117 Phage tail sheath protein 
Ga0114281_1116 hypothetical protein 
Ga0114281_1115 hypothetical protein 
Ga0114281_1114 Bacteriophage HK97-gp10, putative tail-component 
Ga0114281_1113 hypothetical protein 
Ga0114281_1112 hypothetical protein 
Ga0114281_1111 hypothetical protein 
Ga0114281_1110 hypothetical protein 
Ga0114281_119 Phage minor structural protein GP20 
Ga0114281_118 hypothetical protein 
Ga0114281_117 phage putative head morphogenesis protein, SPP1 gp7 family 
Ga0114281_116 phage portal protein, SPP1 family 
Ga0114281_115 phage terminase large subunit 
Ga0114281_114 Uncharacterized protein YjcR 
Ga0114281_113 hypothetical protein 
Ga0114281_112 hypothetical protein 
Ga0114281_111 iron(III) transport system ATP-binding protein 
Ga0114281_114103 hypothetical protein 
Ga0114281_114102 iron(III) transport system ATP-binding protein 
Ga0114281_114101 hypothetical protein 
Ga0114281_114100 ORF6N domain-containing protein 
Ga0114281_114099 Holliday junction resolvase RusA (prophage-encoded endonuclease) 
Ga0114281_114098 hypothetical protein 
Ga0114281_114097 hypothetical protein 
Ga0114281_114096 hypothetical protein 
Ga0114281_114095 hypothetical protein 
Ga0114281_114094 hypothetical protein 
Ga0114281_114093 3'-phosphoadenosine 5'-phosphosulfate sulfotransferase (PAPS reductase)/FAD synthetase 
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Ga0114281_114092 hypothetical protein 
Ga0114281_114091 hypothetical protein 
Ga0114281_114090 hypothetical protein 
Ga0114281_114089 hypothetical protein 
Ga0114281_114088 hypothetical protein 
Ga0114281_114087 iron(III) transport system ATP-binding protein 
Ga0114281_114086 hypothetical protein 
Ga0114281_114085 hypothetical protein 
Ga0114281_114084 phage uncharacterized protein TIGR01671 
Ga0114281_114083 DnaD and phage-associated domain-containing protein 
Ga0114281_114082 recombination protein RecT 
Ga0114281_114081 putative phage-type endonuclease 
Ga0114281_114080 hypothetical protein 
Ga0114281_114079 hypothetical protein 
Ga0114281_114078 Arc-like DNA binding domain-containing protein 
Ga0114281_114077 Arc-like DNA binding domain-containing protein 
Ga0114281_114076 hypothetical protein 
Ga0114281_114075 DNA binding domain-containing protein, excisionase family 
Ga0114281_114074 ORF6N domain-containing protein 
Ga0114281_114073 putative transcriptional regulator 
Ga0114281_114072 Helix-turn-helix 
Ga0114281_114071 hypothetical protein 
Ga0114281_114070 SAP domain-containing protein 
Ga0114281_114069 T5orf172 domain-containing protein 
Ga0114281_114068 hypothetical protein 
Ga0114281_114067 Predicted nuclease of the RNAse H fold, HicB family 
Ga0114281_114066 Site-specific recombinase XerD 
Ga0114281_113834 iron(III) transport system ATP-binding protein 
Ga0114281_113726 PAS domain-containing protein 
Ga0114281_113719 CAAX protease self-immunity 


























Treatment Antibiotic use PPI CRPb (Normal 
range 1-10 
mg/L) 
01-01 Hospital Acquired No 015 0.5 0.5 Vancomycin Yes Yes 131 
02-01 Community Acquired No 070 1 0.5 Vancomycin Yes No 124 
03-01 Hospital Acquired No 015 0.5 0.5 Vancomycin Yes No 49 
04-01(1) Hospital Acquired No 031 0.5 0.25 Metronidazole Yes Yes 111 
04-01(2) Hospital Acquired No 224 1 0.25 
    
05-01 Community Acquired No 005 1 0.25 Metronidazole Unknown Unknown Unknown 
05-02 Community Acquired Yes 005 1 0.25 Vancomycin Unknown Unknown Unknown 
06-01 Community Acquired No 023 1 0.12 Metronidazole Unknown Unknown Unknown 
07-01 Hospital Acquired No 023 0.5 0.12 Vancomycin Yes No 253 
08-01(1) Hospital Acquired No 002 1 0.5 Metronidazole No No 43 
08-01(2) Hospital Acquired No 062 1 0.5 
    
09-01 Hospital Acquired No 005 1 0.5 Vancomycin No No 22 
10-01(1) Hospital Acquired No 062 1 0.5 Vancomycin Yes No 367 
10-01(2) Hospital Acquired No 023 1 0.25 
    
10-02 Hospital Acquired Yes 023 0.25 1 Vancomycin No No 244 
11-01 Hospital Acquired No 002 0.5 0.5 Vancomycin No No 26 
12-01 Hospital Acquired No 023 1 0.25 Metronidazole No Yes 28 
12-02 Hospital Acquired Yes 023 0.12 1 Vancomycin No Yes 171 
13-01 Hospital Acquired No 013 0.5 0.5 Vancomycin Yes No 79 
14-01 Hospital Acquired No 020 0.5 0.5 Vancomycin Yes Yes 135 
15-01 Hospital Acquired No 002 1 0.5 Metronidazole No Yes 95 
16-01 Hospital Acquired No 017 0.5 0.5 Unknown Yes No Unknown 
17-01 Hospital Acquired No 220 1 1 Vancomycin No No 198 
18-01 Hospital Acquired No 078 0.5 0.25 Metronidazole Yes Yes 267 













Treatment Antibiotic use PPI CRPb (Normal 
range 1-10 
mg/L) 
19-02 Community Acquired Yes 015 0.5 0.5 Metronidazole Unknown Unknown Unknown 
20-01 Hospital Acquired No 002 0.25 0.5 Metronidazole No No 12 
21-01 Hospital Acquired No 002 0.25 0.5 Multiple Yes No 171 
22-01(1) Hospital Acquired No 032 0.25 0.5 Metronidazole Yes Yes Unknown 
22-01(2) Hospital Acquired No 050 0.25 1 
    
23-01 Hospital Acquired No 014 0.5 0.5 None Yes No 125 
24-01 Hospital Acquired No 023 0.12 0.5 Vancomycin Yes No 31 
25-01 Hospital Acquired No 056 0.5 1 Metronidazole Yes Yes 13 
26-01 Hospital Acquired No 014 0.5 0.5 Vancomycin No No 25 
27-01 Hospital Acquired No 013 0.5 1 Vancomycin No No 118 
28-01 Hospital Acquired No 027 1 1 Vancomycin No No Unknown 
29-01 Hospital Acquired No 365 0.5 1 Vancomycin No Yes Unknown 
30-01(1) Hospital Acquired No 001 1 0.5 Multiple No No 109 
30-01(2) Hospital Acquired No 005 0.25 1 
    
31-01 Hospital Acquired No 296 0.5 0.5 Vancomycin No No 389 
32-01 Hospital Acquired No 181 0.25 0.5 Metronidazole No No Unknown 
33-01 Hospital Acquired No 003 0.5 0.5 Metronidazole No Yes 181 
34-01 Hospital Acquired No 001 0.5 1 None Unknown Unknown 155 
35-01 Hospital Acquired No 070 0.5 1 Vancomycin Yes No 272 
36-01 Community Acquired No 015 0.25 0.5 Metronidazole Yes No Unknown 
37-01 Community Acquired No 023 0.25 1 Metronidazole Unknown Unknown Unknown 
38-01 Hospital Acquired No 078 0.5 2 Vancomycin Yes No 367 
39-01 Hospital Acquired No 001 0.25 1 Multiple No Yes 81 
39-02(1) Community Acquired Yes 001 0.5 1 Fidaxomicin 
   
39-02(2) Community Acquired Yes 070 0.25 0.5 
    













Treatment Antibiotic use PPI CRPb (Normal 
range 1-10 
mg/L) 
40-01(2) Hospital Acquired No 035 0.5 1 
    
41-01 Hospital Acquired No 002 0.5 1 Multiple No No 37 
42-01 Hospital Acquired No 015 0.25 1 Multiple No No 69 
42-02 Community Acquired Yes 015 0.5 1 Fidaxomicin Unknown Unknown Unknown 
43-01 Community Acquired No 029 0.5 0.5 Metronidazole Unknown Unknown Unknown 
44-01 Hospital Acquired No 078 0.5 0.5 Vancomycin Yes Yes 88 
45-01 Community Acquired No 015 0.5 0.5 Metronidazole Unknown Unknown Unknown 
45-02 Hospital Acquired Yes 015 0.5 0.5 Fidaxomicin No Yes 90 
46-01 Hospital Acquired No 479 0.5 0.5 Unknown Unknown Yes 68 
47-01 Community Acquired No 015 0.25 1 Metronidazole No No 93 
48-01 Hospital Acquired No 005 0.5 1 Metronidazole No No 12 
49-01 Hospital Acquired No 021 0.5 1 Vancomycin Yes No 120 
50-01 Hospital Acquired No 018 0.5 1 None Yes No 113 
51-01 Hospital Acquired No 027 1 1 Metronidazole Yes No Unknown 
52-01(1) Hospital Acquired No 002 0.5 1 Fidaxomicin Unknown Unknown Unknown 
52-01(2) Hospital Acquired No 005 0.25 1 
    
53-01 Community Acquired No 023 0.12 1 Unknown Unknown Unknown Unknown 
54-01 Hospital Acquired No 023 0.25 1 Multiple Yes No 5 
55-01 Hospital Acquired No 054 0.25 0.5 Vancomycin No No Unknown 
55-02 Hospital Acquired Yes 054 0.5 1 None Unknown Unknown Unknown 
56-01 Hospital Acquired No 014 0.5 0.5 Vancomycin No No 233 
57-01 Hospital Acquired No 076 0.5 1 Metronidazole No No 5 
58-01 Hospital Acquired No 076 0.5 1 Vancomycin Yes No 266 
59-01 Hospital Acquired No 015 0.5 0.5 Vancomycin No No 55 
60-01 Hospital Acquired No 002 0.5 1 Multiple No Yes 275 













Treatment Antibiotic use PPI CRPb (Normal 
range 1-10 
mg/L) 
61-02 Hospital Acquired Yes 076 1 0.5 Fidaxomicin Unknown Unknown Unknown 
61-03 Hospital Acquired Yes 076 0.5 1 Fidaxomicin Unknown Unknown Unknown 
61-04 Hospital Acquired Yes 076 0.5 1 Vancomycin No No 169 
61-05 Community Acquired Yes 076 0.5 1 Vancomycin No No Unknown 
62-01 Hospital Acquired No 015 0.25 1 Vancomycin No Yes 144 
63-01(1) Hospital Acquired No 012 0.5 1 Fidaxomicin Yes No 161 
63-01(2) Hospital Acquired No 020 0.5 0.5 
    
64-01 Hospital Acquired No 255 0.5 0.5 Vancomycin No No 25 
65-01 Hospital Acquired No 050 0.25 1 Vancomycin Yes No 23 
66-01(1) Hospital Acquired No 001 0.5 1 Unknown No No Unknown 
66-01(2) Hospital Acquired No 026 0.25 0.5 
    
67-01 Hospital Acquired No 014 0.5 0.5 Unknown Unknown Unknown Unknown 
68-01 Hospital Acquired No 007 1 0.5 Fidaxomicin Unknown Unknown Unknown 
69-01 Hospital Acquired No 054 0.5 1 Multiple No No 308 
70-01 Hospital Acquired No 005 0.25 0.5 Fidaxomicin Yes No 12 
71-01 Hospital Acquired No 011 1 0.5 Vancomycin No No 143 
72-01 Hospital Acquired No 220 0.25 1 Metronidazole Yes No 19 
73-01 Hospital Acquired No 015 0.5 1 None No No 18 
74-01 Hospital Acquired No 054 1 1 Metronidazole No No 167 
75-01 Hospital Acquired No 001 0.5 0.5 Metronidazole No No 124 
76-01(1) Hospital Acquired No 012 0.5 1 Metronidazole Yes Yes 5 
76-01(2) Hospital Acquired No 116 1 0.5 
    
77-01(1) Hospital Acquired No 014 0.5 1 Metronidazole No No 113 
77-01(2) Hospital Acquired No 009 0.5 0.5 
    
78-01 Hospital Acquired No 023 0.5 1 None Yes No 23 













Treatment Antibiotic use PPI CRPb (Normal 
range 1-10 
mg/L) 
80-01 Hospital Acquired No 014 0.5 1 Unknown No No Unknown 
81-01 Hospital Acquired No 020 0.5 1 Metronidazole No No 114 
81-02 Hospital Acquired Yes 020 0.5 1 Fidaxomicin No No 43 
82-01 Hospital Acquired No 020 1 0.5 Unknown 
   
83-01(1) Hospital Acquired No 026 0.5 1 Metronidazole Yes Yes 62 
83-01(2) Hospital Acquired No 002 0.5 1 
    
84-01 Hospital Acquired No 015 0.5 1 Vancomycin Yes No 16 
85-01 Hospital Acquired No 015 0.5 1 Metronidazole Yes Yes 104 
85-02 Community Acquired Yes 015 1 0.5 Unknown Unknown Unknown Unknown 
86-01 Hospital Acquired No 078 0.5 1 Vancomycin No No 80 
87-01 Hospital Acquired No 351 1 1 Metronidazole No Yes 284 
88-01(1) Hospital Acquired No 014 1 1 Vancomycin Yes Yes 56 
88-01(2) Hospital Acquired No 054 1 0.5 
    
89-01 Hospital Acquired No 012 0.5 1 Metronidazole No No 74 
90-01 Hospital Acquired No 078 0.5 0.5 Metronidazole Yes No Unknown 
91-01 Hospital Acquired No 087 0.5 1 Metronidazole No No 15 
92-01 Hospital Acquired No 027 1 1 Unknown Unknown Unknown 258 
93-01 Hospital Acquired No 078 0.5 0.5 Fidaxomicin Yes Unknown 161 
94-01 Community Acquired No 002 0.5 1 Vancomycin Unknown Unknown Unknown 
95-01 Hospital Acquired No 078 0.25 1 Unknown Unknown Unknown 60 
96-01 Hospital Acquired No 001 1 1 Metronidazole No No 11 
96-02 Hospital Acquired Yes 001 0.5 0.5 None No No 10 
96-03 Hospital Acquired Yes 001 0.5 0.5 None No No 32 
96-04 Community Acquired Yes 001 0.5 1 None Unknown Unknown Unknown 
97-01 Hospital Acquired No 078 0.5 0.5 Unknown Unknown Unknown Unknown 













Treatment Antibiotic use PPI CRPb (Normal 
range 1-10 
mg/L) 
99-01 Community Acquired No 062 0.5 0.5 Metronidazole Unknown Unknown Unknown 
100-01 Hospital Acquired No 064 1 1 Metronidazole No No 23 
aMIC – Minimum Inhibitory Concentration, values of >2 mg/L indicate the strain is resistant.  
bCRP – C-reactive protein, normal range is between 1-10 mg/L. 
